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Severe thermal injury results in a profound hypermetabolic response and is 
associated with increased morbidity, mortality and delayed rehabilitation of burn 
survivors. Serum 1H-NMR metabolomics was used to examine early global metabolic 
changes in the response to severe thermal injury (>15% TBSA) in young adults (16-
64 years) and older adults (<15% TBSA). Early changes in the metabolome reflected 
hypoxic metabolism, hyperglycaemia, increased ketogenesis, peripheral lipolysis and 
increased energy production in both cohorts. Early metabolic profiles from the young 
adult group were used to construct OPLSDA models that could discriminate with high 
accuracy between outcome groups. Models from 0-24hrs serum samples predicted 
survival (AUC 0.92), whilst models from 24-96hrs samples predicted Multiple organ 
failure (MOF) (AUC 0.92) and sepsis (AUC 0.89). Untargeted LC-MS metabolomics 
was applied to study the longitudinal changes in the serum metabolome after severe 
thermal injury in 13 young adults, from admission until 6-months post-injury. 
Univariate ANOVA analysis revealed significant changes in 432 metabolite features, 
affecting 35 distinct classes, representing global metabolic disturbance. Changes in 
300 lipid metabolite features may represent a ‘lipid storm’ in serum after severe 
thermal injury. Novel areas of metabolism and metabolites were identified as putative 
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11 Chapter 1: Introduction 
1.1 Epidemiology 
 
Burn injury is one of the most devastating forms of trauma, which has long lasting 
physical, psychological and social consequences for victims. Worldwide burn injury 
remains a significant problem, with 11 million people sustaining burns severe enough 
to seek medical attention annually and the incidence is ranked 4th among all injuries, 
higher than the combined incidence of TB and HIV infection (1). Data from the World 
Health Organisation (WHO) suggests that burn injuries result in 195,000 deaths 
globally each year (WHO burns factsheet 2012). In the UK, an estimated 175,000 
people attend emergency departments annually for burn injures (2) and data from the 
National Hospital Episode Statistics database (HES) suggests the annual admission 
rate has continued to increase since 2002 with over 11,000 admissions in  2010 (3).  
 
The age groups at highest risk for sustaining a thermal injury are the very young and 
the very old. A recent study of UK hospital admissions has shown that the <5-year 
olds and ≥85 year olds experience the highest incidence of burn injury (figure 1) (3). 
The higher susceptibility of young children to burns is related to their inquisitiveness, 
lack of appreciation of danger and decreased ability to escape from it (4). In the UK 
and Europe, just under half of all patients admitted with severe burn injury are 
children and children under the age of 5 years account for 50-80% of all childhood 
burns (2,5). 
Another high-risk group for burn injury is the elderly population, defined as people 
aged 65 years and above. The elderly are more susceptible to sustaining burns and 
injury than younger adults due to increased frailty, visual impairment, age-related 
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deteriorations in judgment and co-ordination and changes in cognition and balance 
(1). Improvements in medicine over the last half-century have resulted in an increase 
in the average life span in the western world of 30 years. This is reflected in the 
increasing proportions of elderly people sustaining burn injuries; a recent analysis of 
the US National burn repository showed a rise in the number of patients admitted 
with burns over the age of 55 years from 11.2% in 1991 to 15.4% in 2003 (6). 
Similarly in Europe, the proportion of patients with severe burns that are elderly has 
increased from 10 to 16% (5). 
 
In terms of aetiology, flame burns account for almost 60% of injuries followed by 
scalds and then contact burns in Europe (5). Data from the US National Burn 
Repository (NBR) mirrors this pattern with flame burns accounting for 44% of 
admissions, Scalds 33% and contact 9% (7). Electrical, chemical and radiation burns 
are less common. The aetiology pattern does vary with age group and in the 
paediatric population, scalds predominate accounting for 60-75% of burn admissions 
(7). In the elderly, flame burns are most common followed by scalds and the majority 
of injuries occur in the home (55.6%) (6). This is in contrast to younger adults, where 
burns are usually sustained due to work related incidents or activities outside of the 
home (8). Overall, there is a male preponderance in burn admissions; in the USA 
70% of burn related admissions are male (7). In the UK, the incidence of burns is 
higher in males than females in all age groups except the 5-9 year olds and the ≥85 




1.2 Outcomes and complications 
 
Outcomes following burn injury can be divided into short term outcomes, those that 
are important during hospitalization and longer term outcomes which impact on the 
burn survivors quality of life and functioning in society once discharged from hospital. 
Historically burn injury was associated with very poor outcomes and many patients 
succumbed to shock from the initial injury and those that survived this died later from 
infectious complications and sepsis (9). Fortunately, outcomes following severe 
burns have improved in recent decades (Figure 1) due to a combination of advances 
in critical care medicine, early burn wound excision and coverage, blood conserving 
surgery and creation of dedicated burn multi-disciplinary teams (MDT) (10). In the 
western world, children with burns to >95% of their total body surface area (TBSA) 




Mortality is now a less relevant outcome following burns in children, however it 
remains an important outcome in adults with major burns (>20% TBSA) and the 
elderly burn patient regardless of burn size (Figure 1). There are three major 
influencing factors on burn mortality: age, total burn size (TBSA %) and the presence 
of inhalation injury (Ryan et al., 1998, Klein et al., 2014). Indeed, many composite 
mortality prediction models include these as variables (Tobiasen 1982; Ryan et al., 
1998; Belgian Outcomes in Burn Injury Study Group 2009). It has been demonstrated 
that there is a gradual monotonic effect of age on burn mortality until the age of 
approximately 50 years with an inflection point somewhere between 50 and 60 years 
(12). In the same study looking at outcomes in the Glue grant consortium cohort and 
 29 
National Burn Repository data, there is a monotonic effect of burn size on mortality 
until a TBSA of 70% is reached (12). At the Birmingham Burn Centre there is a long 
history of analyzing and publishing burn mortality data since the 1940’s when J.P. 
Bull first developed the calculation of the lethal area 50 (LA50) approach using probit 
analysis (13). The LA50 is the burn size (TBSA %) at which there is a 50% mortality 
rate. The most recent publication shows the continuing improvements in the LA50 











Figure 11-1. Plot of the lethal area 50 (LA50) for 4 different age groups treated at the Birmingham 
Burns Centre 1940-2010 (Taken from (14) 
 
 
As can be seen in figure 1, the LA50 demonstrates an inverse relationship with age 
ranging from the children with an LA50 of 85.1% to the elderly with an LA50 of 23.1%. 
Another important finding of this study was that survival gains were found to be least 
in the elderly group, as can be seen by the relatively small change in LA50 over the 
last 70 years. 
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1.2.2 Length of stay (LOS) 
 
 
The continual improvements in burn survival have led to a shift in focus towards other 
outcome measures and length of stay (LOS) is an important and easy to measure 
short term outcome that can be used to compare burns services. The LOS gives an 
indirect measure of morbidity and complications and has been shown to correlate 
with aesthetic and functional outcomes as well as the healthcare costs (15). A recent 
systematic review highlights that age and TBSA are the strongest predictors of LOS 
so must be taken into account in risk adjustment (15). It has been highlighted that the 
total LOS is a poor measure of resource utilization and that the LOS in specific levels 
of care (Intensive care unit (ICU), high dependency unit (HDU) or ward) allows better 
estimation of resource consumption (16). 
 
1.2.3 Infection and sepsis 
The skin forms an important physical and immunological barrier to potential invading 
micro-organisms and a burn injury represents a complete loss of skin epidermal 
integrity and consequently patients with burn injury are susceptible to wound 
colonisation with bacteria and fungi. This colonisation, in the presence of the 
avascular burn eschar, puts burn injured patients at high risk of wound infection (17). 
In addition, there is disruption of normal gut barrier integrity, facilitating translocation 
of bacteria and absorption of bacterial endotoxin (18). This together with the host of 
documented defects in innate and adaptive cellular immunity post-burn, means that 
the severely injured burn patient is highly susceptible to infections which increase 
mortality and morbidity and prolong recovery and hospitalisation. Patients with 
severe burn injury are susceptible to a whole host of nosocomial acquired infections 
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including wound infection, pneumonia, blood stream infection (BSI), urinary tract 
infection (UTI) and vascular catheter related bloodstream infections. The most recent 
prospective data from the US Glue grant cohort of adults and children with burns 
>20% TBSA demonstrates the very high incidence of nosocomial infections after 
severe burn. In this study, 71% of the adult cohort and 68% of the paediatric cohort 
experienced nosocomial infections and burn wound infection was the commonest 
cause in each group (19) (table 1.1).  
 Adults (n = 300) Children (n = 241) 
All nosocomial infections (%) 70.7 67.6 
Wound infection (%) 52.3 93.8 
Pneumonia (%) 47.7 10.4 
Blood-stream infection (%) 28.3 15.8 
Sepsis (%) 10.3 2.9 
 
Table 11-1. Incidence of nosocomial infections and sepsis in adult and paediatric cohorts of 
the US glue grant Host Response to Injury Study. Data adapted from (19). 
 
Sepsis is the deleterious host response to infection and may lead to septic shock, 
multiple organ failure (MOF) and death. A systematic review of epidemiology studies 
of burn injured patients has highlighted that there is higher incidence of sepsis in 
cohorts of burn intensive care patients (28-51%) as compared to cohorts of non-burn 
trauma patients and other populations of intensive care patients. The same study 
also showed that the mortality rate from sepsis is higher in cohorts of burn injured 
patients compared to these other groups, ranging from 28-65% (20). In a study of 
autopsy reports from 144 burned children a shift was seen in leading cause of death 
from respiratory failure in the 1990’s to sepsis in the 2000’s, with 54% of deaths 
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being due to sepsis (21). In a UK study of autopsy reports, the leading cause of 
death was MOF with 54% of these cases being secondary to sepsis (22).  
 
One of the major challenges in the field of sepsis research is defining the condition 
with either clinical or laboratory parameters. The ACCP/SCCM sepsis definitions are 
the most widely used internationally and are based on the systemic inflammatory 
response syndrome criteria (SIRS) (Table 3) and have been recently updated (23). 
These criteria are however, not especially useful in patients with severe burns since 
many patients will persistently meet the SIRS criteria due to their hyperdynamic 
circulation and hyperthermia related to their endocrine stress response. To try to 
tackle this issue, a group of US burn physicians from the American Burn Association 
(ABA) met in 2007 and developed a consensus group of sepsis trigger criteria which 
included 6 items and higher threshold values for temperature and heart rate (table 2). 
One retrospective analysis evaluated the diagnostic utility of these criteria and found 
that devised scoring system was poorly predictive of bacteremia as a surrogate 
marker of sepsis (24). This led the group to develop their own modified sepsis trigger 
criteria which outperformed the ABA trigger criteria, again in terms of predicting 
bacteremia (AUROC 0.775 vs. 0.619) (25). The importance in being able to 
recognize sepsis earlier is earlier treatment and therefore improved outcomes. A 
large multi-centre study of patients with septic shock demonstrated the importance of 
early recognition, with decrease in survival rate by 7.6% for every hour delay in 




1.2.4 Multiple organ failure (MOF) / Multiple organ dysfunction syndrome 
(MODS) 
 
Multiple organ failure (MOF) or Multiple organ dysfunction syndrome (MODS) is 
clinically defined as when two or more organs fail either in parallel or sequentially. 
The terms MOF and MODS are often used interchangeably in the critical care 
literature; although the term MODS has been recommended by the ACCP/SCCM, 
this has not been universally accepted. MOF was a syndrome that emerged in the 
1970’s as advances in critical care medicine meant patients began to survive single 
organ failure. It was initially studied as a final common pathway to death in 
association with sepsis but it became clear in the 1980’s that it occurring following 
trauma and surgery in the absence of infection (27). A number of theories as to the 
underlying pathophysiology of MOF have been proposed including: gut barrier 
dysfunction and bacterial translocation (28), flow-dependent oxygen consumption 
(29) and the two-hit hypothesis of initial inflammatory hits priming the immune system 
for subsequent development of late systemic inflammation and MOF (30) (see 
section 1.4.1). During the 1990’s, post-injury MOF was found to display a bimodal 
phenomenon with >60% of MOF occurring as a late onset rather than early post-
injury, but recent studies suggest this late peak has disappeared (31). 
 
A number of scoring systems have been developed to quantify the severity of MOF 
including the Marshall MODS score (32), the Denver Post-injury multiple organ failure 
score (33) and the Sequential Organ Failure Assessment (SOFA) score (34). The 
Marshall and SOFA scores ascribe scores to 6 organ domains according to the 
degree of failure (Pulmonary, Renal, Hepatic, Cardiovascular, Haematologic, 
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Neurological). The Denver score simplified this to 4 domains by excluding the platelet 
count and neurological assessment and showed equal performance to the Marshall 
score in validation studies (33). The US host response to injury study adopted the 
Denver Score to define MOF outcomes and found within their severe burn injury 
cohort, 26.7% of adults and 27.8% of children developed MOF (19). In a UK study of 
autopsy findings in patients with severe burns, it was found that MOF was the leading 
cause of death (71% of cases) and over half of cases were secondary to sepsis (22).   
 
1.3 Pathophysiology of the burn wound 
 
Cutaneous burn injury can be caused by a variety of mechanisms including thermal 
injury from flame, contact with hot objects or radiated heat. Other mechanisms 
include chemical injury, electrical injury, friction and freezing. Burns are classified 
according to depth, size in terms of total body surface area (TBSA) burnt and 
anatomical location. Depth is internationally classified on a I-III scale but an 
anatomical classification is more practically useful. Superficial burns (Grade I) occur 
from sun exposure, scalds and flash injuries, involve the epidermis only and are 
expected to heal within 7 days. Superficial partial thickness burns (IIa) are typically 
from scalds and involve the epidermis and superficial (papillary) dermis and usually 
heal within 2 weeks by primary intention (regeneration). Deep partial thickness (IIb) 
burns involve the deeper (reticular) dermis and may take 3-6 weeks to heal and 
healing may be associated with abnormal scarring. Full thickness burns (III) are often 
due to flame, electrical or contact injury and will not heal by primary intention and 
require skin grafting for timely healing (35). 
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Thermal injury to the skin results in cell death due to the denaturation of proteins and 
a loss of plasma membrane integrity. The duration of exposure and the temperature 
of the heat source is important as cell necrosis occurs after 1 hour at a temperature 
of 45°C but only 1 second at 69°C ((10) – chapter 10). In 1953, Douglas Jackson 
described that there are three distinct concentric zones of injury within a burn wound 
(figure 2). Centrally there is zone of coagulation consisting of irreversibly necrosed 
tissue and peripherally there is the zone of hyperaemia, which is characterized by 
increased perfusion and usually heals without intervention. In between these two 
zones is the zone of stasis, which contains a mixture of viable and non-viable cells, 
capillary vasoconstriction and ischaemia (36). This zone has the potential to progress 
to complete cell death but with good resuscitation and wound care this zone has the 













1.4 Inflammatory response to severe thermal injury 
 
The definition of a severe burn in the literature is variable, but it is known that burns 
affecting over one third of the TBSA result in a complex systemic pathophysiological 
response in humans (38). This systemic response includes systemic inflammation, 
an endocrine stress response and hypermetabolism which results in a hyperdynamic 
circulation, increased body temperature, increased oxygen consumption, increased 
CO2 production, glycolysis, proteolysis, lipolysis and futile substrate cycling (39-41). 
These responses are common to other major trauma and sepsis, however the 
response after severe burns is both more profound and more prolonged (42,43). 
There is increasing evidence that both the magnitude of the initial inflammatory insult 
and the duration of ongoing inflammation determine patient outcomes after burns and 
trauma. 
 
1.4.1 Immune-inflammatory paradigms following injury 
 
Inflammation is the reaction to tissue injury and is a tightly regulated and localised 
acute host response necessary for haemostasis, protection against invading 
microorganisms and the initiation of wound healing and repair mechanisms. 
However, severe tissue injury as seen in patients with multiple trauma or severe 
burns results in a massive release of inflammatory mediators into the circulation 
resulting in a complex system wide activation of the immune system with deleterious 
effects on a multitude of organ systems. The clinical manifestation of this response is 
termed the Systemic Inflammatory Response Syndrome (SIRS) and occurs in other 
conditions such as sepsis, ischaemia reperfusion injury and pancreatitis (44). The 
concept of SIRS came from a desire to better understand systemic inflammation in 
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trauma and surgical patients with no evidence of infection, previously termed ‘sepsis 
syndrome’. A consensus conference between the American College of Chest 
Physicians (ACCP) and Society of Critical Care Medicine (SCCM) in 1992 resulted in 
the emergence of the definitions of 1) SIRS, defined by clinical criteria (table 2), 2) 
sepsis – SIRS in the presence of documented infection and 3) Multiple organ 
dysfunction syndrome (MODS) – organ dysfunction in the presence of SIRS (44). 
 SIRS criteria Parameters 
1 Body temperature >38°C or <36°C 
2 Heart rate >90 beats per minute 
3 Respiratory rate > 20 breaths per minute 
4 White cell count (leukocyte) 
>12,000 per uL or <4000 per uL or >10% 
immature band forms 
Table 11-2: Systemic inflammatory response syndrome (SIRS) criteria. A score of ≥2 is required 
for a diagnosis of SIRS. (45) 
 
After the introduction of the concept of SIRS in the 1990’s, it was not long after that 
Polly Matzinger proposed the ‘danger model’, which gave an explanation for the 
development of SIRS in the absence of infection. This model proposed that the 
immune system is more concerned with damage than recognition of self or non-self 
and thus responds to alarm signals from damaged tissues in the same way as to an 
infectious pathogen (46). We now know that tissue injury, for example trauma, results 
in release of danger signaling molecules, also termed ‘alarmins’ or ‘damage 
associated molecular patterns (DAMPS)’ and that these can activate the innate 
immune system through receptors on immune cells such as the toll-like receptors 
(TLR) (47). Prior to the emergence of these concepts, it has long been known that 
following trauma and burns, a period of immunosuppression arises during which 
patients are susceptible to the development of infections and sepsis (48). This 
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phenomenon was later coined the ‘compensatory anti-inflammatory response 
syndrome’ (CARS) (49). The SIRS/CARS model of the response to injury or sepsis 
suggested that the initial pro-inflammatory SIRS phase is followed temporally by a 
period of immunosuppression or CARS, characterized by anti-inflammatory cytokine 
production (e.g. IL-10) and defects in adaptive immunity. It was also felt that during 
the CARS phase, patients are susceptible to subsequent episodes of SIRS and 
CARS from a ‘second hit’, e.g. surgery, infection or sepsis, which are responsible for 
adverse clinical outcomes (Figure 3a).  
 
This SIRS/CARS paradigm began to be questioned when a study in a murine model 
of sepsis showed simultaneous production of pro and anti-inflammatory cytokines in 
response to the insult (50). More recently, work from the US host-response to injury 
Glue grant program, demonstrated that following severe blunt trauma and burns, pro- 
and anti-inflammatory gene expression is simultaneously increased in circulating 
leukocytes (51). They propose a new immune-inflammatory model for the response 
to trauma, stating simultaneous pro and anti-inflammatory responses (Figure 3b). 
The study also showed no evidence of ‘second inflammatory hit’ associated with later 
complications, only differences in the size and duration of the transcriptional 
reorganization between patients with complicated and uncomplicated outcomes. In 
summary, the model proposes that the initial magnitude of both the pro-inflammatory 
and anti-inflammatory responses and the time to resolution is important in 




Figure 11-3. Models of inflammation after injury. a) Long held paradigm of the immune-
inflammatory response following trauma showing pro- followed by anti-inflammatory processes. b) 
New model proposed by Xiao et al. based on gene expression profiling of circulating leukocytes in 
trauma and burns patients suggesting concurrent SIRS/CARS immediately post-injury. Taken from 
Xiao et al. 2011. A genomic storm in critically injured humans. JEM 208:2581-2590 (51). 
 
More recently a group from Florida have proposed another model to explain the 
prolonged ICU stay seen in some critically ill patients. They introduced the term 
‘persistent inflammation catabolism syndrome’ (PICS) to describe the phenotype of 
patients who survive their initial inflammatory insult but reside in the ICU for many 
weeks needing organ support and experiencing nosocomial infections, progressive 
protein catabolism with loss of lean body mass and failure to regain muscle strength 
(figure 4) (52). More recently they have utilized genomic microarray data from severe 
blunt trauma patients to show that patients with complicated outcomes exhibit gene 
expression changes consistent with persistent defects in adaptive immunity and 
increased inflammation (53). This clinical syndrome has not yet been studied in a 





Figure 11-4. New proposed model of the human immune-inflammatory response to traumatic 
injury incorporating concepts of SIRS, CARS, chronic critical illness (CCI) and PICS.Taken from 
Vanzant et al., Persistent inflammation, immunosuppression and catabolism syndrome after severe 
blunt trauma. J Trauma Acute Care Surg. 76: 21-30 (53). 
 
1.4.2 Cytokines and chemokines 
 
Pro-inflammatory cytokines, chemokines and non-cytokine inflammatory mediators 
are the primary mediators of SIRS. Non-cytokine mediators include platelet activating 
factor (PAF), eicosanoids (e.g. leukotrienes, prostaglandins) and complement C3a 
and C5a (10). Cytokines play important regulatory roles in immune and inflammatory 
responses, affecting lymphocyte proliferation, cell survival, cell differentiation, antigen 
presentation or cell trafficking (54). They can be broadly classified as either pro or 
anti-inflammatory and subclass of cytokines are the chemokines which act as chemo-
attractants to recruit immune cells to their site of release. 
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Early studies of circulating cytokines in burn injury focused on individual cytokines 
and demonstrated elevations of Interleukin-1 (IL-1) (55-57),, IL-2 (58) , IL-6 (59-61) 
and IL-8 (62). Tumour necrosis factor-α (TNF-α) is a classical pro-inflammatory 
cytokine produced primarily by cells of the monocyte, macrophage lineage and 
promotes endothelial cell permeability, neutrophil release from the bone marrow, 
enhances their recruitment to the site of injury and promotes phagocytosis. It also 
promotes activation of T-helper (Th), promotes fever and the production of acute 
phase proteins on the liver and promotes catabolic metabolism including muscle 
breakdown and lipolysis (63). Although elevated levels have been demonstrated in 
septic shock (64), studies in trauma and burn injured patients have yielded conflicting 
data. Several studies have shown a relationship between elevated circulating TNF-α 
and shock, MODS and mortality (65,66) but others have found no relationship to 
prognosis and outcome following burn injury (55,56). 
 
The Interleukin-1 cytokine family, have also been studied as markers of SIRS and 
includes IL-1α, IL-1β and IL-1 receptor antagonist (IL-1RA) plus other more recently 
discovered members, IL-18, IL-33, IL-36 and IL-37 (67). IL-1 (IL-1α and IL-1β) is a 
pro-inflammatory cytokine and is produced by a wide variety of cell-types including 
monocytes, macrophages, lymphocytes, NK-cells and keratinocytes. It has some 
similar effects to TNF in that it induces other pro-inflammatory cytokine release and 
contributes to the catabolic response to injury (63). IL-RA is anti-inflammatory, 
through its action as a biologically inactive competitive ligand for IL-1 receptor, with 
early studies showing poor correlation with measures of illness severity such as the 
Acute Physiology and Chronic Health Evaluation (APACHE) II score, an inverse 
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relationship to burn size and lower levels in non-surviving patients (55). In contrast, 
one study demonstrated higher levels in non-survivors and those who developed 
infections (57). 
 
The pro-inflammatory cytokine IL-6, more than any other cytokine, has stood the test 
of time as a reliable marker of inflammation and elevations in circulating levels have 
been demonstrated after elective surgery, trauma and burn injury (68). IL-6 is 
inducible in nearly every human tissue and cell type but the most important source is 
from mononuclear phagocytic cells (69). IL-6 is induced by other pro-inflammatory 
cytokines including IL-1 and TNF-α. Akin to TNF-α, it also induces pyrexia and 
activates hepatic production of acute phase proteins but also promotes differentiation 
of B cells and T-cell proliferation (63). It also has anti-inflammatory properties, being 
able to inhibit the synthesis of IL-1 and TNF-α and stimulate the synthesis of IL-1 
receptor antagonist (IL1-RA) (70). Guo et al., showed that IL-6 is elevated on the first 
day after burn injury, peaks on the sixth day and remained elevated for 21 days post-
burn (60). Circulating IL-6 also correlates with the size of the burn injury (61,71), the 
presence of inhalation injury (72) and adverse outcomes include lethal sepsis (73), 
and death (61,74). 
 
The most widely studied chemokine in burn injury is IL-8 (CXCL-8). It is a neutrophil 
chemo-attractant and circulating levels have consistently been shown to be 
profoundly elevated after burn injury, with higher and persistently elevated levels in 
larger burns (75), non-survivors (74) and patients with MOF and sepsis (62). IL-8 
mediated recruitment of neutrophils also appears to be important in the pulmonary 
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inflammation caused by burns and smoke inhalation (72). Another chemokine found 
to be elevated in severe burn injury is monocyte chemoattractant-1 (MCP-1) which 
plays a pivotal role in monocyte recruitment during infection and inflammation, being 
induced in a range of tissues by TNF-α, IL-1 and endotoxins (76). 
 
IL-10 is produced by activated monocytes/macrophages, sub-populations of T and B-
cells and keratinocytes and has pleiotropic effects, regulating a range of pro-
inflammatory processes. It can inhibit the production of cytokines TNF-α, IL-6, IL-1 
and Interferon-γ, stimulate monocytes to produce IL-RA and inhibit effector functions 
of macrophages, T-cells and NK cells (77). Circulating levels correlate with the 
development of sepsis in trauma patients (78) and in burns patients peak levels are 
predictive of ICU mortality (79). In addition to higher early peak levels of IL-10, non-
survivors of burn injury and survivors with sepsis appear to have persistently 
elevated levels compared to survivors and non-septic survivors respectively (79,80). 
Similarly, IL-1RA levels correlated with burn size, area of full thickness burn and 
serum CRP and the development of infectious complications (57) and mortality (81). 
 
The most recent studies to study cytokine production following thermal injury have 
shown that SIRS and the cytokine storm differs between adults and children (82) and 
between surviving and non-surviving major paediatric burn patients (74). The same 
group have shown in a large cohort of children with burns >30% TBSA that a severe 
burn induces an inflammatory and hypermetabolic response that persists for up to 3 
years post injury (42). All of these recent studies, point to IL-6, IL-8, MCP-1, GCS-F 
and IL-RA as the most important cytokines in terms of prognosis of outcome. It is 
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apparent that across the vast swath of burn cytokine response literature there are 
inconsistencies and this may relate to differences in measurement, heterogeneity of 
patient populations and the presence of genetic polymorphisms within cytokine 
genes which effect treatment response (83,84). To date, monotherapies targeting 
reduction of individual cytokines as well as approaches to global reduction of pro-
inflammatory cytokines such as continuous veno-venous haemofiltration (CVVH) 
have been unsuccessful in treating systemic inflammation and sepsis. Future 
therapies need to take account the complex balance of these pleiotropic mediators in 
order to confer outcome benefit after severe injury. 
 
1.4.3 Damage associated molecular patterns (DAMPS)  
The concept that the immune system is not simply concerned with distinguishing 
‘self’ from ‘non-self’, but rather to detecting signals that indicate danger to cells was 
proposed by Matzinger in her ‘Danger hypothesis’ (46). Innate immune cells 
recognise and are activated by the presence of pathogenic organisms through the 
detection of highly conserved motifs called Pathogen Associated Molecular Patterns 
(PAMPs). PAMPs are recognised by Pattern Recognition Receptors (PRRs) and 
include a vast array of different molecules including Peptidoglycan, endotoxin, 
flagellin and double-stranded RNA (dsRNA) (85). These same PRRs, such as Toll-
like Receptors (TLRs), also recognise self-derived molecules that are released during 
tissue stress or injury and necrotic cell death and are termed Damage Associated 
Molecular Patterns (DAMPs). In healthy tissues, DAMPs are hidden from PRRs 
either by compartmentalisation within cells (intra-cellular DAMPs) or sequestration in 
the extra-cellular matrix (ECM) (extra-cellular DAMPs) (86). DAMPs released from 
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injured tissues are therefore able to generate innate immune responses through the 
same signalling pathways as PAMPs. These highly conserved molecules are very 
heterogeneous and have a normal physiological role but signal danger or damage in 
their ‘DAMP role’ when become exposed to PRRs.  
 
DAMPs can be broadly grouped according to their normal physiological location: 1) 
Nuclear DAMPs e.g. Histones, genomic DNA, High Mobility Group Box-1 (HMGB-1); 
2) Cytosolic DAMPs e.g. adenosine triphosphate (ATP), heat shock proteins (HSPs), 
uric acid crystals, S100 proteins; 3) Mitochondrial DAMPs e.g. mitochondrial DNA 
(mtDNA), formyl peptides and 4) Endoplasmic reticulum (ER) DAMPs e.g. 
Calreticulin (87). A classical DAMP is HMGB-1, a DNA chaperone that is expressed 
in most cell types and acts as a DAMP when its becomes extra-cellular. This can 
occur passively after necrotic cell death but not programmed cell death (apoptosis) or 
can be actively secreted by stressed cells (88). It has a range of actions depending 
upon its redox state and which PRR it binds e.g. in its reduced state, it can bind to 
RAGE (receptor for advanced glycation products) and induce cell migration and 
autophagy or in its disulphide state it can bind to TLR-4 to induce cytokine and 
chemokine release by immune cells (87). 
 
Within the field of injury research, DAMPs have become the link between tissue 
injury and systemic inflammation in the absence of infection. Studies of HMGB-1, 
showed that in patients with severe blunt trauma (Injury severity score (ISS)>15), 
levels increased 30-fold after injury (89). The levels of HMGB-1 have been shown to 
correlate with ISS and mortality (90). More recently, there has been attention focused 
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on mitochondrial derived DAMPs (mtDAMPs). It makes logical sense, that 
mitochondrial derived molecules can act as DAMPs, since they hypothesised to 
originate from alpha-protobacteria which lived in eukaryotic cells in a symbiotic 
relationship. They therefore have retained some clues to their bacterial ancestry, 
including methylated CpG repeats in their genome and formylated peptides (91).  In 
in vitro studies, mtDAMPs, which include mtDNA, ATP, cytochrome c and formyl 
peptides, activate and produce functional changes in neutrophils (47). Murine in vivo 
studies demonstrated that injection of DAMPs into mice resulted in a SIRS 
phenotype with priming of circulating neutrophils and associated organ damage (92). 
In clinical studies, Zhang et al. have shown that following blunt human trauma, 
mtDNA is released into the circulation at level several thousand-fold higher than 
control subjects. They also showed that mtDAMPs were able to activate PMNs in a 
dose-dependent manner through TLR-9 signalling pathways and that they caused 
systemic inflammation and organ injury when administered to healthy rats (47). 
 
Within the field of burn injury, mtDAMPs have been shown to activate ld T-Cells in 
vitro, increasing their expression of Toll-like receptors (TLRs) 2 and 4 and production 
of pro-inflammatory cytokines (93). In a murine burn injury model, mtDAMP 
administration increased systemic inflammation and led to an acute lung injury (ALI) 
phenotype (94). The same group have also found in patients with inhalation injury 
and burn injury that early elevations in the DAMPs hyaluronic acid and dsDNA in 
bronchial lavage specimens were associated with subsequent positive bacterial 
respiratory cultures (95). 
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1.5 Immune dysfunction following thermal injury 
It has long been known that following extensive thermal injury and other forms of 
major trauma there is a period of immunosuppression. The innate immune system is 
immediate acting but in a relatively broad and non-specific fashion. Its main role is 
the rapid recognition of widely conserved components of infectious agents and 
damaged tissue, leading to destruction or removal using a variety of mechanisms. 
Another important role is to activate the adaptive immune system, whose responses 
are more delayed but highly antigen specific (96). Both arms of the immune response 
are affected by trauma. The key cellular components of the innate immune response 
are neutrophils, macrophages and dendritic cells. The actions of the adaptive 
immune system are mediated by T and B-lymphocytes (T cells and B cells), which 
have a large repertoire of antigen-receptors to recognize pathogens. The following 
section focuses on the impact of thermal injury on neutrophils, one of the main 
effector cells of the innate immune system. The effects of thermal injury on other 
immune cells are summarized in table 3.  
 
1.5.1 Neutrophil dysfunction following thermal injury 
 
Neutrophils are a critical element of the innate immune system, providing a rapid 
response to bacterial and fungal pathogens. To perform these tasks, they armed with 
an array of functions including chemotaxis, phagocytosis, generation of reactive 
oxygen species (ROS), degranulation and production of Neutrophil Extracellular 
Traps (NETs). Numerous studies have demonstrated defects in most of these 
functions following burn injury and early immunological studies established a link 
between infection and reduced bactericidal activity of neutrophils (97). This 
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depressed bacterial killing action has been demonstrated with staphylococcus aureus 
for more than 150 days post burn (98).  
The first functional defect identified in neutrophils post-burn was in chemotaxis, the 
process of migrating towards chemoattractant molecules produced at a site of 
infection or injury. Warden et al showed that defective chemotactic indices correlated 
with burn size and that measurements taken after 72hrs were predictive of mortality 
(99). More recent studies using microfluidic devices have demonstrated that human 
neutrophil motility is depressed as early as 24hrs after burn injury and that the 
degree of migration speed (chemokinesis) inhibition correlated with severity of injury 
(100). The same group employed the devices to show neutrophil directionality was 
impaired in a rat burn model and restoration of this defect using Resolvin D2 
conferred increased survival following a septic insult (101). More recent human 
studies have identified a spontaneous neutrophil migration phenotype from blood 
samples that were taken during episodes of sepsis in patients with severe burns 
(102). The consequences of these defects would not only represent reduced ability to 
deal with pathogens but also increased potential for neutrophils to migrate into and 
damage healthy tissues, contributing to organ dysfunction (103). 
 
Microbicidal functions of neutrophils may be classified as oxygen dependent and 
oxygen independent and microbe killing is most efficient when phagocytosed within a 
membrane bound phagosome. Oxygen dependent killing involves the NADPH 
oxidase dependent generation of reactive oxygen species (ROS) such as hydrogen 
peroxide, superoxide anion and nitric oxide. Oxygen independent mechanisms 
involve release of numerous proteins, contained within granules, into the 
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phagosomes, including the defensins, cathelicidins, protegrins, cathepsin-G, 
lysozyme and lactoferrin (104).  
Immune cell Type Immune defects associated with thermal injury 
Innate immunity 
Neutrophil 
Depressed bacterial killing (98) 
Defective chemotaxis (99) 
Inhibited chemokinesis (100) 
Spontaneous migration phenotype during sepsis (102) 
Decreased superoxide burst/ROS production (105) 
Reduced phagocytosis of opsonized bacteria (106) 
Reduced FCRlIII receptor expression (107) 
Increased CD11b expression, reduced CD16 expression (108) 
Increased IL-10 production (109) 
Monocyte 
Initial monocytosis (110), monocytopaenia in non-survivors and septic 
patients (111) 
Shift in differentiation of myeloid progenitors towards monocytopoiesis (112) 
Impaired chemotaxis (113) 
Impaired phagocytosis (114) 
Reduced CD47 expression in sepsis and MOF (115) 
Reduced HLA-DR expression delayed recovered associated with sepsis and 
mortality (116-118) 
Macrophage 
Initial hyperactivity – increased production of TNF, IL-6, IL1 and PGE-2 (119) 
Increased initial TLR-2 and TLR-4 expression and reactivity to LPS 
(120,121) 
Increased late production of IL-10 (121) 
Impaired phagocytic activity (123) 
Dendritic cell (DC) 
Reduced numbers of circulating DCs, prolonged in septic patients (124) 
Reduced expression of HLA-DR reduced up to 4 weeks post-injury (125), 
reduced expression in patients developing sepsis (118) 




Impaired delayed hypersensitivity type response (127) 
Impaired in-vitro lymphoproliferative response to mitogens 
Defective cytotoxic T-lymphocyte (CTL) function (128,129) 
Reduction in CD4+ T-Helper (Th) cells, greater in sepsis (130) 
Increased apoptosis (131) 
Decreased production of Th1- associated cytokines (IFN-g, IL-12), increased 
production of Th2 cytokines (IL-4, IL10) (132) 
Increased regulatory T-cell activity (T-Reg) (133) 
B-lymphocyte 
Decreased expression of activation marker CD25 (134) 
Suppression of antigen-specific antibody production (135) 
Impairment of IgM synthesis (136) 
Impairment of clonal expansion and proliferation (136) 
Table 1-3. Summary of innate and adaptive cellular immune defects demonstrated following thermal 
injury 
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Studies in human burn injured patients have shown decreased neutrophil oxidative 
capacity, early after injury and a return to normal function at 3.5 months post-injury 
(105). Reduced phagocytosis of opsonised bacteria has been shown with a positive 
correlation to burn size (106) and this could be related to changes in phagocytosis 
receptor expression e.g. FCRlIII receptor (107).  
 
1.5.2 Ageing and the immune-inflammatory response to injury 
Older adults are at increased risk of sustaining burn injuries (137) and experience 
much poorer outcomes for a given burn injury size compared to younger patients. 
They are also more likely to experience significant morbidity from infectious 
complications such as pneumonia and sepsis (138), contributing to increased 
mortality and greater length of stay in hospital. A number of contributing factors have 
been proposed to explain poorer outcomes in this group, including co-morbid disease 
(139), frailty (140) and thinner skin resulting in deeper thermal injury (141). There is 
also increasing interest in investigating the age-related changes in immune function, 
termed immunesenescence and its role in outcomes after injury in the older adult 
(142). Immunesenescence encompasses age-associated changes in the 
composition, phenotype and function of innate and adaptive immunity. It also 
includes inflammaging, a low level chronic inflammatory state, defined by elevated 
circulating levels of pro-inflammatory cytokines such as IL-6 and reduced levels of 
anti-inflammatory cytokines such as IL-10 (Wei et al 1992, Stowe et al 2010, Bartlett 
et al 2012). The key innate immune defects associated with ageing have been 
recently reviewed (143) and include decreased neutrophil phagocytosis, chemotaxis 
and NET formation and decreased phagocytosis, ROS production and IL-6 and TNF-
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a production by monocyte/macrophages.  Age-related functional deficits have also 
been demonstrated in Natural killer (NK) cells and DCs. 
  
It is hypothesized that immunesenescence in older patients leads to increased 
susceptibility to infectious complications and altered responses to the injury itself, 
leading to worse outcomes. To date, studies to test this notion have been limited to 
animal studies. A murine burn model, utilizing a 15% TBSA scald injury, 
demonstrated worse survival in aged mice, impaired delayed type hypersensitivity 
(DTH) response and significant elevations in circulating IL-6 levels compared to 
younger mice (144). Further work from the same group, showed a greater shift in the 
cytokine profile from Th1 to Th2 in aged mice after burn injury and this could be 
partially recovered using oestrogen replacement (145). This has not yet been 
followed up in human studies, but work on other types of injury, including hip fracture 
have shown further reduction in neutrophil function, specifically ROS generation, 
induced by the injury (Butcher et al 2005). Subsequent studies by the same group 
revealed that patients who develop depression after hip fracture had a range of 
immune dysfunction including reduced neutrophil function (Duggal at eal 2014). 
Clearly, further research is needed to fully explore the role of immunesenesence in 
determining outcomes in older patients with burn injury. 
 
 
1.6 The Metabolic and Endocrine Response to thermal injury 
 
1.6.1 The ‘Ebb and Flow’ hypothesis 
Surgery, infection, trauma, burns and haemorrhage all result in an endocrine stress 
response accompanied by profound changes in metabolism that parallel the 
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inflammatory response. Cuthbertson, in the 1930’s, was the first to identify that 
patients enter a catabolic state after trauma and described the post-injury metabolic 
response as a two-phase phenomenon. There is an immediate ‘ebb phase’, a 24-
48hr period of depressed metabolic activity, reduced oxygen consumption, reduced 
cardiac output, hyperglycaemia and peripheral vasoconstriction. This phase is 
followed by a ‘flow-phase’ during which metabolic activity, nitrogen excretion and 
oxygen consumption increase, typically within the first 5 days post-injury (146).  
 
1.6.2 Burn shock 
 
Since these earlier descriptions of ‘ebb and flow’ phases, the ebb phase can also be 
termed ‘Burn shock’, an acute period characterized by profound reductions in cardiac 
output which can be depressed for as long as 48hrs (147). In the face of the reduced 
cardiac output, arterial pressure is maintained through increases in total peripheral 
resistance (TPR) (148) and redistribution of blood flow to the brain, heart and the 
liver (149). The underlying pathophysiology behind burn shock is complex and multi-
factorial but it has been demonstrated that severe burn injury results in systemic 
endothelial dysfunction and increases in capillary permeability with resultant protein 
loss into the interstitial space (150). This in turn results in significantly decreased 
colloid osmotic pressure (COP) allowing fluid to escape into the interstitial space 
giving rise to hypovolaemia and tissue oedema (151). If the resultant hypovolaemia is 
not corrected promptly, hypotension and inadequate tissue perfusion ensues (10). 
There is much evidence that the metabolic disturbance during the burn shock phase 
is secondary to reductions in blood flow, with fluid resuscitation restoring decreased 
metabolic rate (152) and preventing a reduction in oxygen consumption (153). 
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Improvements in the acute care and fluid resuscitation of severely burn injured 
patients, with consequent improvements in early survival has led to a shift in focus to 
the ‘Flow phase’ of the burn response (154). 
 
1.6.3 The ‘hypermetabolic response’ to thermal injury 
The metabolic response to burn injury is similar to that seen after other forms of 
trauma and critical illness; however, the magnitude and duration of the response is 
far greater (155). This profound metabolic disturbance has been termed the 
hypermetabolic response (HMR) and is characterized by increased metabolic rate 
(measured as resting energy expenditure (REE), a hyperdynamic circulation, altered 
temperature regulation and a number of biochemical defects resulting in 
hyperglycaemia and an overall catabolic state (10). The magnitude of the HMR is 
proportional to the size of the burn injury (71) and is influenced by the age of the 
patient (156) and the mechanism of the burn injury (157). The presence of inhalation 
injury in children with severe burns appears to have little influence on indices of 
hypermetabolism (158). The relationship between REE and burn size is curvilinear, 
with patients with <10% TBSA burns having close to normal predicted values and 
those with >40% TBSA burns having greater than twice the normal predicted values 
(159). In a large study of children with >30% TBSA burns, the REE at thermal 
neutrality was shown to be 140% of predicted on admission, reducing to 130% at full 
wound healing and 120% at 6-months post-injury (38). More recent studies from the 
same group have shown the HMR to persist for longer than previously appreciated, 
with evidence of hypermetabolism at 3-years post-injury in children with >30% TBSA 
burns (42). 
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1.6.4 The Endocrine stress response 
The metabolic response to thermal injury is clearly complex and multiple mediators 
have been implicated in initiating and driving the response. To date, endotoxin, 
tumour necrosis factor α (TNFα), platelet activating factor (PAF), the cytokines IL-1β 
and IL-6, arachidonic acid metabolites, neutrophil adherence complexes, reactive 
oxygen species (ROS), nitric oxide (NO), the complement system and the 
coagulation cascades have all been implicated in driving this response (159). In 
addition to inflammatory mediators released from the site of injury, tissue damage 
and pain triggers impulses along afferent neurons, which ascend to the 
hypothalamus and brain stem of the central nervous system (CNS). These signals 
stimulate the ‘stress response’ or ‘fight-or-flight’ system that is composed of the 
sympathetic-adrenal-medullary (SAM) axis and the hypothalamic-pituitary adrenal 
(HPA) axis. These highly conserved responses facilitate both increased mental 
awareness and elevated metabolic and cardiovascular activity in readiness for a 
rapid increase in muscular work. 
 
1.6.5 The Sympathetic-adrenal-medullary (SAM) axis 
 
The SAM axis comprises the sympathetic nervous system (SNS) and the adrenal 
medulla. The SNS is one arm of the autonomic nervous system (ANS) and consists 
of neurons with cell-bodies within the CNS (pre-ganglionic fibres) and neurons that 
project outside the CNS to the viscera (post-ganglionic fibres). Injury, pain, anxiety, 
hypotension, hypothermia, hyperthermia and psychological stressors result in 
hypothalamic activation of the SNS with release of noradrenaline from sympathetic 
nerve endings and release of adrenaline from the adrenal medulla resulting in 
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tachycardia, increased cardiac output and changes in carbohydrate, lipid and protein 
metabolism (160) . In addition, neurons arising in the locus ceruleus in the brainstem 
release noradrenaline within the brain to increase alertness and attention (161).  
 
Severe burn injury results in profound SNS activation which is directly proportional to 
burn size (162,163). Levels of urinary noradrenaline and adrenaline increase 10-fold 
and 4-fold, respectively, after severe thermal injury in children. The duration of the 
stress response to thermal injury is prolonged with urinary levels of cortisol, 
noradrenaline and adrenaline levels being elevated for 36 months, 24-months and 
18-months respectively (42). In addition to the cardiovascular and visceral changes, 
catecholamines have been demonstrated to influence some of the key metabolic 
changes that characterize the HMR, including increased REE (164,165), 
glycogenolysis (166), gluconeogenesis (166) and lipolysis (165,167-169). The 
prolonged SNS activation may also contribute to immune dysfunction post-burn, with 
evidence from murine studies that noradrenaline modulates bone marrow 
myelopoiesis after burns sepsis  (170) and that depletion of noradrenaline in bone 
marrow influenced the functional phenotypes of bone marrow derived macrophages 
after burn injury and burn sepsis (171). 
 
1.6.6 The Hypothalamic-pituitary-adrenal (HPA) axis 
 
The HPA axis comprises the hypothalamus, pituitary gland and the adrenal gland 
and is the other key component of the stress response. The paraventricular nuclei 
(PVN) of the hypothalamus are stimulated to release both corticotrophin releasing 
hormone (CRH) and arginine vasopressin (AVP or anti-diuretic hormone, ADH). CRH 
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then acts upon the anterior pituitary (AP) to stimulate release of adrenocorticotrophic 
hormone (ACTH), which in turn drives production of cortisol from the adrenal cortex. 
Cortisol is a catabolic glucocorticoid hormone with pleiotropic effects on metabolism, 
immune function, endocrine function and the cardiovascular system (172). In the 
context of the stress response, cortisol is geared towards mobilizing energy 
substrates, particularly glucose through increased gluconeogenesis in the liver, 
inhibition of peripheral uptake and utilisation of glucose. 
 
Following severe burn injury in children, urinary and serum cortisol levels are 
elevated 8-10 fold and remained elevated about control levels for up to 36 months 
post-injury (42). Glucocorticoids have been shown to contribute to the wide-ranging 
effects on metabolism during the flow phase of hypermetabolism following thermal 
injury. They contribute to hyperglycaemia through increasing rates of 
gluconeogenesis (173,174) and glycogenolysis in the liver via opposing the anabolic 
effects of insulin (175) and stimulation of glucagon secretion (176,177). 
Corticosteroids are also associated with increased REE (178-180), skeletal muscle 
proteolysis (181-184), increased liberation of free fatty acids (FFA) from adipose 
tissue (185) and abnormal bone metabolism (186). In addition, corticosteroids 
increase hepatic protein synthesis to generate elevated levels of acute phase 
proteins (174)  and gluconeogenic enzymes. They also contribute to post-burn 
immunosuppression and have been shown to reduce lymphocyte numbers (187) and 
suppress neutrophil function (188) and monocyte/macrophage activity (189). 
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The adrenal androgens, Dehydroepiandrosterone (DHEA) and 
dehydroepiandrosterone sulfate (DHEAS) are also affected by severe burn injury and 
have been shown to be at low levels for 4-weeks post-burn (Lephart et al., 1987). 
The relationship of these finding in relation to patient outcomes is unclear but studies 
in elderly hip fracture patients show that the cortisol:DHEAS ratio was increased in 
compared to age-matched controls and young patients with similar orthopaedic 
trauma. The study also reported that a higher cortisol:DHEAS ratio was associated 
with increased incidence of infection in the first 6-weeks post injury and that in vitro 
the suppression of neutrophil function by cortisol could be overcome by co-incubation 
with DHEAS (190).  
 
1.6.7 Increased resting energy expenditure post-burn 
The standard or basal metabolic rate (SMR/BMR) is defined as basal metabolism 
under standardized conditions of fasting, immobility, thermal-neutral environmental 
temperature (26-33°C) (40). The SMR represents two-thirds of the total daily energy 
expenditure and therefore is a key determinant of daily nutritional requirements. In 
critically ill patients, the REE is a more practical indirect measure of SMR derived 
from measurements of oxygen consumption [Vo2] and carbon dioxide production 
[Vco2] using indirect calorimetry.  
 
A hallmark of the post-burn hypermetabolism, is increases in REE with studies 
showing a 25% TBSA burn injury results in metabolic rates 118-210% above that 
predicted by the Harris-Benedict equation (191). In children with burns >40% TBSA, 
the REE compared to predicted BMR at thermal neutrality is 180% on admission, 
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150% at full wound healing, 140% at 6 months, 120% at 9 months and 110% at 12 
months (41). The same group subsequently published data on a much larger cohort 
of children with >30% TBSA burns showing persistence of this elevated resting 
metabolic rate even up to 2 years post-burn (42). This elevated oxygen consumption 
is due to increased energy expenditure in organs and tissues and following burn, in 
particular the liver and skeletal muscle (192).  
 
A series of stable isotope studies have shown increases in substrate oxidation which 
matches the increases in energy expenditure with 132% increases in fatty acid 
oxidation, 33% increases in glucose oxidation and 41% increases in protein oxidation 
(193). The same study revealed significant alteration in ATP consuming metabolic 
pathways including protein turnover, gluconeogenesis and urea production. In 
addition, increases in substrate cycling were demonstrated following thermal injury, 
with 450% increases in glycolytic-gluconeogenic cycling and 250% increases in 
triglyceride-fatty acid cycling which contributes to thermogenesis and increased 
energy expenditure (194). Substrate cycles exist when opposing non-equilibrium 
pathways are active concurrently and consume ATP to produce heat without net 
changes in the amount of substrate or product. These ATP consuming processes 
have been calculated to account for only 57% of the increase in REE post-burn and 
the remainder has been hypothesized to due to increased Na+-K+-ATPase activity 
and increases in proton leakage across the mitochondrial inner membrane (40). Until 
recently evidence to support this theory has been lacking, but a group from 
Galveston, Texas has shown that in severely burned children with hypermetabolism, 
skeletal muscle mitochondria show a more thermogenic phenotype with two thirds of 
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mitochondrial respiration being devoted to thermogenesis (195). The molecular basis 
for this alteration in mitochondrial physiology is currently under investigation but this 
is felt to be an adaptive response to maintain thermoregulation in the context of major 
skin loss. 
 
1.6.8 Post-burn hyperglycaemia and insulin resistance 
The inflammatory and stress hormone milieu after severe burn injury, with increased 
levels of circulating catecholamines and glucagon, results in altered glucose 
metabolism and hyperglycaemia. This aspect of metabolic dysfunction is particular 
pertinent since both early hyperglycaemia and continued hyperglycaemia post-burn 
is associated with increased mortality (196,197) and higher plasma glucose levels 
are associated with more graft losses (198) and higher incidence of sepsis (196). 
 
Post-burn hyperglycaemia is due to: 1) increased glucose production, via 
gluconeogenesis and glycolysis; 2) Loss of the normally suppressive action of 
exogenous glucose on endogenous glucose synthesis; 3) Reduced rates of glucose 
uptake and utilization due to insulin resistance (199). Even though glucose delivery to 
the peripheral tissue is actually enhanced, there is no proportional increase in 
glucose oxidation to match (192). Hepatic glucose synthesis is augmented by the 
increased availability of gluconeogenic substrates, namely glycerol from lipolysis in 
adipose tissue ((168) and 3-carbon amino acids, mainly alanine, from skeletal muscle 
proteolysis. The amount of lactate liberated from skeletal muscle is far greater than 
that normally present, so the additional source is likely to be through transamination 
of muscle pyruvate through degradation of other muscle branched chain amino acids 
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(200). In addition, there is significant glucose flux directed towards the burn wound 
where fibroblasts, endothelial and immune cells utilize glucose via anaerobic 
oxidation to yield lactate which is then converted back to glucose in the liver via 
gluconeogenesis (201). This cycling of lactate to the liver, conversion to glucose and 
anaerobic metabolism back to lactate is termed the Cori cycle. 
 
Under normal healthy conditions, post-prandial elevations in serum glucose stimulate 
the release of insulin from the pancreatic β-cells, this mediates peripheral uptake of 
glucose in skeletal muscle and adipose tissue and suppresses hepatic 
gluconeogenesis to restore homeostasis. Within the first week post-burn, insulin 
stimulated glucose uptake by tissue is 50% reduced in severely burned children 
compared to healthy controls (202). In children with burns >40% TBSA, although 
blood glucose levels returned to normal levels within 6 months, peripheral insulin 
resistance was still present for up to 3-years post-injury (203). The molecular 
mechanisms underlying post-burn insulin resistance are being unravelled with post-
insulin receptor signaling defects being identified. Catecholamines attenuate insulin-
stimulated glucose uptake by reducing translocation of the GLUT-4 glucose 
transporter to the cell surface membrane in both muscle and adipose tissue 
(204,205). Muscle biopsy studies of burned children taken in the flow-phase (day 7) 
revealed impaired Insulin Receptor Substrate-1 (IRS-1) at its tyrosine binding site 
and inhibition of AKT (206). Wolfe and colleagues have identified an association 
between muscle and liver mitochondrial oxidative dysfunction, altered lipolysis rates 
and impaired insulin signaling affecting insulin-mediated inhibition of hepatic 
gluconeogenesis and peripheral glucose uptake (173,194,206,207). Pro-
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inflammatory cytokines influence post-burn hyperglycaemia both indirectly, via 
induction of stress hormones and directly (TNF, IL-6 and MCP-1) via modulation of 
the insulin signaling pathway (208-210). 
 
1.6.9 Lipid metabolism 
Burn injury results in profound increases in lipolysis in adipose tissue with hydrolysis 
of triacylglycerol (TAG) into free fatty acids (FFAs) and glycerol and this has been 
attributed to elevated levels of catecholamines, in particular β-2 adrenergic 
stimulation. Indeed, lipolysis is consistently reduced in burn injured patients treated 
with beta-adrenergic blockers (169,194). However, this increased availability of FFAs 
is not matched by a sufficiently increased utilization via beta oxidation to generate 
ATP. In starvation states, lipids are the most physiologically desirable source of 
energy as they constitute more than 80% of the fuel stores and fatty acids can be 
readily metabolized by most tissue types. Indeed, in the non-stressed starvation 
state, 90% of FFAs undergo oxidation but following burn injury this figure is 30% 
(199). The remainder of FFAs are involved in futile cycling from breakdown of muscle 
and adipose TGs into FFA and then subsequent re-esterification back to triglycerides 
(TG) or very-low density lipoprotein (VLDL) in the liver (211). This cycling is a result 
of two simultaneous activities of catecholamines: 1) Stimulation of hormone-sensitive 
lipase (HSL) which facilitates lipolysis in adipose tissue and 2) Up-regulation of re-
esterification in the liver (154). 
 
What are the consequences of this deranged lipid metabolism for the severely burn 
injured patient? Firstly, the increased peripheral lipolysis and recycling of fat through 
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the liver, in combination with no proportional increase in beta-oxidation, leads to 
increased storage of TG in hepatocytes. This is compounded by low VLDL secretion 
which is unresponsive to increases TG synthesis (212). Pathological and 
spectroscopic studies of burned children have shown that by 1-week post-burn, 
hepatic TG (HTG) was increased 3-5 fold above normal (213-215). This fatty 
infiltration of the liver has been shown to be associated with increased incidence of 
infection, sepsis and poor outcome (216). A prospective study of severely burned 
children has shown profound hepatomegaly occurs post-injury, with liver size being 
185% of predicted at 1 week and peaking at 2 weeks but with increased size for up to 
12 months. This was associated with prolonged liver dysfunction as measured by 
hepatic protein synthesis for 12 months post-injury (217). Both hepatomegaly and 
hepatic steatosis were associated with increased mortality in a rat 40% TBSA burn 
model (218). In a recent study, children with severe burns were stratified into three 
lipid metabolism groups according to plasma levels of FFA and TGs. The group with 
elevated TGs demonstrated significantly increased liver size over the first month. 
Moreover the study also highlighted that this group of patients had significantly worse 
outcomes in terms of mortality, MOF and LOS in the ICU (219). 
 
As discussed previously, patients with major burn injury develop significant peripheral 
insulin resistance, leading to hyperglycaemia and its associated complications 
including increased skin graft loss and sepsis (196,198). Studies in type 2 diabetes 
mellitus (T2DM) have implicated derangements in lipid metabolism and mitochondrial 
dysfunction in the development of insulin resistance and there is some evidence to 
suggest similar mechanisms are at play following burn injury (207). Indeed, animal 
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studies carried out by Cree and colleagues have shown that following burn injury the 
basal palmitate oxidation rate is reduced by 50% during hyperinsulinaemia and that 
palmitate oxidation correlated with the degree of insulin sensitivity suggesting the two 
are related (220). Initial hypotheses were that reduced fatty acid oxidation was 
related to the inhibition of carnitine palmitoyltransferase enzymes (CPT) 1 or 2, which 
are required for combining palmitate with carnitine allowing translocation across the 
mitochondrial membrane. However, the group found that mitochondrial oxidation of 
both glucose and palmitate was reduced, suggesting more generalized mitochondrial 
dysfunction (221).  
 
The molecular mechanisms linking altered lipid metabolism and insulin resistance 
post-burn remain elusive. One area of focus has been on increased levels of 
intramyocellular lipids (IMCL), which have been shown to be associated with insulin 
resistance in healthy humans (222,223) and offspring of type 2 diabetic patients 
(224). Using in-vivo and ex-vivo proton NMR spectroscopy, Astrakas et al., showed 
that IMCLs accumulate in murine myocytes following burn injury and this was 
associated with apoptosis and mitochondrial dysfunction (225). The same group went 
on to show in their murine burn model that IMCL levels correlated significantly with 
elevated plasma FFAs. In the same animals, significant downregulation of gene 
expression of Glut4, Insulin receptor substrate-1 (IRS1) and peroxisome proliferator-
activated receptor coactivator-1b (PPARl coactivator-1b or PGC-1b) were observed. 
PGC-1 coactivators plays a critical role in glucose, lipid and energy homeostasis and 
PGC-1b is an upstream regulator of the IRS-1 gene. The authors of the study 
conclude that IMCLs are a useful metabolic biomarker post-burn, in particular of 
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insulin resistance. They hypothesise that PGC-1b is a potential link between 
increased plasma FFAs, accumulation of IMCL and altered insulin signaling leading 
to insulin resistance post-burn. More recent IMCL research suggests that elevated 
IMCL levels are not sufficient alone to disrupt insulin signaling, however the specific 
composition of the IMCL lipid droplets may be more important as they may yield toxic 
lipid signaling metabolites. Such metabolites that have been implicated in the 
development of insulin resistance include long-chain acyl CoAs, diacylglycerol 
(DAG), phosphatidic acid and ceramides (226). 
 
1.6.10 Protein-amino acid metabolism 
The composition of the human body may be divided into the fat containing 
component, or fat mass and the non-fat containing component, or lean body mass 
(LBM), comprising 25% and 75% of the human body weight respectively. Protein 
makes up 20% of the LBM component and the majority (60%) of the protein content 
is found within skeletal muscle (227). During health there is a dynamic relationship 
between whole body protein breakdown and protein synthesis resulting in a net 
protein balance (228). In contrast to fat, which serves as our major energy store, 
there are no intracellular stores of amino acids, rather they are all incorporated into 
functional proteins. During non-stressed prolonged starvation, metabolic adaptations 
in tissues result in a switch from glucose as the major fuel to fatty acids and ketone 
bodies, thus limiting protein degradation and loss of function (229). The severity of 
loss of LBM in chronic illness and malnutrition states correlate with increased 
morbidity and mortality with just 10% loss of LBM resulting in impaired immunity and 
increased susceptibility to infection and 40% resulting in death (Table 4.) (199,230). 
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Lean body mass 
(% loss) Complication Mortality (%) 
10 Impaired immunity, increased infection 10 
20 Decreased wound healing, failure to wean 30 
30 Too weak to sit, pressure sores, pneumonia 50 
40 Death, usually from pneumonia 100 
 
Table 11-4: Complications arising due to catabolism and loss of lean body mass (LBM) (Assuming 
 
Burn injury results in a shift of net protein balance in favour of breakdown leading to 
skeletal muscle catabolism and loss of LBM with the consequences of immune 
suppression and impaired wound healing (231), growth disturbance for up to 2-years 
in children (232), delayed rehabilitation and increased mortality (233). Clinical 
parameters that influence the degree of skeletal muscle catabolism include 
increasing burn size, admission weight, time to burn wound excision, the extent of 
hypermetabolism and the presence of sepsis (234). Studies using isotope tracer 
labelled amino acids have demonstrated that burn injury brings about significant 
increases in skeletal muscle protein synthesis by 50%, but this is outstripped by 
protein breakdown which is increased by 83% (235). The same studies also showed 
that despite a hyperdynamic circulation and increased delivery rate of amino acids, 
the muscle transmembrane amino acid uptake was reduced by 50-63%. However, 
outwards transmembrane transport was elevated  in burn patients, facilitating their 
export to be delivered to other tissues (235). 
 
Is this protein catabolism a maladaptive or useful response to injury? It is 
hypothesized that the mobilization of amino acids from skeletal muscle protein post-
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injury is an adaptive response with the goal of providing amino acid substrates for 
wound healing (Figure 5.) (228). Evidence to support this comes from a study in 
which 10 patients with >40% TBSA burns were subjected to assessment of protein 
kinetics, using tracer labelled phenylalanine, in skeletal muscle, burn wound and 
skin. They demonstrated that there was a net release of amino acid from muscle but 
a net uptake by the wound. Moreover, protein synthesis rates were higher in the 
wound compared to unburnt skin and skeletal muscle (236). In addition to this, 
skeletal muscle catabolism may play a role in providing amino acid substrates, such 
as alanine, for hepatic gluconeogenesis. The rate of alanine appearance in the blood 
is twice that of healthy controls in children with severe burns (237).  
 
Skeletal muscle protein catabolism post-burn, persists well beyond the time of wound 
closure and in a cohort of children with >40% TBSA burns. Hart et al., showed that 
whole body and cross-leg nitrogen balance was profoundly negative with 
concomitant loss of LBM at 6 and 9 months post injury, long after wounds had fully 
healed. Between 9 and 12 months post-injury, LBM increased, protein breakdown 
decreased and protein balance improved (41). These data could be used to argue 
against the wound protein accretion model, however it is possible that there are 
ongoing protein requirements for scar remodeling or perhaps this aspect of metabolic 
dysfunction simply persists in the presence ongoing inflammation and endocrine 
dysfunction that has been demonstrated for a long as 3 years post-burn (42). 
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Figure 11-5. Proposed theory for redistribution of protein with flux from skeletal muscle to the burn 
wound, donor sites and liver. Adapted from Porter et al., 2013 (228). 
 
1.6.11 Other consequences of the HMR for the burn patient 
It is clear that the hypermetabolic response to thermal injury is complex and involves 
a number of areas of metabolism and a range of different tissues. In addition to the 
profound effects on protein, lipid and glucose metabolism other organ systems 
affected by post-burn hypermetabolism include the heart, liver, haematopoietic 
system, immune system and bone metabolism. Longitudinal studies have shown in 
burned children heart rates, cardiac output, cardiac index remained significantly 
elevated above control ranges for 12 months (42). In the same study, ultrasound 
scanning revealed that hepatomegaly occurs with an average 75% increase in liver 
size compared to healthy controls. Fatty liver infiltration has been demonstrated in 
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burn victims as autopsy and is associated with increased incidence of sepsis and 
mortality (216). Bone and mineral metabolism is also impaired with 
hypoparathyoidism, hypocalcaemia, hypophosphataemia and compromised vitamin 
D metabolism (238). 
 
1.6.12 Modulation of the HMR 
 
Severe thermal injury thus results in a profound and prolonged inflammatory and 
hypermetabolic response, which although aimed at wound healing and recovery from 
the insult, may have deleterious effects contributing to adverse outcomes and 
mortality. There has therefore been a strong focus within burn care research, on 
trying to ameliorate the hypermetabolic response. Strategies to achieve this include 
prevention of infection and sepsis, early excision of the burn eschar and wound 
closure, nutritional support, environmental warming to thermal neutral temperature 
(28-33°C) and various pharmacotherapies (192). Drug treatments studied to date 
include: beta-adrenergic blockade with propranolol (239-241); the use of 
Oxandralone, a testosterone analogue (242-244); insulin (245); recombinant human 
growth hormone (rHGH) (246,247); Insulin-like Growth factor-1 (IGF-1) (248); 
Insulin–like Growth Factor Binding Protein-3 (IGFBP-3) (249); Fenofibrate (250) and 
ketoconazole (251). Undoubtedly, these pharmacological and non-pharmacological 
interventions may have contributed to improved outcomes after severe burn injury, 
however none have been shown to completely abolish the response. Further 
research is needed to unpick the complex nature of the post-burn response and 
identify new therapeutic targets.  
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1.7 Metabolomics to study thermal injury 
1.7.1 Systems biology 
Systems biology is a holistic approach to the scientific study of complex biological 
systems and aims to provide qualitative and quantitative descriptions of their 
emergent properties (252). Rather than studying changes in individual genes or 
molecules, this approach looks simultaneously at all changes across the whole 
interacting network of molecules of functional genes, mRNA transcripts and proteins. 
This global approach is making advances in a number of human diseases and the 
US Glue grant Host Response to Injury program has already given us new insights 
into the complexity of the human response to blunt trauma and thermal injury (51). 
Biomarkers can be utilized to predict, prognosticate, diagnose and monitor disease 
and systems biology is now at the forefront of molecular biomarker discovery. 
Biomarkers are also essential tools in the current drive to develop truly individualized 
healthcare approaches that have the potential to revolutionize the practice of 
medicine and improve outcomes from the treatment of disease. 
 
1.7.2 What is Metabolomics? 
Metabolites are low molecular weight (typically <1.5kDa) organic or inorganic 
biochemicals that participate in metabolic reactions and are either synthesized or 
consumed. They are typically not proteins, but include small peptides and are sub-
divided into polar (e.g. amino acids, carbohydrates) and non-polar metabolites (e.g. 
fatty acids, glycerophospholipids). They may be endogenous or be derived from 
microorganisms in addition to xenobiotic, dietary and other exogenous sources (253). 
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 Metabolomics is a relatively recent addition to the ‘omics’ family and its aim is to 
seek a full quantitative description of all the low molecular weight metabolites in a 
biological system. The metabolome can be thought of as the full complement of all 
metabolites in a system or biofluid and is further sub-categorised into the 
endometabolome (intra-cellular metabolites) and the exometabolome (extra-cellular 
metabolites) (252). Metabolomics also encompasses the study of changes in the 
metabolome in response to biological stimuli or genetic modification (254).  
 
The metabolome falls farthest downstream of genetic variation and the processes of 
gene transcription, protein translation and post-translational modification (Figure 6). It 
is therefore the most sensitive and dynamic indicator of the true functional state 
(phenotype) of a biological system and takes into account the influences of diet, 
lifestyle, drugs, environment and disease. Although there are fewer human 
metabolites (>6500) when compared to the 25,000 functional genes in the genome 
and the 1 million proteins in the proteome, to say metabolomics is easier to apply is 
an oversimplification (252). Advances in the chief analytical platforms used to 
conduct metabolomics experiments, Nuclear Magnetic Resonance (NMR) 
spectroscopy and mass spectrometry (MS), has meant that analysis times are 
measured in minutes and that per sample costs are relatively lower than genomics or 




Figure 11-6. Metabolomics is downstream of other complex biological processes influencing 




1.7.3 Experimental strategies 
Metabolomics studies may be either hypothesis generating or hypothesis testing in 
their approach. If there is limited metabolite data available for a particular organism 
or disease state for example, then an a priori hypothesis cannot be made regarding 
the importance of specific metabolites. In this situation, an untargeted (discovery 
phase or inductive) metabolomics strategy is employed. In the study of human 
disease, such strategies aim to identify either a single biomarker, a panel of 
biomarkers or identify new biological information which can give insight into 
pathophysiological mechanisms (254). Untargeted metabolomics is also called 
metabolic profiling and is a holistic approach is used to obtain the greatest coverage 
of the metabolome. In this approach, sample preparation must maximize the yield of 
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a broad range of metabolites from different classes and advanced analytical 
instrumentation is needed to measure, typically thousands, of metabolites in each 
sample. It is accepted that in order to obtain data on a vast number of metabolites 
from different parts of the metabolic network, there must be some compromise on 
precision and accuracy. With current technology, this means that metabolomics data 
is typically semi-quantitative, allowing relative differences in measured responses 
(rather than concentrations) to be detected (252).  
 
If there is prior information regarding important metabolites or metabolite classes in a 
disease, which may have been gained from a discovery phase study, then a targeted 
metabolomics approach may be used. In this strategy, a much smaller number of 
metabolites, which may be related in terms of class or pathway or measured with a 
high degree of accuracy. Sample preparation is tailored to the metabolite class of 
interest e.g. glycerophospholipids to maximize their yield whilst filtering out as many 
other metabolites as possible. In order to obtain the highly accurate quantitative data, 
internal chemical standards are used where available. With the recognised difficulties 
in performing discovery phase studies, semi-targeted approaches have also been 
developed. In these studies, sample collection, preparation and analysis is geared 
towards generation of highly accurate semi-quantitative or quantitative data for up to 
400 metabolites (255). The advantage here is being able to move more quickly 
towards translational research but the trade-off of this approach is loss of potentially 




1.7.4 Study Design and Metabolomics Workflow 
The study design of a metabolomics study will depend on the research questions and 
whether an untargeted or targeted study is most appropriate. Sample collection is a 
vital part of any metabolomics study and care must to be taken to ensure that 
samples are collected at the same time of day for every sample, to avoid influences 
of diurnal variation in metabolism (256). Samples should be collected in identical 
blood/urine collection tubes and all plasticware and reagents involved in sample 
handling and preparation should be identical throughout the study. Blood samples 
should be processed into serum or plasma as soon as possible after collection and 
stored at -80°C. Sample preparation varies depending on the analytical method to be 
employed, but generally protein containing samples require a deproteinisation step, 
using either organic solvents or ultra-centrifugation (254). An important consideration 
in MS based metabolomics is the use of Quality Control (QC) samples to control for 
instrument variation across runs. This is particularly important if large numbers of 
samples are being run in different batches. In untargeted studies, it is impossible to 
provide internal standards for all metabolites for QC purposes. Instead, the use of 
pooled QC samples, which contain an aliquot of every sample in a run is 
recommended. The pooled QC sample is useful to condition the analytical system, to 
allow signal correction for drift, to assess reproducibility within the experiment and 
allow data integration from multiple batches (254). 
 
After sample analysis, the next steps in the metabolomics pipeline or workflow is data 
processing and metabolite annotation using commercially or freely available 
databases such as the Human Metabolome Database (HMDB) (257). In order to 
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identify which metabolites are important to the research question, groups are 
compared using multivariate statistical modelling techniques designed for very large 
datasets and such as Principle Components Analysis (PCA) and Partial Least 
Squares Discriminant Analysis (PLSDA). Putative biomarkers highly weighted in 
these models can then undergo further confirmatory identification using spectral 
databases, MS/MS fragmentation data or spike in experiments. It has been 
recommended that following discovery phase biomarker studies, study validation is 
undertaken with an independent sample set. Candidate biomarkers emerging from 
these studies are then tested in a cohort validation study with larger numbers of 
subjects (n=>1000), but using targeted assays (252). 
 
1.7.5 Metabolomics analysis platforms 
The two most commonly employed analytical platforms in metabolomics are mass 
spectrometry (MS) and Nuclear Magnetic Resonance (NMR) spectrometry. 
1.7.5.1 Nuclear Magnetic Resonance (NMR) Spectroscopy 
The principle behind Nuclear Magnetic Resonance (NMR) is certain nuclei (1H, 13C, 
14N and 31P) demonstrate non-zero magnetic moments. This means that when 
placed in a magnetic field, these nuclei absorb electromagnetic energy in the radio 
wavelength range and then re-emit this at the same frequency. The frequency of this 
absorption is dependent on the strength of the magnetic field, the type of atomic 
nucleus and the nearby electronic environment surrounding the nucleus. The most 
commonly used type of NMR in metabolomics is 1H-NMR due to hydrogen being 
present in most organic metabolites and the very high abundance (99.98%) of the 1H 
isotope (258). During a 1H-NMR experiment, samples are placed in glass tubes in 
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between two powerful superconducting cryomagnets which bring all protons within 
the sample into alignment. A radiofrequency (RF) pulse signal is transmitted into the 
sample, which is absorbed by protons, altering their magnetization vector. After the 
pulse the vectors return to equilibrium, emitting their absorbed RF energy and this is 
known as free induction decay (FID) which can be measured by a detector. This 
signal is transformed into a frequency using Fourier Transformation (FT) and each 
proton in an organic molecule has a unique frequency or chemical shift which is 
measured in parts per million (ppm) units (254). A typical 1H-NMR spectrum is shown 
in Figure 7 and is a plot of chemical shift on the x-axis and signal intensity on the y-
axis. The area under the NMR spectral peaks is directly proportional to the molar 
concentration of the protons within each compound and highly accurate 
concentrations can be calculated by adding an internal chemical standard such as 
Trimethylsilyl-propanoic acid (TMSP) or 4,4-dimethyl-4-silapentane-1-sulfonic acid 
(DSS) (259).  
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Figure 11-7. Typical 1H-NMR spectrum of a serum sample with key spectral peaks annotated. 
 
1.7.5.2 Mass spectrometry 
In simple terms, mass spectrometry (MS) measures the mass-to-charge ratio (m/z) of 
positively or negatively charged ions formed from the analytes of interest. In the field 
of metabolomics, samples are often complex mixtures of metabolites, necessitating 
the coupling of MS to a chromatographic separation technique such as liquid 
chromatography (LC), gas chromatography (GC) and capillary electrophoresis (CE). 
Liquid-chromatography mass spectrometry (LC-MS) is the most widely used method 
in metabolomics studies due to its ability to separate a broad range of metabolites, 
provide quantitative and structural information and achieve rg/mL sensitivity (260). 
LC allows separation of metabolites based on the rate at which they elute from a 
solid stationary phase within a liquid mobile phase. The stationary phase is a 















and the mobile phase solvent. The polarity of molecules is related to their structure 
and electron charge distribution and this property determines how they interact with 
the stationary and mobile phases. The differing affinities of molecules for the two 
phases determines how fast they will transit through the column, which is termed 
their retention time (RT). Dependent on the classes of metabolites of interest different 
column chemistries can be applied to improve their resolution and reduce peak 
widths.  
 
The most commonly applied column chemistries are reversed-phase (RPLC), which 
employ a non-polar stationary phase (e.g. C18) and mobile phase solvent which is 
aqueous, allowing greatest retention of non-polar metabolites (261). The mobile 
phase can be either of constant composition (isocratic) or the composition may be 
varied during the separation (gradient elution) which improves resolution for complex 
mixtures (262). One of the main issues with RPLC is that polar metabolites, such as 
organic acids or amino acids, are relatively poorly retained and are not well resolved. 
To tackle this, Hydrophilic Interaction Chromatography (HILIC) is increasingly being 
used in metabolomics studies, increasing the coverage of the metabolome, 
particularly the urine metabolome (261). HILIC utilizes a hydrophilic stationary phase 
with gradient elution running from less polar organic solvents to increasingly aqueous 
solvents, thus increasing retention of polar analytes (263). 
 
In standard LC, a number of key factors influence the resolving power of the 
technique including: column length and diameter, particle size, stationary and mobile 
phase chemistry and temperature (252). Advances in the field of liquid 
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chromatography in the 1970’s led to the development of High Pressure Liquid 
Chromatography (HPLC), which combined high pressure pumps with stronger 
columns (264). Further developments led to the introduction of Ultra-High 
Performance Liquid Chromatography (UHPLC) with enhanced separation, greater 
resolution and faster analysis times. UHPLC combines sub 2 µm particle size, short 
length columns and improved instrumentation capable of withstanding high pressures 
up to 15,000 psi (265).  
 
In addition to the various options for the coupled chromatography methods above, 
there are a multitude of MS instrument designs. The key aspects of the MS workflow 
are an ion source which generates charged species from the sample metabolites and 
a mass analyser in combination with a detector to accurately measure the mass of 
each ion species. The exact combination used will depend on the sample type (fluid, 
tissue etc.), the desired mass resolution, accuracy and analysis speed. Ion sources 
for fluid samples include Electrospray Ionisation (ESI) and Atmospheric Pressure 
Chemical Ionisation (APCI). ESI is the most commonly used source in LC-MS 
metabolomics and samples are generally analysed in both positive and negative ion 
modes to optimize results for different metabolite sub-classes (261). The commonly 
used instruments for metabolomics studies include Quadrupole (Q), Triple 
Quadrupole (QQQ), Time-of-flight (TOF), hybrid Q-TOF and ion-trap instruments. 
The QQQ and Q-TOF instruments are advantageous in being able to perform MS/MS 
experiments to gain additional structural information for biomarker elucidation (266). 
In such experiments, intact ions can be fragmented using collision induced 
dissociation (CID) and their mass analysed improving accuracy of metabolite 
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identification (262). Ion trap MS instruments are extremely high resolution and are 
able to trap and accumulate ions of low abundance to permit MS or MSn analyses. 
Two ion traps most useful in metabolomics studies are the Penning trap, used in 
Fourier Transform Ion-cyclotron Resonance (FT-ICR) (267) and the Orbitrap, 
invented by Makarov (268). 
 
1.7.5.3 Comparison of NMR and MS for metabolomics 
 
MS and NMR are able to analyse a range of sample types including biofluids and 
tissues in-vivo or ex-vivo. GC-MS extends the capability to gas analysis, useful for 
example in breath analysis. NMR has a number of advantages as an analytical 
platform for metabolomics. It is highly reproducible allowing cross instrument and 
inter-lab studies to be performed. It provides highly accurate quantitative 
measurement of a broad range of metabolites with the use of a single internal 
standard. Its sensitivity is not affected by the hydrophobicity or pKa of samples and 
provides large amounts of structural information for compounds. NMR is non-
destructive to the sample, allowing multiple replications of experiments and has 
relatively quick sample preparation and data acquisition. In MS the sample is 
destroyed during analysis and interacts with the instrument causing response 
variation during runs. It is therefore vital to include quality control (QC) procedures to 
adjust for this variability.  
 
In untargeted studies MS has a number of advantages over NMR which has lower 
resolution so is most useful to detect the most abundant metabolites in samples. MS 
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provides increased coverage of the metabolome, being able to detect a large mass 
range from 20 – 1500 Da and typically identify hundreds to thousands of metabolites 
per sample compared to <100 by NMR. Advances in NMR probe technology, higher 
frequency instruments and 2D-NMR techniques are however increasing the 
sensitivity of this technique (252). The compromise of increased metabolome 
coverage is less accurate quantification of metabolites, in untargeted analyses data 
are typically semi-quantitative offering only relative concentrations. For accurate 
quantification in MS, internal standards are required for each metabolite of interest.  
 
1.7.6 Metabolomics studies of thermal injury 
Metabolomics approaches have been used to study burn injury and to date at total of 
four studies have used untargeted strategies. The first study was published in 2009 
by Righi and colleagues, who applied a novel solid state NMR technique called 
adiabatic Total through Bond Correlation Spectroscopy (TOBSY) to study metabolic 
changes in a murine hind-limb burn model (269). In this study mice were subjected to 
a 5% TBSA hind-limb burn and underlying muscle and contralateral healthy muscle 
was harvested 3-days post-injury. They demonstrated elevated levels of intra-
myocellular lipids (IMCLs) in muscle from burned mice consistent with known TAG-
FFA cycling and lipolysis following burn injury. They also showed elevated levels 
amino acid anti-oxidants, glutathione, taurine, hypotaurine, which they speculate is 
related to increased mitochondrial stress and ROS production post burn. Other 
findings of the study include elevated glycine, phosphocreatine and ceramide in 
muscle tissue from the burned limb, the latter being an apoptotic second messenger, 
possibly reflecting burn induced muscle apoptosis. Watanabe and colleagues  in 
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2011, aimed to use NMR metabolomics to study post-burn muscle metabolism in an 
in vitro myotube model (270). The study focused on muscle tissue metabolic 
responses to inflammatory cytokines (TNF-alpha and IFN-gamma) and the effects of 
intervention with des-acyl ghrelin. It is thus difficult to evaluate whether these findings 
are relevant to the complex systemic inflammatory and hypermetabolic response that 
occurs in-vivo following burn injury. 
 
Human metabolomics studies of thermal injury have been lacking until the recent 
publication of a 1H-NMR metabolomics study from a group in China (271). This study 
analysed blood samples from a cohort of 21 patients with severe burns (mean burn 
size 77% TBSA) and used multivariate analysis techniques to compare changes in 
the plasma metabolome with data from just 3 healthy volunteers. The study identified 
12 metabolites significantly discriminating between burn injured subjects and controls 
and the most significant of these were a-ketoisovaleric acid, 3-methylhistidine and b-
hydroxybutyric acid. Despite some experimental flaws in the study and no attempt to 
correlate changes in the metabolome with the outcomes of their study group, the 
study shows the potential of metabolomics as an approach to study burn injury.  
 
Only one study has used metabolomics as an approach to the study of sepsis post-
burn. Liu and colleagues used UPLC-Q-TOF MS metabolomics with the aim of 
identifying a biomarker panel diagnostic of sepsis in a rat 30% scald injury model 
(272). Caecal ligation puncture (CLP) was used as a model of polymicrobial sepsis. 
They performed metabolomics analysis of plasma samples and used multivariate 
analysis techniques to compare four groups: sham injury, burn injury, sepsis and 
 82 
combined burn and sepsis. Univariate analysis showed a total of 9 metabolites that 
were significantly elevated in groups compared to sham injury. The most promising 
sepsis biomarker metabolites from the study were uracil and nitrotyrosine, both being 
elevated in sepsis and sepsis/burn injury but not elevated in burn injury alone. There 
have been no human metabolomics studies specifically looking at sepsis in the 
context of burn injury, but a number of studies have been published recently using 
the approach to study human sepsis. These studies have been conducted in 
neonates (273), children (274), adults with trauma (275) and adults with pneumonia 
(276-278). Metabolomics approaches have shown promise in identifying candidate 
biomarkers in the diagnosis of human septic shock (279,280) and in predicting 
mortality from human sepsis (277,281,282). 
 
1.8 Summary and Thesis aims 
Survival following severe burn injury has improved significantly over the last 70 years 
(283) and some argue survival gains have plateaued (284), though mortality in older 
patients remains stubbornly high. There is now an increasing shift towards focusing 
on reducing morbidity and other complications of burn injury. Adults and children with 
>20% TBSA burns are still experiencing high rates of infection and multiple organ 
failure (285) and sepsis remains a significant problem with high mortality (286). A 
step change is required to push improvements in burn care further and to improve 
the prognosis for older burn patients. Recent systems biology and omics based 
studies are just starting to increase our understanding of the complex systemic 
response to injury (51). The hypermetabolic response to injury and subsequent 
immuneparesis is responsible for a significant part of the morbidity associated with 
major burns and current treatments cannot fully ameliorate these effects. In order to 
 83 
develop more effective therapies, for this profound disturbance of metabolism and 
immunity, new holistic approaches are needed to gain new insight. Metabolomics is 
one approach that is ideally suited to look at global changes in metabolism following 
thermal injury and reveal clinically useful diagnostic and prognostic biomarkers. No 
studies to date have used this technique to study the early post-burn response in 
relation to outcomes and to look at longitudinal changes weeks to months post-injury. 
The technique is also an important tool in the armamentarium to identify novel 
sensitive and specific biomarkers of disease and these are so desperately needed to 
improve the early recognition of sepsis in the burn injured patient.  
 
 
The aims of this thesis are therefore to: 
1. Determine the impact of age on clinical outcomes for burn injured patients via 
a retrospective analysis of outcomes and epidemiology of a population of older 
burn injured patients admitted to our regional burns centre; 
2. Investigate the early changes in the metabolome following thermal injury in 
young and old adults with severe burns and their association with clinical 
outcomes; 
3. Investigate the key longitudinal changes in the metabolome following severe 
thermal injury in young and old adults to identify new biological information 
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2 Chapter 2: Outcomes of burn injury in the elderly 
2.1 Introduction 
The United Nations estimate that the proportion of the world population aged over 60 
years will triple to reach two billion by 2050 (287). In the UK, the proportion of the 
population aged >65 years is currently 17 % and it is predicted that this will rise to 23 
% by 2035. Moreover, the ‘oldest old’, those 85 years and over, are the fastest 
growing group with a projected two-and-a-half-fold increase in size of this age group 
to 3.5 million by 2035 (288).  
 
An increasingly ageing population will have substantial global implications on health 
care systems and burn care provision. The elderly are particularly susceptible group 
to sustaining burn injury due to impairments in judgment, co-ordination, balance and 
reaction times together with reduced ability to escape from harm . Following their 
injury, lower physiological reserves and co-morbid disease may complicate their 
management and recovery [4]. Age itself is a major prognostic factor after burn injury. 
After controlling for percentage total body surface area (TBSA) burned and the 
presence of inhalation injury, it is a powerful independent predictor of mortality [5-7]. 
Age has therefore been included in most prognostic scoring systems of burn survival 
[8-11]. Elderly patients, who survive their injury, experience significantly increased 
morbidity, particularly from infectious complications such as pneumonia [12]. They 
are more likely to stay in hospital longer, are discharged back home less often and 
an age dependent increase in the use of post-hospitalization resources has been 
shown [13-14]. 
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Survival following burn injury has improved in recent decades due to advances in 
burn care; including resuscitation; early excision and wound closure; nutritional 
support; skin substitutes; and modulation of the hypermetabolic response [15]. 
However, improvements in survival are lagging behind in the elderly [15-19]. Prior to 
embarking on a prospective study investigating the pathophysiology of the response 
to burn injury in elderly patients, we wanted to explore the demographics, 
epidemiology and outcomes of a recent cohort of such patients. We previously 
published a small cohort of elderly burn admissions admitted between 1999 and 
2003, which showed an observed mortality rate of 34.9 % [20].  
 
The aim of this study was therefore to:  
1) Determine admission demographics and outcomes of a recent cohort of elderly 
patients admitted to the Birmingham Burn Centre with burn injury. 
2) Compare epidemiological data and outcomes for elderly burns admissions during 
the 2004-2012 period with the previously published cohort. 
 
2.2 Materials and methods 
2.2.1 Study Group 
Patients aged 65 years and above admitted to the Birmingham Burns Centre with 
acute burns from 1st January 2004 to 31st December 2012 were identified from the 
International Burn Injury Database (IBID) and Hospital Episode Statistics (HES). 
Between January 2004 and June 2010, all patients were admitted to the Burns 
Centre based at Selly Oak Hospital, Birmingham, UK. For the remainder of the study, 
patients were admitted to the Burns Centre at its location in the new Queen Elizabeth 
Hospital Birmingham (QEHB), Birmingham, UK. Patients admitted with non-
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cutaneous burns, skin-blistering conditions and those with no medical notes available 
for review were excluded. Additionally, patients in whom a comfort care decision was 
made within 24hrs of their admission were excluded from the analysis. The exclusion 
criteria for the study group was identical to that used in the previously published 
cohort of elderly burn patients treated between 1999-2003 [20]. 
 
2.2.2 Patient management 
The aspects of patient management described below have not changed between the 
two study periods. However, during the second period of study, clinical guidelines 
were formalized for the treatment of inhalation injury, nutritional support, blood 
product transfusion and thromboprophylaxis. The fluid resuscitation calculation 
employed was the Parkland formula (4mLs/kg/% TBSA) for all patients with burns 
≥15 % TBSA, however in cases where there was a history of cardiovascular disease, 
balanced fluid resuscitation was initiated at 2mLs/kg/% TBSA. Invasive central 
venous pressure and arterial blood pressure monitoring was utilized for all patients 
requiring fluid resuscitation. Target urine output was 0.5ml/kg/hr.  
 
Decisions regarding excisional surgery were made once a full medical history was 
obtained from informants and a review by a Consultant anaesthetist specializing in 
burn care. Patients with full thickness burns who were deemed unsuitable for surgical 
excision in the first two weeks post-injury were treated with daily topical application of 
silver sulfadiazine (SSD)/cerium nitrate. The goal of this approach is to maintain a dry 
adherent eschar until the patient has been medically optimized for excisional surgery. 
Inhalation injury was primarily diagnosed on clinical grounds if there was history of 
entrapment in a house or industrial fire or explosion in an enclosed space together 
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with clinical signs e.g. carbonaceous sputum, respiratory symptoms and signs and 
change in voice [21]. However, patients requiring mechanical ventilation had further 
confirmation of the diagnosis by fibre-optic bronchoscopy according to the minimum 
presence of carbonaceous deposits and erythema within the bronchi [22]. All 
decisions regarding the withdrawal of active care were made by a minimum of two 
Consultants, at least one being a Consultant Burn surgeon. 
 
2.2.3 Data collection and statistical analysis 
Data on patient demographics, burn injury details, co-morbidities, timing of surgery, 
complications and outcomes, including length of stay (LOS) and in-hospital mortality 
was extracted from the medical notes and IBID. The revised Baux score [8], 
Abbreviated Burn Severity Index (ABSI) score [10], Belgian Outcomes in Burn Injury 
(BOBI) [11] score were calculated for each patient along with a Canadian Study of 
Health and Aging (CSHA) Clinical Frailty Scale score [23]. Data was collated in a 
Microsoft® Excel® spreadsheet (Microsoft® Corporation, Redmond, WA) and 
statistical analysis was performed using PASW Statistics version 18 (SPSS Inc., 
Chicago, Illinois, USA). Data was obtained from the previously published 1999-2003 
cohort [20] and comparisons were made with the current data set.  
 
 The lethal area 50 (LA50), a measure of burn survivability for the TBSA at which 
there will be 50 % mortality, was calculated using both probit analysis and logistic 
regression analysis as previously described [15]. In brief, probability unit (probit) 
analysis uses data on a dichotomous outcome and one or more explanatory 
variables to predict the outcome probabilities based on the assumption that their 
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probits are linearly related to the values of the explanatory variables. The logit of a 
probability p is the value of log (p/1-p). Binary logistic regression analysis uses data 
on a dichotomous outcome and one or more explanatory variables to predict the 
outcome probabilities based on the assumption that their logits are linearly related to 
the values of the explanatory variables. A single logistic regression analysis, with age 
and TBSA burn as continuous explanatory variables, was performed. To enable valid 
comparisons with previous data this study follows the format of previous studies 
produced by this group. 
 
Categorical variables were compared using Fisher’s exact test and continuous non-
parametric variables were compared using a Mann-Whitney U-test. To assess the 
effects of age, TBSA and inhalation injury, we constructed multi-variable logistic 
regression analysis models. Odd ratios were also calculated using these models. 
Data is presented as medians and interquartile ranges (IQR) unless stated. Statistical 




A total of 250 patients aged 65 years and above were admitted during the study 
period. After 22 exclusions (12 patients had a burn injury that was deemed non-
survivable and medical case notes were unavailable for 10 patients) case-notes were 
reviewed for the remaining 228 patients (116 males and 112 females) (Figure 2.1). 
Females were significantly older than males (80.6 years vs. 76.9 years, p=0.047), but 
there was no significant difference in burn size. The extracted data is summarized in 
Table 2.1. Co-morbid disease was present in 185 patients on admission (Figure 2.2a) 
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and the median CSHA Clinical Frailty Scale score was 3.5 (IQR 3-4). The most 
common mechanism of injury was by flame (40%) followed by scald (26%) and 




















Figure 2-1. Scatter plot of percentage total body surface area (TBSA) burn versus age for 
elderly burn injured patients admitted during the study period. Black markers represent 
survivors and white markers represent non-survivors. Solid black line indicates the patient age + 






















Figure 2-2 (a) Recorded co-morbidities and (b) aetiology of burn injury in elderly burn patients 
admitted from 2004-2012. HTN = hypertension; DM = diabetes mellitus; IHD = ischaemic heart 




1999-2003 2004-2012 P-value 
Number of patients n 63 228 
 
Male n (%) 28 (44) 116 (51) 0.395 
Age years 81 (74-87) 79 (71-84) 0.095 
TBSA % 7 (5-11) 5 (2-10) <0.001 
Co-morbidities % 87 81 0.35 
Inhalation injury n (%) 9 (14) 29 (13) 0.833 
ABSI score /18 7 (6-8) 7 (6-8) 0.753 
BOBI score /10 3 (2-3) 3 (2-3) 0.900 
Revised Baux score * 91 (83-97) 86 (78-96) 0.021 
Surgery n (%) 30 (48) 113 (50) 0.887 
Time to 1° excision days 6 (4-10) 5 (2-8) 0.046 
SSD/CN dressings n (%) 18 (28) 62 (27) 0.874 
 
Table 2-1. Comparison of admission characteristics, surgical treatment and length of hospital 
stay (LOS) between the two cohorts 1999-2003 and 2004-2012. All values are medians with inter-
quartile ranges (IQR), or proportion as a percentage in parentheses. TBSA = total body surface area; 
ABSI = abbreviated burn severity index; BOBI = Belgian outcome in burn injury; SSD/CN = Silver 






























2.3.2 Outcomes in the study group 
The observed mortality for the study group was 14.9 %. Using probit analysis, the 
LA50 for the study group was 26 % TBSA (95% CI 17-89 %). The highest mortality 
(50%) was seen in patients with burns >20% TBSA. Mortality was lower in the 
surgically treated group compared to those that were managed non-surgically. Of the 
192 survivors living independently pre-injury, 70 % were discharged successfully 
back home, 15 % were transferred to other hospitals to complete their care and the 
remainder required intermediate or higher level care. Complications occurred in 26 % 
of patients with 129 recorded complications in total: the most common being 
pneumonia (11 %) and urinary tract infection (6 %).  
 
Parameter  1999-2003 2004-2012 P-value 
LOS survivors days 17 (7-33) 12 (4-30) 0.094 
LOS survivors/% 
TBSA 
days 3.1 (1.0-5.7) 2.4 (1.3-5.2) 0.987 
Mortality     
Overall n (%) 22/63 (34.9) 34/228 (14.9) 0.001 
Burn TBSA 0-5%: n (%) 1/19 (5.3) 6/121 (5.0) 1.000 
Burn TBSA 5-10%: n (%) 6/27 (22.2) 7/52 (13.5) 0.350 
Burn TBSA 10-20%: n (%) 11/12 (91.7) 14/41 (34.1) <0.001 
Burn TBSA >20%: n (%) 4/5 (80.0) 7/14 (50.0) 0.338 
Surgical mortality  n (%) 7/30 (23.3) 13/113 (11.5) 0.135 
Non-surgical mortality  n (%) 15/33 (45.5) 21/115 (18.3) 0.003 
 
Table 2-2. Comparison of outcomes between 1999-2003 and 2004-2012 cohorts. LOS = 
Length of stay; TBSA = Total body surface area 
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The commonest causes of death were respiratory failure, pneumonia and sepsis 
(Table 2.3). Non-survivors were significantly older, had a larger overall TBSA and a 
greater proportion sustained inhalation injury compared to the survivors (Table 3). 
There was an association between increased TBSA and mortality with the OR 
increasing for each successive TBSA group (Figure 2.3). As well as this, the mortality 
was higher in the inhalation injury group (52 %) than in the non-inhalation injury 
group (10 %; p<0.001). Using the same multivariate model, inhalation injury was 
associated with an OR of 10.8 (95% CI: 3.8-30.8). Almost equal numbers of patients 
underwent surgical management (n=113) with excision and skin-grafting compared to 
non-surgical management (n=115), which are summarized in Table 4. The LA50 
values calculated for the age-groups 65-74 years, 75-84 years and over 85 years, 
showed an inverse relationship to age as expected (Figure 2.4). 
 
Primary cause of death n % 
Respiratory failure 10 29 
Pneumonia/chest sepsis 9 26 
Sepsis other 4 12 
Multiple-organ failure 2 6 
Major burns 2 6 
Acute renal failure 2 6 
Unknown 2 6 
Cardiac failure 1 3 
Myocardial infarction 1 3 
Perforated duodenal ulcer 1 3 
 






Parameter  Survivors Non-survivors P-value 
Number of patients n 194 34 
 
Male:female n:n 99:95 17:17 
 
Age years 77 (70-83) 84 (77-89) 0.001 
TBSA % 5 (2-9) 14 (7-20) <0.001 
BSA:FT % 1 (0-3) 7 (0-14) <0.001 
Inhalation injury n (%) 14 (7) 15 (44) <0.001 
ABSI score /18 7 (6-7) 8 (7-9) <0.001 
BOBI score /10 3 (2-3) 2 (2-3) 0.620 
Revised Baux score * 84 (76-93) 103 (96-112) <0.001 
Patients treated 
surgically 
n (%) 100 (52) 13 (38) 0.193 
Injury to excision days 5 (2-8) 3 (1-6) 0.759 
 
Table 2-4: Comparison between burn survivors and non-survivors in the 2004-2012 cohort. 
All values are medians with inter-quartile ranges (IQR), or proportion as a percentage in 
parentheses. TBSA = total body surface area; BSA:FT = body surface area: full thickness; ABSI = 
abbreviated burn severity index; BOBI = Belgian outcome in burn injury. 
 
 
Figure 2-3. Observed mortality rate stratified by burn size group (percentage TBSA). Odds ratios 
of mortality (OR) calculated by multi-variable logistic regression as compared to the smallest burn-size 
























Parameter  Surgical Non-surgical P-value 
Number of patients n 113 115 
 
Age years 75 (69-83) 81 (74-86) <0.001 
TBSA % 7 (3-12) 4 (2-7) <0.001 
BSA:FT % 2 (1-4) 0 (0-2) <0.001 
Co-morbidities % 84 85 0.856 
No. co-morbidities n 2 (1-3) 2 (1-3) 0.086 
Inhalation injury n (%) 16 (14%) 13 (11%) 0.556 
ABSI score /18 7 (6-8) 7 (6-7) 0.007 
BOBI score /10 3 (2-3) 3 (2-3) 0.676 
Revised Baux score * 85 (78-96) 88 (78-97) 0.427 
Mortality % 11.5 18.3 0.193 
LOS days 17 (9-35) 7 (2-14) <0.001 
LOS/% TBSA days 2.8 (1.7-5.5) 1.5 (0.8-4.0) <0.001 
 
Table 2-5. Comparison of burns patients treated surgically compared to non-surgical 
management 2004-2012 cohort. All values are medians with inter-quartile ranges (IQR), or 
proportion as a percentage in parentheses. TBSA = total body surface area; BSA:FT = body surface 
area: full thickness; ABSI = abbreviated burn severity index; BOBI = Belgian outcome in burn injury; 
LOS = length of stay. 
 
Figure 2-4. Comparison of logistic regression (dotted lines) and probit analysis (solid lines) for 
mortality probability in different age-groups (85+ years, 75-84 years and 65-74 years) when related to 

























2.3.3 Comparison to previously published data 
The admission characteristics of elderly burn injured patients between the two study 
periods (1999-2003 and 2004-2012) were comparable in terms of age and gender 
(Table 2.1). The average burn size was smaller in the more recent cohort reflected in 
a significant difference in revised Baux scores (p=0.021). The aetiology was similar 
with flame and scalds predominant in both cohorts, however an increased incidence 
of flash burns was seen (2 % versus 11 %; p=0.014). Burns to the head and buttocks 
became more common, but burns to the lower limb and perineum became less 
frequent. The overall observed mortality decreased from 34.9 % to 14.9 % (p=0.001). 
When stratified into burn size groups (minor (<5 % TBSA), small (5-10 % TBSA), 
medium (10-20 % TBSA) and large (≥20 % TBSA)), reductions in mortality were seen 
in all groups, but the difference was significant in the medium burn size group 
(p<0.001). Mortality reduced in surgically treated patients from 23 % to 11.5 % 
(p=0.135) and in non-surgically managed patients from 45.5% to 18.3% (p=0.003) 
the difference being statistically significant in the latter group. Comparing surgical 
management, there was no change in the proportions of patients managed surgically, 
however the median time to first excisional surgery reduced from six to five days 
(p=0.046). There was no significant difference in the proportions of patients treated 
with topical silver sulfadiazine-cerium nitrate, which includes patients who required 
late surgery after eschar separation. 
 
2.3.4 Comparison with previously published studies 
A literature search of the MEDLINE and EMBASE journal databases was conducted 
using OVID (https://ovidsp.ovid.com/) and using the keywords ‘elderly’, ‘geriatric’, 
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‘aged’ AND ‘burn*’ OR ‘thermal injury’ OR ‘burn injury’. Articles published in English 
after the year 2000 to present day were reviewed and key data extracted. Articles 
that did not include key demographic (lower age cut off and burn size) and mortality 
outcome data were excluded. A total of 16 studies were identified that met the 
inclusion criteria (table 2.6) and the lower age cut-off used varied across studies from 
55-75 yrs. The smallest cohort reported included only 59 patients (289) and the 
largest was a study from the US National Burn Repository database (NBR) of 23,180 
patients (6). Flame burn was the common mechanism of sustaining a burn in 69% 
(11/16) of the studies. Only two studies reported scald as the most common 
mechanism and both were from China (289,290).  The average burn size reported 
was very variable and ranged from 7.6% TBSA in a study from Northern Ireland (291) 
up to 23.0% TBSA in a large study from the USA (292). Mortality rate was the only 
outcome that was consistently reported across all studies and ranged from 48% in a 
study from Chile (141) to 6.8% in at study from China (289). 
 
Comparing our 2004-2012 cohort to other studies from other developed world burn 
centres, our mean burn size is one of the smallest published, but similar (7.5 vs 7.6 
% TBSA) to a cohort published in 2009 by a group in Northern Ireland. Our observed 
mortality is also comparable to this cohort and also other developed world cohorts 




Table 2-6. Summary demographic and mortality data for published studies of elderly burn injured patients since 2000, subdivided by age group cut 









injury (%) TBSA (%) 
Mortality 
(%) 
(a) Wearn et al, 2014 2004-2012 UK ≥65 y 228 78.5 13 Mean 7.5 14.9 
 Albornoz et al, 2011 [25] 2006-2009 Chile >65 y 66 -- 28 Median 13.0 48.0 
 Khadim et al, 2009 [26] 1996-2005 UK ≥65 y 143 76.7 7 Mean 7.6 12.5 
 Lumenta et al, 2008 [27] 1990-2003 France ≥65 y 265 76.5 17.7 Mean 17.1 30.6 
 Macrino et al, 2008 [28] 2003-2006 USA ≥65 y 179 75.4 23 Mean 10.6 16.0 
 Rao et al, 2006 [20] 1999-2003 UK ≥65 y 63 80.4 14 Mean 9.9 34.9 
 Chang et al, 2005 [29] 1998-2002 USA >65 y 94 76.1 21.3 Mean 15.5 23.4 
(b) Lionelli et al, 2005 [30] 1972-2000 USA ≥75 y 201 81.0 27 Mean 23.0 47.0 
 Mahar et al, 2008
 
[31] 2002-2006 Australia ≥70 y 80 79.5 19 Mean 15.5 18.8 
(c) Liu et al, 2013 [32] 2003-2009 China ≥60 y 103 69.5 13.6 Mean 19.7 11.7 
 Yin et al, 2010 [33] 1996-2004 China ≥60 y 201 69.3 -- Mean 11.7 8.0 
 Wong et al, 2007 [34] 2000-2005 China ≥60 y 59 -- -- Mean 12.0 6.8 
 Mabrouk et al, 2003 [35] 1995-2001 Egypt ≥60 y 97 64.5 12 Mean 21.4 31.9 
 Wibbenmeyer et al, 2001 [17] 1977-1996 USA ≥60 y 308 71.5 16 Median 13.0 30.2 
 Ho et al, 2001 [36] 1993-1999 China ≥60 y 94 73.8 4.3 Mean 13.3 7.4 
(d) Pham et al, 2009 [13] 1991-2005 USA ≥55 y 23,180 -- 11.3 Mean 9.6 17.1 
 Lundgren et al, 2009 [37] 1999-2003 USA ≥55 y 325 68.0 11.3 Mean 14.9 18.5 
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2.4 Discussion 
The Birmingham Burns Centre is a high-throughput burn centre in the UK admitting 
approximately 450 patients with burn injuries every year and has a long pedigree of 
publishing analyses of its mortality data [15,24-26]. The main finding from our study 
is an improvement in observed mortality compared to the previously published cohort 
(1999-2003). The mortality rate was reduced in all TBSA groups. This improvement 
follows the continued trend of improved burn survival in all age-groups over the last 
65 years at our institution [15]. We believe this improvement is partly attributable to 
changes in injury severity of admitted patients, but also to technological advances, 
improved infrastructure and implementation of clinical guidelines. 
 
Firstly, the proportion of smaller burn size admissions has increased from 30 % to 53 
% in the more recent study period (p=<0.001). This increase in the proportion of 
minor elderly burn admissions may be due to an increased number of referrals of 
smaller injuries from peripheral hospitals. Following the National Burn Care Review 
report in 2001 [40], the British Burn Association published national referral guidelines 
which stated that patients >60 years of age and those with co-existent disease e.g. 
cardiac limitation, respiratory limitation and diabetes should be referred to a 
specialized burn service. It may also reflect an increasing need to admit patients with 
smaller injuries due to increasing demands of an ageing population on the social care 
system but we have no data to support this hypothesis. In order to examine this, it 
would be useful to obtain data on pre-injury living status versus discharge status for 
the two cohorts. 
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The results of our study show a reduction in the time from injury to first burn excision, 
from a median of six, down to five days. It is unclear if this modest change has had 
an impact on elderly burn survival as the number of deaths in our study prohibited the 
use of multivariate logistic regression analysis taking into account all key 
confounders of age, % TBSA burn and inhalation injury, to fully examine its effect. 
Moreover, despite early burn excision being a modern paradigm of burn care, the 
question as to the benefit of this approach specifically in the elderly remains 
unanswered with several early studies showing mortality benefit [41-42] and others 
since showing no benefit [43-46]. Recent advances in peri-operative medicine, 
anaesthesia and surgical techniques may allow elderly patients to be more safely 
negotiated through an early surgical approach that has been shown to be beneficial 
in younger age groups [47]. In addition, during the second cohort, early Geriatric 
medicine and specialist anaesthetic support allowed optimization for early surgical 
intervention. Within our anaesthetic team a number of specialists have developed a 
special interest in elderly burn care and this has made an impact on outcomes of 
surgery in this group of patients. 
 
All patients have benefited from the implementation of clinical guidelines including 
thromboprophylaxis, nutrition, infection control, antibiotic prescribing, gastro-
protection and treatment of inhalation injury. Patients managed in the ICU have also 
benefited from increased adoption of lung protective ventilation strategies [48] and 
the increased use of care bundles to prevent and treat complications such as sepsis 
and ventilator associated pneumonia [49-50]. Between the two study periods, there 
have been improvements in infrastructure and systems within our hospital trust. 
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These include the creation of a critical care outreach team, allowing smoother 
transition of patients stepping down from ICU level care and earlier recognition of 
deterioration in ward patients. Information technology has undoubtedly had an 
impact, with the introduction of an electronic clinical decision support system during 
the early part of the second study period. This comprehensive rule based system 
combines drug prescribing, laboratory results, radiology, operation notes and clinical 
observations and has revolutionized patient care at our centre [51]. The system 
generates real-time early warning scores (EWS) to alert the medical team to any 
deterioration and the critical care outreach team automatically if thresholds are met. 
 
Pre-existing or co-morbid disease has previously been shown to have an impact on 
the survival of the elderly burn patient. The number of co-morbidities appears to be 
an important independent predictor for the development of in hospital pneumonia, 
which is associated with increased risk of mortality [13]. We and other groups have 
shown the number of co-morbidities to influence burn survival [20, 38] and a recent 
study of 66,611 patients from the UK IBID database has shown that ≥3 pre-existing 
conditions is associated with an odds of death of 2.381 [52]. The number and type of 
co-morbidities are clearly important variables, however, they are confounded by the 
varying impact on the individual patient. An important concept within geriatric 
medicine is frailty, which is a multi-dimensional syndrome resulting in loss of reserve 
in multiple organ systems that increases an individuals vulnerability [23]. Clinical 
frailty scoring (FS) gives us information on the biological age of patients and has 
been shown in elderly burn patients to be an independent predictor of burn mortality 
[53,54] and risk of discharge to a skilled nursing facility [54]. In this study we 
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retrospectively assessed clinical frailty from the patient records using the Canadian 
Study for Health and Ageing (CSHA) clinical frailty scale and showed that non-
survivors have a significantly higher median frailty score than survivors. This adds 
further weight to the existing literature (140,294) demonstrating the importance of this 
measure in determining outcomes in the elderly burn patient and further prospective 
research is warranted to investigate this more rigorously.  
 
A review of the published cohorts of elderly patients admitted with burn injury 
worldwide since 2000 (table 2.6) revealed interesting differences across the world in 
terms of definitions of elderly and injury characteristics. Flame burns were the most 
common mechanism of injury except in China, where several groups have shown 
scald injuries to be more common. This may have a bearing on the lower mortality 
rates observed compared to other cohorts in addition to the linked observation of 
lower incidences of inhalation injury, which is widely excepted to impact on mortality. 
Variability was seen in the average size of burn and this may be confounded by 
national or even regional differences in healthcare provision and burn referral and 
admission policies. It is possible that in some countries with a higher incidence of 
burn injury in the population and therefore higher demands on burn services, only 
patients with more severe injuries are admitted.  
 
Due to the confounding effects of age, inhalation injury, burn size and possibly 
differences in frailty and co-morbid disease, it is difficult to make direct comparisons 
of outcomes between burn centres based only on the observed mortality rate. 
Moreover, there are differences between countries in approaches to palliative care 
 103 
and in many of the reviewed studies, it was unclear if early non-survivors were 
included in the datasets. If we had included the 12 patients in whom a very early (first 
24hrs) decision to treat the patient with comfort care only then the overall observed 
mortality rate would indeed be higher at 19.1% (46/240). As expected, these were 
more severely injured patients with a mean TBSA of 65% (+/-8), mean age of 79 
years (+/-4) and 100% had inhalation injury. Very few of the studies attempted to 
calculate the LA50 value for their cohort, an approach developed at the Birmingham 
Burns Centre (13) which takes into account burn injury size of the cohort. Another 
group, took the concept a step further in using the Baux score (age + burn size 
TBSA) and calculating the Baux50 which also takes into account the influence of age 
on mortality (295).  
 
Improvements in overall mortality rate and the LA50 in elderly burn patients reflect a 
continuing trend across all age groups at our burn centre and worldwide. This 
improvement appears to be related to an increased proportion of smaller burn injury 
referrals but is also likely to have been impacted by improvements in surgical, 
anaesthetic and critical care and local infrastructure. There is a trend towards earlier 
burn excision, which may have contributed to these improved outcomes but further 
research is needed into the potential benefits of this approach in this age group. 
Although mortality improvements have been shown, it is evident from the change in 
the LA50 over time in this age group, that these gains are lagging behind those seen 
in children and younger adults. Research priorities must therefore include obtaining a 
more complete understanding of the pathophysiological responses to burn injury in 
the elderly and how they compare to younger age groups. One important area to be 
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targeted is the impact of frailty on outcomes and whether an early assessment of 
frailty might aid in the stratification of care approaches. Also given the importance of 
infections and sepsis in determining outcomes in patients with burns, further study is 
needed on the age-associated decline in immune function, termed 
immunesenesence (143), in older patients with burn injury.  Further clinical research 
is also needed into the benefits of early burn wound excision in the elderly in the 
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3 3. NMR Metabolomics Analysis of the early metabolic 
response to severe thermal injury 
3.1 Introduction 
Severe thermal injury involving more than 30% of the total body surface area (TBSA) 
is associated with significant metabolic dysfunction, termed the hypermetabolic 
response (HMR) (38). The HMR begins after the initial shock or ‘ebb’ phase following 
thermal injury, typically 3-5 days after injury and is characterized by a hyperdynamic 
circulation (296), increased metabolic rate (297) and increased core body 
temperature (193). This accompanies significant derangements in glucose synthesis, 
uptake and utilization (298); lipid metabolism (168), increased skeletal muscle 
proteolysis (234) and futile substrate cycling (194).  
 
Evidence to date points to multiple mediators in the induction and maintenance of the 
highly conserved HMR and is felt to be an attempt to 1) maintain normothermia in the 
context of massive skin loss and 2) provide adequate substrates to fuel wound 
healing processes. These mediators include the pro-inflammatory cytokines such as 
IL-6 and IL-1β acting synergistically with the elevated levels of stress hormones: 
noradrenaline, adrenaline, glucagon and cortisol. The increases in metabolic rate 
have been measured as increases in resting energy expenditure (REE) (193) and 
have been shown to be more pronounced following thermal injury as compared to 
other forms of trauma (299) and may be prolonged for up to 2 years post-injury (42).  
The consequences of the HMR for the thermally injured patient, include massive 
calorie consumption requiring early nutritional support, loss of lean body mass (LBM) 
and skeletal muscle wasting (41). The dramatic metabolic disturbances and loss of 
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LBM result in growth impairment in children, liver dysfunction, immune dysfunction, 
poor wound healing and resultant increased risk of infections, sepsis and mortality 
(300). A wealth of studies to-date have identified key metabolic defects including 
increased peripheral insulin resistance, a switch to protein catabolism as a major 
source of fuel with inefficient oxidation of lipids in contrast to starvation states. In 
addition, stable isotope studies have demonstrated that during the HMR, glycolytic-
gluconeogenic cycling is increased by 250% and triglyceride-fatty acid cycling is 
increased by 450% (194). Pharmacological therapies try to ameloriate this 
maladaptive response include the use of anabolic agents such as insulin, 
oxandralone, propranolol and growth hormone (300). These therapies, in addition to 
the modalities of ambient temperature control, early enteral nutrition and early burn 
excision and grafting have no doubt contributed to improved outcomes for patients 
suffering severe burns. However, complete amelioration of the response has not 
been possible due to an incomplete understanding of this complex response.  
 
Recognizing the complexity of human responses to trauma and thermal injury, 
researchers are starting to employ an array of systems biology approaches to try to 
gain more biological insight and identify novel therapeutic strategies. A number of 
genomic studies, using DNA microarray data from the Glue grant Host Response to 
injury study have led the charge in this data-driven approach with a number of new 
insights (301). These include a shift away from the post-injury temporally separate 
SIRS/CARS phase paradigm, with the genomic data showing pro-inflammatory 
genes and anti-inflammatory gene expression changing simultaneously within hours 
of injury (51). Metabolomics is another systems biology approach which focuses on 
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analysis of all small products of metabolism in biological systems (302) and has been 
recently applied to study groups of critically ill patients with acute lung injury, 
(303,304), ARDS (305) and sepsis (278,306,307). Individual metabolites and 
metabolite profiles derived from this approach can predict clinical outcomes in 
critically ill patients with high accuracy (281,308). We hypothesized that a 
metabolomics approach could be used to study early metabolic dysfunction in 
patients with severe thermal injury and that it could generate metabolite profiles 
predictive of later clinical outcomes. 
 
3.2 Aims and objectives 
1. To identify the key changes in the serum metabolome in the acute phase after 
severe human thermal injury in adults (aged 16-64 years) with severe burns 
(>15% TBSA). 
2. To assess the utility of metabolomics in the prediction of later clinical 




3.3.1 Study group 
Patients included in the study were recruited as part of a UK multi-centre 
observational study called the SIFTI study (Scientific Investigation of biological 
pathways Following Thermal Injury) (UKCRN ID: 13654) and were admitted to the 
adult Burns Centre at Queen Elizabeth Hospital Birmingham (QEHB), UK (2012-
2014). The studies in this thesis include two cohorts of patients recruited to the SIFTI 
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study: 1) Adults aged 16-64 years presenting with ≥15% total body surface area 
(TBSA) burns; 2) Elderly patients aged ≥65 years with ≥1% TBSA full-thickness 
burns (but <15% total TBSA). The data presented in this chapter are obtained from 
only ‘adult patients’ and analysis of data from ‘elderly patients’ is presented in 
Chapter 5.  
  
Patients initially unable to consent to the study due to lack of capacity (injury severity, 
unconsciousness due to intubation) were recruited through a legal consultee advice 
process until they regained capacity to consent themselves. As a comparison group, 
six healthy volunteers (aged 18-64) underwent blood sampling in the morning 
between the hours of 8-10am. For each volunteer, age (years), sex, height (m), 
weight (kg) and body mass index (BMI) (kg/m2) was recorded.  
 
3.3.2 Treatment of subjects 
Patients received treatment according to standardized local burn care guidelines 
which includes fluid resuscitation with Hartmann’s solution according to the Parkland 
Formula (4mLs/kg/% TBSA burn), invasive monitoring of arterial blood pressure (BP) 
and central venous pressure (CVP) and thromboprophylaxis with low-molecular 
weight Heparin (LMWH). Resuscitation targets were urine output 0.3-0.5 mLs/kg/hr 
and mean arterial pressure (MAP) of >60 mmHg. Patients with persistent oliguria or 
hypotension despite adequate crystalloid volumes were given 5% human albumin 
solution (HAS) and inotropic support with noradrenaline. All patients received early 
enteral nutrition according to standard formulae in addition to enteral 
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supplementation of glutamine and intravenous supplementation of trace elements 
until wound closure. Patients requiring surgery underwent burn excision within 72hrs 
of admission and coverage with split-thickness skin autograft. Patients with burns 
>40% TBSA typically required wound coverage with combinations of autograft, 
cadaveric allograft and skin substitutes.  
3.3.3 Data Collection 
Patient demographics, burn injury details and clinical outcomes were recorded 
prospectively using case-report forms (CRF). Key outcomes included: 
• In-hospital mortality 
• Sepsis - American Burn Association (ABA) 2007 consensus trigger criteria 
(309) 
• Multiple organ failure (MOF) - Denver 2 MOF score (33) 
• Hospital length of stay (LOS) 
• Intensive care LOS (ICU-LOS) 
• Mechanical ventilation days 
• Time to organ recovery (TTR).  
 
3.3.4 Sampling 
During the study, study day 1 (D1) was defined as the calendar day of injury and day 
2 (D2) the second calendar day and so forth. All patients underwent an initial blood 
sampling within 24hrs of their injury. A second blood sample was taken in the 
morning (8-10am) between 48 and 96hrs post-burn, either on D3 or D4. Patients 
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admitted to the intensive care unit (ICU) had 6ml blood samples collected from the 
indwelling arterial catheter using a Vacuette® blood collection system into Vacuette® 
Z-serum clot activator tubes (Greiner Bio-One Ltd, Gloucester, UK). Patients 
admitted to burns ward beds typically did not have insertion of arterial catheters and 
therefore 6 mL blood samples were collected by peripheral phlebotomy using an arm 
tourniquet using the same blood collection system and tubes as above. Healthy 
volunteers were sampled in the same way. Blood samples were kept upright and 
allowed to form clot at room temperature for 30mins before processing. 
3.3.5 Sample processing 
Blood samples were allowed to clot for 30 minutes at room temperature with the 
tubes placed upright and were then centrifuged at 3000 rpm for 10 minutes at 20°C in 
a swinging bucket rotor centrifuge (Eppendorf Centrifuge, model 5804 R, 
ThermoFisher Scientific). Aliquots of 400-600 μl were placed in 1.5 ml plastic 
cryovials and stored upright in a freezer at -80°C. When ready for batch processing, 
frozen serum aliquots of 400 μl were removed thawed gently on ice. Nanosep® 
Omega 3000 Da (Pall Lifesciences, UK) molecular weight cut-off (MWCO) filters 
were prepared by washing 6 times with 500 μl of deionized water at 38°C and 
centrifugation in a benchtop centrifuge at 3000 x g for 15 minutes at room 
temperature. This step was necessary to remove any glycerol from the membrane. 
Following the final wash, any residual water was poured off and extra care was taken 
to ensure all filter membranes were free from visible water droplets.  
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Serum samples were vortexed and 250 μl pipetted into a fresh sterile 1.5 ml 
centrifuge tube. Tubes were then centrifuged at 4°C, 15,000 g for 5 minutes. Finally 
200 μl of the supernatant was taken from the middle of the sample (taking care to 
avoid the lipid rich layer at the top) and loaded centrally onto the washed Nanosep® 
filter. Filters were then centrifuged at 10,000 xg for 15 mins at 4°C. Finally 1.5 ml 
glass champagne vials were labeled and 15 μl of 4x concentrated NMR buffer added 
(NMR buffer: D20/H20 (40%) containing 2,2,3,3-tetradeuteropropionic acid [TMSP] 
(2mM) sodium azide (0.4% w/v) and sodium phosphate (100mM) pH 7.0). A 45 μl 
aliquot of each serum filtrate was then pipetted into a glass champagne vial and 
gently mixed by pipetting. Vials were then stored upright at -80°C until ready for 
spectroscopic analysis. 
3.3.6 NMR Spectroscopy 
Champagne vials containing prepared serum were defrosted at room temperature 
and the order of the samples randomized. A 35 ul aliquot of sample was loaded into 
1.7 mm SampleJet glass NMR tubes (Bruker Corp., USA) using a Bruker 
Autosampler robot (Bruker Corp., USA). NMR tubes were cleaned with filter paper 
and methanol to remove dust and the 96-tube rack placed in the Bruker SampleJet 
sample changer at 6°C. One- dimensional (1D) 1H NMR spectra were acquired at 
300 K using a standard spin-echo NOESY (Nuclear Overhauser Effect 
SpectroscopY) pulse sequence with water suppression using pre-saturation on a 
Bruker AVANCE II 600 MHz NMR spectrometer (Bruker Corp., USA) equipped with a 
1.7 mm cryoprobe. Spectral width was set to 12 ppm and scans were repeated 128 
times. 
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3.3.7 Pre-processing of NMR spectra 
The 1D-NMR spectral data was imported into MATLAB V2013a (MathWorks, Natick, 
USA) and were pre-processed using software packages called NMRLab (V3.5) (310) 
Metabolab (V3.5) (311). Spectra were individually inspected and any abnormal 
spectra were excluded e.g. spectra with significant artefact from protein content. 
Spectra were autophased and then calibrated by aligning TMSP peak to 0 ppm. 
Baseline correction was applied using a spline fit, the water region and TMSP 
standard peaks were removed and spectra were truncated to 0.8-10 ppm). Spectra 
were then aligned using a MATLAB algorithm icoshift (312) and divided into 0.005 
ppm (2.5 Hz) chemical shift bins. Spectral normalization was performed using 
Probabilistic Quotient Normalization (PQN) (313) and a g-log transformation was 
applied (Parsons et al., 2007). The data were then assembled into a data matrix, 
each row representing an individual bin. 
3.3.8 Statistical analysis of metabolomics data 
Data analysis was performed using PLS Toolbox software Version 7.5.2 (Eigenvector 
Research, INc. Manson, USA) running in MATLAB (Release 2013a, Mathworks, 
Natick, USA). Data bins were mean-centred and subjected to first unsupervised 
analysis using principle components analysis (PCA) (314) and scores plots 
constructed. PCA, also known as singular value decomposition (SVD) or eigenvector 
analysis, allows an initial overview and decomposition of the multi-variate data, 
identification of major sources of variation in the data, reveal possible clustering of 
samples and identification of outliers (315). Outliers are defined as those falling 
outside of the 95% confidence interval of the Hotelling’s T-squared (T2) distribution. 
 114 
This is seen as an ellipse on the PCA scores plot (315). Outliers were then removed 
from subsequent supervised multi-variate analyses as these can bias the resulting 
models masking true differences between classes. Loadings plots were also 
constructed which can be used to identify NMR spectral peaks that are responsible 
for clustering or separation among the sample set (254).  
Data were also analysed using Partial Least Squares Discriminant analysis (PLS-DA) 
and orthogonal PLS-DA (OPLS-DA). Both techniques are supervised classification 
methods that aim to create models that explain the maximum covariance between 
the metabolite dataset (x) (predictor variables) and two or more classes (training 
variables) e.g. burn injured patients and healthy control groups. OPLS-DA is a 
modification to PLS-DA which separates the systematic variation in the dataset into 
two components: 1) the predictive component – summarizes variation in the dataset 
that is related to discrimination of classes 2) the orthogonal component – this 
summarizes variation in the dataset that is unrelated to the class response and 
therefore unhelpful in class discrimination. The advantages of this modification are 
easier interpretation of models and in highlighting unexpected systematic variability 
as a result of biological variation or experimental bias (316). These techniques are 
prone to model over-fitting of that data and therefore cross-validation was applied 
using 10-fold Venetian blinds cross-validation which randomly selects and excludes 
blocks of the data from the model to determine its accuracy in assigning class 
membership (317). PLS-DA and OPLS-DA outputs can be visualized graphically in 
the form of scores plots constructed from two or more latent variables (LVs) which 
are linear combinations of the original variables preserving as much co-variance 
between the dataset (X) and the classes (Y) as possible from the original dimensions 
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(318). These plots are also outputs from PCA and allow identification of patterns, 
clustering and outliers in ‘statistical space’. The loadings vectors from PCA, PLS-DA 
and OPLS-DA are visualized on loadings plots which can be used for identification of 
the NMR spectral signals and thus metabolites responsible for separation or 
clustering of samples (254). 
The performance of PCA, PLS-DA and OPLS-DA models was evaluated with metrics 
provided by the PLS-Toolbox software including the R2 and Q2 metrics. R2 is the 
percentage of variation explained by the model, a quantitative measure of well the 
models are able to mathematically reproduce the data in the dataset (319). Q2 is the 
predicted variation or quality of prediction and was obtained through cross-validation. 
A Q2 value of >0.5 shows good predictive ability but >0.9 is outstanding; the 
difference between Q2 and R2 is also important and this should not exceed 0.2-0.3 
(319). In order to evaluate the discriminatory power of the multi-variate models to 
predict class groups (e.g. burn patient vs. healthy control) confusion matrices were 
constructed and accuracy (%), sensitivity (%), specificity (%), negative predictive 
value (NPV) and positive predictive value (PPV) were calculated. In addition, 
Receiver Operator Characteristic Curves (ROC) were constructed using PLS-
Toolbox and the area under the receiver operating curve (AUROC) values calculated 
for each model both before and after cross-validation. 
In order to assess the most important contributing metabolites to multivariate models, 
we sought to identify the metabolite peaks with the highest contribution to each 
model using their variable importance in projection (VIP) scores (320,321). The 
metabolite peaks with the 20 highest VIP scores >1 in each model were then 
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identified from the 1D NMR spectra using Human Metabolome Database version 3.6 
(www.hmdb.ca) and Chenomx NMR suite (Chenomx, professional version 4.0, 
Chenomx Inc, Canada).  
3.3.9 Statistical analysis of demographic data 
Demographic and injury data were compared using SPSS v23.0 statistical software 
(IBM, USA). Datasets were assessed for normal distribution using the Shapiro-Wilkes 
test. Parametric data are displayed as means with standard deviation and groups 
compared using the Independent Samples T-Test. Non-parametric data are 
displayed as medians with interquartile range (IQR) and groups compared using 
Mann-Whitney U-test. Categorical variables were compared using Fisher’s exact test. 












3.4.1 Demographics and outcomes 
A total of 37 patients were included in this cohort with a mean age of 36 (+/-12) 
years, a male:female ratio of 1.6:1 and mean burn size of 39.2 (+/-21.9) % TBSA. 
The demographics of the cohort are summarized in Table 3.1. The majority of 
patients sustained flame burns (78%) with the remainder of injuries being due to flash 
or scald mechanism (Figure 3.1). In terms of outcomes, 10 patients did not survive 
their admission giving a mortality rate of 27%. A total of 16 patients (43%) 
experienced at least one episode of multiple organ failure (MOF) and 19 patients 
(51%) experienced sepsis. The outcomes for the study cohort are summarized in 
table 3.3 and the demographics of the outcome groups are summarized in Table 3.2 
(survivors vs. non-survivors), Table 3.4 (sepsis vs. no-sepsis) and Table 3.5 (MOF 
vs. no MOF). Demographics for the healthy volunteers are summarised in Table 3.6. 
 











Admission parameters Values 
n 37 
Age (years) 36.0 (+/- 12.0) 
Male n (%) 23 (62) 
BMI (kg/m2) 26.2 (+/-4.6) 
TBSA (%) (IQR) 38 (22-54) 
TBSA-FT (%) (IQR) 17 (7-50) 
Inhalation injury n (%) 17 (46) 
ICU Admission n (%) 23 (62) 
APACHE II first 24hrs (IQR) 26 (9-30) 
SOFA first 24hrs (IQR) 7.0 (2-11) 
Denver MOF first 24hrs (IQR) 2 (0-3) 
R-Baux 83.0 (+/-31.1) 
ABSI (IQR) 8 (6-11) 
BOBI (IQR) 3 (1-5) 
Table 3-1. Demographic and injury data. Abbreviations: APACHE (Acute physiology, age and 
chronic health evaluation score), SOFA (Sequential organ failure assessment) score, ABSI 
(Abbreviated burn severity of illness) score and BOBI (Belgian outcomes in burn injury) score. 
 
Admission data Survivors Non-survivors p-value 
n 27 10  
Age (years) 32.4 (+/-11.2) 46.0 (+/-8.1) 0.001 
Male n (%) 17 (63) 6 (60) 0.580 
BMI (kg/m2) 25.5 (+/-4.6) 27.9 (+/-4.8) 0.173 
TBSA (%) 27.5 (17.0-45.0) 50.0 (44.5-62.8) 0.004 
TBSA-FT (%) 15.0 (4.5-36.0) 50.0 (36.8-60.0) 0.001 
Inhalation injury n (%) 8 (30) 9 (90) 0.002 
ICU Admission n (%) 13 (48) 10 (100) 0.006 
APACHE II first 24hrs 17 (7-28) 31 (30-35) <0.001 
SOFA first 24hrs 5 (1-10) 13 (9-14) <0.001 
Denver first 24hrs 0 (0-3) 3 (2-6) 0.004 
R-Baux 71.5 (+/-27.1) 114.2 (+/-17.0) <0.001 
ABSI 7 (5-8) 11 (10-12) 0.003 
BOBI 1 (1-4) 5 (5-6) <0.001 
Table 3-2. Comparison of admission characteristics of survivors and non-survivors. 
Abbreviations: APACHE (Acute physiology, age and chronic health evaluation score), SOFA 
(Sequential organ failure assessment) score, rBaux (Revised Baux Score), ABSI (Abbreviated burn 




Outcome variable Value 
Mortality n (%) 10 (27) 
MOF (Denver 2) n (%) 16 (43) 
Time to organ recovery (days) 13.5 (+/- 20.8) 
Sepsis n (%) 19 (51) 
Number of septic episodes/patient (n) 2 (+/-2) 
ICU LOS (days) 18.2 (+/- 24.9) 
Mechanical Ventilation days 14.9 (+/- 22.8) 
Hospital LOS (days) 45.9 (+/- 45.4) 
LOS (days/% TBSA) 1.1 (+-0.8) 
Table 3-3. Clinical outcomes for cohort of adults with ³15% TBSA burns. Abbreviations: MOF (multiple 
organ failure), ICU (Intensive care unit), LOS (length of stay), TBSA (total body surface area). 
 
Admission data Sepsis No sepsis p-value 
n 26 11  
Age (years) 37.9 (+/-12.5) 31.7 (+/-10.1) 0.159 
Male n (%) 15 (58) 8 (73) 0.477 
BMI (kg/m2) 25.9 (+/-4.7) 31.7 (+/-10.1) 0.669 
TBSA (%) 43.5 (27.3-55.5) 17.0 (16.0-31.0) 0.005 
TBSA-FT (%) 31.5 (14.1-52.6) 11.0 (0.0-25.0) 0.019 
Inhalation injury n (%) 15 (58) 2 (18) 0.036 
ICU Admission n (%) 20 (77) 3 (27) 0.008 
APACHE II first 24hrs 29 (18-30) 7 (2-18) 0.009 
SOFA first 24hrs 10 (6-12) 1 (0-2) 0.006 
Denver first 24hrs 2 (1-3) 0 (0-0) 0.033 
R-Baux 92.3 (+/-27.8) 61.2 (28.6) 0.004 
ICU LOS (days) 25.6 (+/-26.5) 0.9 (+/-2.1) <0.001 
Hospital LOS (days) 59.8 (+/-47.7) 13 (+/-5.6) <0.001 
LOS (days/TBSA) 1.3 (+/-0.8) 0.6 (+/-0.3) 0.001 
MVD (days) 20.9 (+/-24.9) 0.72 (+/-2.1) <0.001 
Mortality 8 (31) 2 (18) 0.361 
MOF 14 (54) 2 (18) 0.071 
Table 3-4. Comparison of admission characteristics of septic and non-septic groups. 
Abbreviations: APACHE (Acute physiology, age and chronic health evaluation score), SOFA 
(Sequential organ failure assessment) score, rBaux (Revised Baux Score), LOS (length of stay), ICU 
(Intensive Care Unit), TBSA (Total body surface area burned), FT (full thickness burn), MVD 
(mechanical ventilation days) 
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Admission data MOF No MOF p-value 
n 16 21  
Age (years) 43.0 (+/-9.5) 30.7 (+/-11.2) 0.001 
Male n (%) 9 (56) 14 (67) 0.733 
BMI (kg/m2) 28.0 (+/-4.6) 24.7 (+/-4.4) 0.034 
TBSA (%) 51.0 (43.0-65.8) 23.0 (16.5-30.5) <0.001 
TBSA-FT (%) 42.4 (29.3-55.0) 13.0 (4.0-18.3) <0.001 
Inhalation injury n (%) 13 (81) 4 (19) <0.001 
ICU Admission n (%) 16 (100) 7 (33) <0.001 
APACHE II first 24hrs 30 (29-34) 10 (6-25) <0.001 
SOFA first 24hrs 11 (10-14) 2 (0-6) <0.001 
Denver first 24hrs 3 (2-4) 0 (0-2) <0.001 
R-Baux 111.8 (+/-20.2) 61.1 (+/-16.5) <0.001 
ICU LOS (days) 37.1 (+/-27.8) 3.9 (+/-6.2) <0.001 
Hospital LOS (days) 64.7 (+/-59.2) 31.6 (+/-24.0) 0.049 
LOS (days/TBSA) 1.1 (+/-0.9) 1.1 (+/-0.6) 0.964 
MVD (days) 31.2 (+/-26.9) 2.5 (+/-4.5) 0.001 
Mortality 10 (63) 0 (0) <0.001 
Sepsis 14 (88) 12 (57) 0.071 
Table 3-5. Comparison of admission characteristics of MOF and non-MOF groups. 
Abbreviations: APACHE (Acute physiology, age and chronic health evaluation score), SOFA 
(Sequential organ failure assessment) score, rBaux (Revised Baux Score), LOS (length of stay), ICU 
(Intensive Care Unit), TBSA (Total body surface area burned), FT (full thickness burn), MVD 
(mechanical ventilation days). 
 
Parameter Healthy controls Patients p-value$ 
n 6 25  
Age (years) 36.2 (+/-4.9) 34.7 (+/-2.2) 0.762 
Male n (%) 3 (43) 15 (60) 0.669 
BMI (kg/m2) 24.1 (+/-0.6) 25.3 (+/-0.8) 0.277 
Table 3-6. Comparison of demographics between burn injured patients and healthy controls. 
Abbreviations: BMI (Body mass index). $ = Fisher’s Exact test for comparison of proportions, 




3.4.2 Changes in the early post-burn metabolome in young adults 
A total of 79 blood samples were collected from 37 patients and 6 healthy controls. 
Metabolomics data were analysed from 69 patient serum and 6 healthy control 
samples, as 4 patient samples (5%) contained residual protein which perturbed the 
quality of the NMR spectra. The full pre-processed dataset was first subjected to 
PCA to identify any general trends or unexpected clustering. A 3 principle component 
(PC) model was able to explain the following percentages of variation: PC1 (18.32%), 
PC2: (14.05%), PC3 (11.63%) (Figure 3.2) after removal of 5 outlier samples that fell 
outside the Hotelling’s T2 ellipse. A PLS-DA model with 4 LVs discriminated between 
samples from the patients and healthy controls with 100% sensitivity and 100% 
specificity with scores plots confirming good separation of the two classes (R2: 0.8, 
Q2 0.6) (Figure 3.3). The AUROC for this model was 1.00 after 10-fold cross-
validation, confirming the model accurately predicted samples as being from burn 










Figure 3-2. PCA 3D scores plot, 3-PCs. Adult severe burn samples and healthy control samples. 
Green circles = healthy controls, red circles = patient samples from adults with burn >=15% TBSA. 








PC 2 (14.05%) 
 122 
 
Figure 3-3. PLS-DA scores plot showing good discrimination of burn injured patient samples (red 
circles) and healthy control samples (green circles). Model sensitivity = 100% and specificity = 100% 
(R2: 0.8, Q2 0.6). 
 
To study the influence of time of sampling from the time of injury, the samples were 
grouped as follows: 1) 0-24 hrs post-injury 2) 24-48 hrs post-injury, 3) 48-72 hrs post-
injury 4) >72hrs post-injury. Using these classes PLS-DA analysis revealed a 
grouping of the 0-24hrs samples away from the other 3 groups which clustered 
together mostly separated by latent variable (LV) 1 (Figure 3.4). OPLS-DA was then 
performed, grouping the samples into two groups 1) 0.24 post-injury and 2) 24-84 hrs 
post injury and the model was able to discriminate between the two groups of 
samples with 97% sensitivity and 100% specificity (R2 0.8, Q2 0.5) (Figure 3.5). 
These results highlighted the need to use these two time-point groups separately for 



















Figure 3-4. PLS-DA Scores plot with samples classified into four groups according to the time of 










Figure 3-5. OPLS-DA Scores plot with samples grouped into 0-24hrs post-injury samples and 24-
84hrs post-injury samples. The model shows good discriminatory ability to classify these time-point 
groups. (Sensitivity 97%, specificity 100%, AUROC 0.94, R2: 0.8, Q2: 0.5). 
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Given that time-dependent differences in the post-burn metabolome within the first 
96hrs post-injury were demonstrated, a multi-variate analysis of the initial sample 
(taken £24hrs) metabolomics data in relation to healthy controls data was performed. 
OPLS-DA discriminated between the first 24hr patient samples (n=37 and matched 
control samples (n=7) with 100% sensitivity and specificity (5 LVs, Q2: 0.9, R2: 0.6, 
AUROC: 1.00, permutation test p=0.008). The scores plot from this model (Figure 
3.6) shows good discrimination of the two groups and the VIP loadings plot (Figure 
3.7) shows the key metabolite peaks contributing to the model. 
 
Figure 3-6. Scores plot of OPLS-DA of samples taken in the first 24hrs post-injury compared to 
healthy control samples showing good model discrimination (Q2: 0.9, R2: 0.6, p=0.008).  
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Figure 3-7. VIP (variable importance in projection) loadings plot from OPLSDA showing NMR 
spectral peaks contributing to the model. The height of the peaks corresponds to VIP score and 
therefore greatest contribution to the variance between the first 24hrs samples from burn patients 
and healthy controls. 
 
Spectral fitting to identify metabolites was performed for NMR peaks falling within the 
top ranked 50 spectral bins according to their VIP score. A total of 14 unique serum 
metabolites fell within these bins and are listed in Table 3.7 and are ranked according 
to VIP scores. The chemical shift values (ppm) for all peaks identified for each 
metabolite in the top 50 spectral bins are listed. The model showed that ketone 
bodies (e.g. acetoacetate, 3-Hydroxybutyrate, 2-Hydroxybutyrate, acetone), lactate, 
glucose, pyruvate, glycerol and polyethylene glycol were higher in burn patients 
compared to controls. Amino-acid metabolites such as alanine, glycine, proline, 
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valine and glutamine were all lower in the burn patients compared to the controls. 
 
Rank Metabolite Change$ VIP* Chemical shift of peak bins (ppm) 
1 3-Hydroxybutyrate ­ 36.72 1.17, 1.19, 1.21, 2.37  
2 Pyruvate ­ 32.01 2.38 
3 Lactate ­ 27.16 1.31, 1.32, 1.33, 1.34, 1.35, 4.11, 4.12, 
4.13  
4 Acetoacetate ­ 24.82 2.28, 3.43 
5 Propylene glycol ­ 18.69 1.14, 1.15 
6 Glycine ¯ 16.14 3.57, 3.58 
7 Glucose ­ 15.64 
3.40, 3.42, 3.44, 3.45, 3.47, 3.4.8, 3.49, 
3.50, 3.51, 3.52, 3.74, 3.75, 3.83, 3.86, 
3.87, 3.89, 3.91  
8 Acetone ­ 10.69 2.24 
9 Proline ¯ 10.19 3.37 
10 Glycerol ­ 8.46 3.54, 3.57, 3.66, 3.67 
11 Alanine ¯ 8.12 1.48, 1.49 
12 2-Hydroxybutyrate ­ 7.16 0.90 
13 Valine ¯ 5.79 0.98, 1.00, 1.04, 1.05 
14 Glutamine ¯ 5.32 2.14 
 
Table 3-7. Metabolites identified within the top 50 ranked peaks in OPLS-DA model discriminating 
samples from burn patients within first 24hrs post injury (n=37) and from matched healthy controls 
(n=7). Metabolites are ranked according to highest VIP score. $ ­ indicates metabolites that are higher 
in burn injured patient serum relative to healthy controls, ¯ indicates metabolites that are lower in burn 
injured patient serum relative to controls.* Highest VIP (Variable Importance Projection) score for any 
peak for each metabolite PPM: Parts per million. 
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To determine if the presence of these metabolites persisted PCA and OPLS-DA was 
then applied to the NMR data from patient sera collected in the period 24-84 hrs 
post-injury and the same healthy control sera. Two outlying samples were removed 
following the PCA and OPLS-DA with 3 LVs showed excellent discrimination 
between the 24-84hrs post-injury samples and the control samples as shown by the 
scores plot (Figure 3.8). The model showed 100% sensitivity and specificity at 
discriminating between patient and control samples (R2 0.84, Q2 0.66, permutation 
p=0.010) and ROC analysis yielded an AUROC of 1.00. The loadings VIP plot shows 
the most highly weighted peaks in the model (Figure 3.9). 
 
Figure 3-8. Scores plot from OPLS-DA of serum samples from two groups: 1) Burn injured patients 
taken >24hrs and <84hrs post-injury 2) Matched healthy volunteers (control). The 3 LV model, after 
10-fold cross validation shows 100% sensitivity, 100% specificity, R2: 0.84 and Q2: 0.66, AUROC: 
1.00.  
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Figure 3-9. VIP loadings plot from OPLSDA showing NMR spectral peaks contributing to the model. 
The height of the peaks corresponds to VIP score and therefore greatest contribution to the variance 
between the 24-84hrs samples from burn patients and healthy controls. 
 
As before, spectral fitting was performed for NMR peaks within the 50 highest 
weighted spectral bins in the OPSL-DA model. A total of 12 unique serum 
metabolites fell within these bins and are listed in Table 3.8 and are ranked according 
to VIP scores. The chemical shift values (ppm) for all peaks identified for each 
metabolite in the top 50 spectral bins are listed. The most highly weighted 
metabolites changed compared to the first 24hr samples. Reduced levels of alanine 
and glycine were most significantly contributing to the model but again pyruvate, 
glucose and ketone bodies were increased compared to controls. Lactate did not 
feature in the top 50 bins as in the early samples, suggesting a return towards normal 













Rank Metabolite Change$ VIP* Chemical shift of peak bins (ppm) 
1 Alanine ¯ 35.72 1.48, 1.49 
2 Glycine ¯ 30.17 3.57 
3 Pyruvate ­ 26.32 2.38 
4 3-Hydroxybutyrate ¯ 25.62 1.19, 1.20 
5 Glucose ­ 22.42 3.43, 3.45, 3.46, 3.47, 3.48, 3.49, 3.51, 
3.52, 3.73, 3.75, 3.81, 3.82, 3.83, 3.85, 
3.86, 3.87, 3.89, 3.92  
6 Acetate ¯ 15.36 1.92, 1.93 
7 Glutamine ¯ 14.81 2.45, 3.57 
8 Ethanol ¯ 13.67 1.18 
9 Acetoacetate ­ 12.22 2.28, 3.45 
10 Citrate ¯ 10.35 2.67 
11 2-Hydroxybutyrate ­ 8.19 0.90 
12 Proline ¯ 6.64 3.35 
 
Table 3-8. Metabolites identified within the top 50 ranked peaks in OPLS-DA model discriminating 
samples from burn patients taken 24-84 hrs post injury (n=37) and from matched healthy controls 
(n=7). Metabolites are ranked according to highest VIP score. $ ­ indicates metabolites that are higher 
in burn injured patient serum relative to healthy controls, ¯ indicates metabolites that are lower in burn 
injured patient serum relative to controls.* Highest VIP (Variable Importance Projection) score for any 







3.4.3 Metabolomics to predict clinical outcomes 
3.4.3.1 Prediction of mortality 
To determine if the metabolic profile of patient’s serum during the first 24hrs post 
burn-injury could predict clinical outcomes, NMR metabolomics data from 37 patients 
were subjected to PCA and OPLSDA. PCA revealed two samples lying outside the 
Hotelling’s confidence Ellipse and were removed before generating OPLSDA models. 
An OPLSDA model with 3 LVs showed good discrimination between survivor and 
non-survivor groups with high sensitivity and specificity (Table 3.10). The score 
scatter plot shows the model discrimination is mainly with the first LV (Figure 3.10). 
Receiver Operating Characteristic Curve (ROC) analysis demonstrated excellent 
discriminatory ability to predict survival with a cross–validated area under the ROC 









Table 3-9. Summary of statistical measures of performance of cross-validated OPLSDA model to 
predict mortality of patients from early serum metabolomics profiles. PPV = Positive predictive value, 
NPV = negative predictive value, AUROC = Area under the receiver operating characteristic curve. 
Parameter Value 
Latent variables (n) 3 
Samples 35 
Accuracy % (95% CI) 89 (72-97) 
Sensitivity % (95% CI) 78 (40-97) 
Specificity % (95% CI) 92 (75-99) 
PPV % (95% CI) 78 (46-94) 








Figure 3-10. A) Scores plot from OPLSDA 3 LV model discriminating between early (0-24hr) serum 
samples from survivors and non-survivors. The 3 LV model, after 6-fold cross validation shows 89% 
accuracy, 78% sensitivity, 92% specificity, R2: 0.76 and Q2: 0.47. B) ROC curve generated from 
OPLSDA model showing excellent discriminatory ability to predict survival (AUROC = 0.92). 
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The 50 highest weighted spectral peaks in the OPSLDA survival model were 
identified by spectral fitting. Within that group, 12 metabolites featured with significant 
increases in non-survivors of 9 metabolites (75%), including 3-hydroxybutyrate, 
ethanol and glycerol. Relative reductions were seen in the amino acids lysine, 
alanine and glutamine in non-survivors. 
Rank Metabolite Change$ VIP* Chemical shift of peak bins (ppm) 
1 3-Hydroxybutyrate ­ 114.03 1.18, 1.19, 1.20, 1.21 
2 Ethanol ­ 85.15 1.15, 1.16, 1.17, 1.18 
3 Glycerol ­ 76.27 3.64, 3.65, 3.66, 3.68 
4 Kynurenine ­ 65.77 3.67, 3.68 
5 Acetate ­ 45.69 1.91, 1.92, 1.93 
6 Propylene glycol ­ 27.54 1.14, 1.15 
7 Methylmalonate ­ 6.51 1.21, 1.22 
8 Glucose ­ 2.94 
3.23, 3.25, 3.35, 3.50, 3.51, 
3.54, 3.55, 3.56, 3.73, 3.74, 
3.92, 5.24 
9 Lysine ¯ 2.90 3.04 
10 Lactate ­ 2.65 1.33, 1.34, 1.35, 4.12, 4.13 
11 Alanine ¯ 2.28 1.48, 1.49 
12 Glutamine ¯ 2.28 2.45, 2.46 
 
Table 3-10. Metabolites identified within the top 50 ranked peaks in OPLS-DA model discriminating 
later non-survivors from survivors from serum samples taken within the first 24hrs post injury (n=37). 
Metabolites are ranked according to highest VIP score. 
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The above metabolomics workflow was used to investigate if serum metabolic 
profiles from the second blood samples taken after admission could predict later non-
survival after burn injury. An OPSLDA model including 30 samples was created after 
exclusion of outliers on the PCA scores plot. A 2 LV model showed poor ability to 
discriminate between survivors and non-survivors with an AUROC of 0.69 (Accuracy 
63% (49-80), sensitivity 76% (66-88), Specificity (33% (10-62), PPV 73% (63-84) and 
NPV (38% (11-69). The first 24hr serum metabolic profile therefore had better 
discriminatory ability to predict non-survivors than the serum profile taken 24-84 hrs 
post-injury. 
3.4.3.2 Prediction of multiple organ failure (MOF) 
The same analysis workflow was applied to examine if the metabolic profile of early 
serum samples taken in the first 24hrs could predict later development of multiple 
organ failure (MOF) as defined by a Denver MOF score of >3 for two consecutive 
days during admission. After exclusion of two outliers on the PCA scores plot, PCA 
did not show any clear clustering of the two groups (MOF vs. no MOF). A 4 LV 
OPLSDA model was constructed and showed discrimination of groups on the scores 
plot. However, after 6-fold cross-validation the model had poor discriminatory ability 
with AUROC to predict later MOF of 0.64 (Table 3.11).  
The same workflow was then applied to serum processed from the second blood 
sample collected post-injury, taken 24hrs-84hrs post-injury, for the same patient 
group. PCA applied to this dataset showed some separation of groups mainly in the 
first two components. A 4 PC model was able to explain the following percentages of 
variation: PC1 (32.97%), PC2 (18.15%), PC3 (12.16%) and PC4 (6.75%) after 
removal of three outliers that were outside of the Hotelling’s T2 ellipse on the PCA 
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scores plot. OPLSDA was then applied to the dataset and a 4-LV model showed 
good discrimination of the two clinical outcome groups on the scores plot (Fig. 3.11a) 
and good discriminatory ability with an AUROC of 0.92 (Fig. 3.11b) (Table 3.11).  
Table 3-11. Summary statistics for metabolomics OPLDA models discriminating serum samples from 
patients who either did not develop MOF or who did develop MOF. Models developed based on early 
samples taken in the first 24hrs post-injury and from later samples, taken 24-84hrs post-injury, are 
compared. CV = cross validated, CI – confidence interval, PPV = Positive predictive value, NPV = 
negative predictive value, AUROC = area under the receiver operating characteristic curve.  
 
Spectral fitting was performed for NMR peaks within the 50 highest weighted spectral 
bins in the OPSLDA model. A total of 12 unique serum metabolites fell within these 
bins and are listed in Table 3.12 and are ranked according to VIP scores. Glucose 
peaks featured highly, occupying 23/50 (46%) of the 50 highest weighted bins. Eight 
of the 12 (67%) metabolites were shown to be reduced in patients who later 
developed MOF, these included several amino acids including alanine, proline, lysine 
and the branched chain amino acids (BCAA), leucine and valine. 
Parameter Values Values 
Samples (time from injury) 0-24hrs >24-84hrs 
Number of samples/patients 35 29 
Latent variables (n) 4 4 
CV Accuracy % (95% CI) 66 (47-81) 86 (66-96) 
CV Sensitivity % (95% CI) 53 (27-78) 83 (59-96) 
CV Specificity % (95% CI) 75 (51-90) 88 (71-97) 
PPV % (95% CI)  62 (32-85) 83 (59-96) 
NPV % (95% CI) 68 (45-85) 88 (71-97) 
AUROC 0.64 0.92 
R2 0.76 0.87 
Q2 0.01 0.48 




Figure 3-11. A) Scores plot from OPLSDA 4 LV model discriminating between serum samples 
from patients who developed MOF and those who did not. B) ROC curve generated from 
OPLSDA model showing excellent discriminatory ability to predict later MOF (AUROC = 0.92). 
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Rank Metabolite Change$ VIP* Chemical shift of peak bins (ppm) 
1 Glucose ­ 39.09 
3.51, 3.52, 3.69, 3.71, 3.76, 
3.77, 3.78, 3.79, 3.81, 3.82, 
3.85, 3.86, 3.88, 3.89, 3.90, 
3.92 
2 Acetoacetate ¯ 16.54 2.28 
3 Glycerol ­ 16.10 3.58, 3.65, 3.68 
4 Alanine ¯ 14.75 1.48, 1.49 
5 Leucine ¯ 13.97 0.95, 0.96, 0.97 
6 Proline ¯ 13.42 3.35, 3.36 
7 Lactate ¯ 11.54 1.32, 1.34 
8 Valine ¯ 10.19 0.98. 0.99, 1.04 
9 3-Hydroxybutyrate ¯ 8.08 1.19, 1.21 
10 Creatine ­ 7.61 3.93 
11 Lysine ¯ 7.44 3.04 
12 Propylene glycol ­ 6.37 1.14, 1.15 
Table 3-12. Metabolites identified within the top 50 ranked peaks in OPLS-DA model discriminating 
serum samples from patients who later developed MOF and from those who did not.  Metabolites are 
ranked according to peaks with the highest VIP score. Arrows indicate the direction of change in 
patients who developed MOF relative to those who did not. 
 
3.4.3.3 Prediction of sepsis 
Two non-septic patients were excluded from the first 24hr serum samples dataset 
due to early non-survival within the first 7-days post-injury and therefore having an 
uncertain septic outcome. A final NMR dataset from 35 serum samples taken within 
the first 24hrs post-injury was subjected to PCA and 4 outlying samples were 
identified as lying outside the Hotelling’s ellipse and were removed from the dataset. 
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The PCA was re-run and the resultant model explained the following variation in the 
dataset: PC1 = 22.72%, PC2 = 18.67% and PC = 12.07%. The PCA scores plot 
showing clustering of the septic group but not the non-septic group. Some minor 
separation of the groups was observed in PC1. The dataset was then subjected to 
OPLSDA which resulted in 2LV model explaining 29% of the variance in the data. 
The scores plot shows of the groups in separation in LV1 but some overlapping 
samples were observed. The model was able to discriminate between septic and 
non-septic samples with an accuracy of 74%, sensitivity of 75%, specificity of 73% 
and an AUROC 0.78, however the Q2 metric was poor (0.16) suggesting poor model 
performance (Table 3.13). 
The workflow was repeated for NMR data from 31 serum samples taken from the 
same group of patients taken 24-84hrs post burn. One patient sample was removed 
due to the patient being an early non-survivor and therefore having an uncertain 
diagnosis of sepsis. The data was subjected to PCA and three outliers on the scores 
plot were identified and removed before re-running the PCA. The final PCA model 
with 2 PCs explained the following variation in the dataset: PC1 = 35.86% and PC2= 
16.38%. The scores plot showed some clustering of septic and non-septic groups 
and separation was observed mainly in PC2. The filtered dataset was then subjected 
to OPLSDA, producing a model with 2 LVs explaining 49% of the variance in the 
data. The scores plot again shows good separation of groups in LV1, however, with 
some overlapping of samples from the two outcome groups (Figure 3.12a). The 
model could discriminate between the septic and non-septic groups with 79% 





Figure 3-12 A) Scores plot from OPLSDA 2 LV model discriminating between serum samples 
from patients who developed sepsis and those who did not. B) ROC curve generated from 
OPLSDA model showing good discriminatory ability to predict later sepsis (AUROC = 0.89). 
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Parameter Values Values 
Samples (time from injury) 0-24hrs 24-84hrs 
Number of samples 31 (16 Sepsis, 15 no sepsis) 
28 
(15 Sepsis, 13 no-sepsis) 
Latent variables (n) 2 2 
CV Accuracy % (95% CI) 74 (53-89) 79 (57-92) 
CV Sensitivity % (95% CI) 75 (55-89) 80 (60-93) 
CV Specificity % (95% CI) 73 (52-88) 77 (53-92) 
PPV % (95% CI) 75 (55-89) 80 (60-93) 
NPV % (95% CI) 73 (52-88) 77 (53-92) 
AUROC 0.78 0.89 
R2 0.60 0.63 
Q2 0.19 0.47 
Permutation test p-value 0.163 0.027 
Table 3-13: Summary statistics for metabolomics OPLDA models discriminating serum samples from 
patients who did and did not develop sepsis during their admission. Models developed based on early 
samples taken in the first 24hrs post-injury and from later samples, taken 24-84hrs post-injury, are 
compared. CV = cross validated, CI – confidence interval, PPV = Positive predictive value, NPV = 
negative predictive value, AUROC = area under the receiver operating characteristic curve. 
  
 
Spectral fitting was performed for the top 50 NMR peak bins weighted by VIP score 
in the OPSLDA model (Table 3.14). This yielded 14 unique metabolites whose 
change in serum was highly weighted in the model discriminating patients who later 
developed sepsis from those who did not. The direction of change was biased 
towards decreases in metabolites in the septic group, with 12 of 14 metabolites 
(86%) being decreased relative to the non-septic group. Only glucose and propylene 
glycol were increased in the septic group relative to the non-septic group. In the 
septic group serum, relative decreases were seen in keto-acids, ethanol, methanol 
and amino acids including alanine, lysine, leucine and glutamine. 
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Rank Metabolite Change$ VIP* Chemical shift of peaks (ppm) 
1 Ethanol ¯ 40.55 1.18, 1.19 
2 Alanine ¯ 29.71 1.48, 1.49 
3 Lysine ¯ 28.94 3.04 
4 Acetoacetate ¯ 26.71 2.28 
5 3-Hydroxybutyrate ¯ 18.15 1.20, 1.21 
6 Lactate ¯ 16.86 1.32, 1.33, 1.34, 1.35, 4.10, 4.12, 4.14 
7 Glucose ­ 16.09 
3.50, 3.51, 3.52, 3.69, 3.75, 
3.76, 3.80, 3.81, 3.85, 3.86, 
3.87, 3.88, 3.89, 3.92, 3.93 
8 Methanol ¯ 13.03 3.35, 3.36, 3.37 
9 Leucine ¯ 11.63 0.95, 0.96, 0.97 
10 2-Hydroxybutyrate ¯ 11.51 0.90 
11 Valine ¯ 8.99 0.98, 0.99 
12 Glutamine ¯ 8.74 2.14, 2.17, 2.46 
13 Propylene glycol ­ 6.44 1.14, 1.15 
14 Carnitine ¯ 5.81 3.23 
 
Table 3-14. Metabolites identified within the top 50 ranked peaks in OPLS-DA model discriminating 
24-84hrs post-injury serum samples from patients who later developed sepsis and from those who did 
not.  Metabolites are ranked according to peaks with the highest VIP score. Arrows indicate the 






3.4.3.4 Comparison of metabolomics models with clinical prediction tool 
performance 
Comparison was made in the discriminatory performance of the metabolomics 
predictive models and a number of clinical scoring and prognostic tools currently in 
use. Discriminatory performance was assessed by calculation of the AUROC for 
each model and each clinical outcome (mortality, MOF and sepsis) and the results 
are summarized in tables 3.15, 3.16 and 3.17. The metabolomics model performed 
comparably with the highest performing clinical tools with the same AUROC as for 
APACHE II score and the Revised Baux Score. For the outcomes sepsis and MOF, 
the metabolomics models also performed comparably but were outperformed by the 
clinical tools. The sepsis metabolomics model had the least discriminatory ability 
compared to the other two outcome models. 
Mortality prediction (Total 35 Patients, 25 Survivors: 9 Non-survivors) 
Model AUROC 
Metabolomics (Serum <24hrs post injury) 0.92 
Apache II first 24hrs 0.92 
Revised Baux 0.92 
Baux 0.90 
BOBI 0.89 
SOFA Score first 24hrs 0.86 
ABSI 0.79 
Denver Score first 24hrs 0.78 
Table 3-15. Comparison of ability to predict mortality in young patients (aged <65 years) with >15% 
TBSA burn using serum metabolomics model vs. clinical prognostic tools as assessed by AUROC. 
Models are ordered according to AUROC value. 
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Multiple Organ Failure (MOF) prediction  
(Total 30 Patients, 16 MOF: 18 No-MOF) 
Model AUROC 
Revised Baux 0.99 
Baux 0.97 
Apache II first 24hrs 0.94 
BOBI 0.94 
Denver Score first 24hrs 0.94 
SOFA Score first 24hrs 0.93 
ABSI 0.93 
Metabolomics (Serum 24-84hrs post-injury) 0.92 
Table 3-16. Comparison of ability to predict multiple organ failure (MOF) in young patients (aged <65 
years) with >15% TBSA burn using serum metabolomics model vs. clinical prognostic tools as 
assessed by AUROC. Models are ordered according to AUROC value. 
 
Sepsis prediction  
(Total 27 Patients, 15 Sepsis: 12 No-Sepsis) 
Model AUROC 
Apache II first 24hrs 1.00 
BOBI 1.00 
SOFA Score first 24hrs 1.00 
Revised Baux 0.99 
Denver Score first 24hrs 0.97 
Baux 0.96 
ABSI 0.92 
Metabolomics (Serum 24-84hrs post-injury) 0.89 
Table 3-17. Comparison of ability to predict later sepsis in young patients (aged <65 years) with >15% 
TBSA burn using serum metabolomics model vs. clinical prognostic tools as assessed by AUROC. 




3.4.4 The effect of inhalation injury on the early post-burn metabolome 
 
The clinical data from our cohort of 37 patients shows inhalation injury has a dramatic 
effect on mortality with 30% of the survivor group and 90% of the non-survivor group 
having concomitant inhalation injury (p=0.002) (Table 3.2). Moreover, patients in the 
study who had inhalation injury had a higher mortality (9/17, 53%) compared to those 
who did not (1/20, 5%) (p=0.002). The acute changes in the serum metabolome 
following thermal injury were therefore further analysed considering the presence of 
inhalation injury on admission. The serum NMR data was analysed separately from 
the early (<24hrs post-injury) samples and the second serum samples (24-84hrs 
post-injury). 
 
3.4.4.1  The effect of inhalation injury on changes in the early post-burn 
metabolome (<24 hrs post-injury) 
 
Serum NMR metabolomics data from 37 patient samples was subjected first to 
unsupervised PCA analysis and then to supervised OPLSDA analysis, comparing 
samples from burn injured patients with and without inhalation injury. A 4 PC model 
could explain the following percentages of variation: PC1 (44.24%), PC2 (12.29%), 
PC3 (9.27%) and PC4 (8.51%). The PCA scores plot revealed no significant 
clustering of the two groups (Figure 3.13a). After removal of three outliers from the 
dataset, a 5 LV OPLSDA model showed good discrimination of clinical groups on the 
scores plot (Figure 3.13b). It could distinguish between samples from the inhalation 
injury group and the non-inhalation group with 75% accuracy, 72% sensitivity and 
79% specificity. The Q2 metric of 0.17 and non-significant permutation test suggests 
significant overfitting of the model (Table 3.18.). Metabolite identification was 




 Figure 3-13. A) PCA Scores plot from serum NMR data, blood samples taken first 24hrs post burn 





3.4.4.2  The effect of inhalation injury on changes in the post-burn metabolome 
(24-84 hrs post-injury) 
 
Serum NMR data from 32 patient samples, taken between 24 and 84 hours post-
injury was subjected first to unsupervised PCA analysis and then to supervised 
OPLSDA analysis as before. A 4 PC model could explain the following percentages 
of variation: PC1 35.59%), PC2 (16.79%), PC3 (10.92%) and PC4 (8.76%). The PCA 
scores did reveal some separation of the groups, particularly in PC1 (Figure 3.14a). 
Two outlier samples were removed as they fell outside the Hotelling’s 95% 
Confidence ellipse and the data from the remaining 30 samples were subjected to 
OPLSDA, producing a 5 LV model with good discrimination of clinical groups on the 
scores plot (Figure 3.14b). The resultant metabolomics model could discriminate 
between inhalation injury and non-inhalation injury serum samples with 80% 
accuracy, 82% sensitivity and 79% specificity. The model showed acceptable R2 
(0.9) and Q2 metrics (0.5) and a permutation test p-value of 0.024, demonstrating 
that there was not significant overfitting of the model.  
 
As the model demonstrated good discriminatory and model fitting characteristics, 
spectral fitting was performed to identify the top 50 ranked spectral bins in the 
OPLSDA model, according to VIP score. A total of 7 metabolites were identified with 
the top 50 bins with glucose predominating 88% (44/50) of the peak bins (Table 
3.19). Glucose was increased in the samples from patients with inhalation injury 
relative to those from patients with no inhalation injury. Other metabolites that were 
increases in the inhalation injury group included kynurenine, glycerol and allantoin, a 




Figure 3-14. A) PCA scores plot from serum NMR data derived from blood samples taken 24-84hrs 





Table 3-18. Summary statistics for OPLSDA models generated from serum NMR metabolomics data. 
Comparison of discriminatory performance and fitting metrics between models generated from 
samples taken <24hrs post injury and samples taken 24-84hrs post-injury. CV = cross validated, CI – 
confidence interval, PPV = Positive predictive value, NPV = negative predictive value, AUROC = area 
under the receiver operating characteristic curve. 
 
Table 3-19. Metabolites identified within the top 50 ranked peaks in the OPLSDA model discriminating 
between samples from burn injured patients with inhalation injury and those without inhalation injury. 
Parameter <24hrs post-injury 24-84hrs post-injury
Samples (n) 34 30
Latent variables (n) 5 5
CV Accuracy % (95% CI) 0.75 (0.55-0.88) 0.80 (0.59-0.91)
CV Sensitivity % (95% CI) 0.72 (0.54-0.84) 0.82 (0.54-0.96)
CV Specificity % (95% CI) 0.79 (0.56-0.93) 0.79 (0.63-0.87)
PPV % (95% CI) 0.81 (0.61-0.94) 0.69 (0.46-0.82)




Permutation test p-value 0.177 0.024
Rank Metabolite Change$ VIP* Chemical shift of peak bins (ppm)
1 Glucose ­ 35.16
3.24, 3.26, 3.4, 3.41, 3.42, 3.46, 3.47,
3.48, 3.50, 3.51, 3.52, 3.69, 3.70, 3.71,
3.72, 3.75, 3.76, 3.77, 3.78, 3.79, 3.80,
3.81, 3.82, 3.83, 3.85, 3.86, 3.87, 3.88,
3.89, 3.90, 3.92, 5.24,5.25
2 Lysine ¯ 12.74 3.04
3 Kynurenine ­ 12.58 3.69
4 3-Hydroxybutyrate ¯ 10.55 1.19
5 Glycerol ­ 10.27 3.67
6 Acetoacetate ¯ 10.16 2.28
7 Allantoin ­ 7.65 5.42
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3.5 Discussion 
3.5.1 Early changes in the post-burn metabolome  
In this study, we applied 1H-NMR metabolomics to study the acute changes in the 
metabolome in a cohort of patients with severe thermal injuries. 1H-NMR analysis of 
serum samples taken during the first 96-hrs post-injury demonstrated changes in 
keto-acids, lactate, carbohydrates and amino acids reflective of hypoxic metabolism, 
increased energy production and derangements in glucose and protein metabolism. 
Multi-variate statistical analysis produced metabolite models that could distinguish 
between burn injured patients and healthy control subjects. The most highly weighted 
metabolites in these models were therefore reflective of the key changes in the 
serum metabolome after thermal injury. It was evident that metabolic changes during 
the first 24hrs after thermal injury were distinguishable from those during the next 24-
84hrs post injury. This may represent a metabolic shift from the early ‘ebb’ phase 
towards entry into the ‘flow’ phase which demonstrated a different pattern of 
metabolites that differentiated healthy controls from patients with thermal injury.  
The cohort studied was appropriate to the study of severe thermal injury, being a 
relative large cohort of 37 patients with an average burn size of approximately 40% 
TBSA. This group of patients demonstrated significant physiological derangement 
and organ dysfunction during the first 24hrs of hospital admission, as evidenced by 
high average APACHE II, SOFA and Denver MOF scores. Commensurate with a 
severely injured cohort, there was a high incidence of complications, including MOF 
(43%), sepsis (51%) and non-survival (27%). The non-survivors were significantly 
older, had larger TBSA injuries, greater full thickness burn area and had a higher 
incidence of inhalation injury and greater levels of organ dysfunction on admission.  
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In the OPLSDA model able to discriminate serum samples taken from patients within 
the first 24hrs post-injury from control samples, there were changes in metabolism 
reflecting alterations in glucose homeostasis, increased TCA cycle activity, increased 
lipolysis and increased production of pyruvate and lactate (Figure 3.16).  
 
Figure 3-15. Overview of key pathways and metabolites discriminating early first 24hr serum samples 
taken from patients with severe thermal injuries and healthy control samples. Red metabolites were 
elevated relative to controls and blue metabolites were decreased relative to controls. 
 
The most highly weighted metabolites in the model included the keto-acids (‘ketone 
bodies’) 3-Hydroxybutyrate (3-HB) and acetoacetate and lactate. In starvation states 
and during exercise, ketone bodies become a protein sparing energy substrate. In 
these scenarios, carbohydrate availability decreases, whilst peripheral lipolysis 
increases. There is increased uptake and beta-oxidation of fatty acids in the liver, 





































































Simultaneously, there is upregulation of gluconeogenesis, resulting in increased 
utilization of oxaloacetate. This leads to an excess of acetyl CoA which is converted 
to acetoacetate, which can be either reduced to 3-HB in the mitochondrial matrix or 
slowly converted to acetone (229). 
Acetoacetate and 3-HB are not simply degradation products, they are utilized by the 
brain, cardiac muscle and renal cortex as energy substrates (ketolysis) (322) and 
also have signaling activities that can influence chromatin modifications through 
inhibition of histone deacetylases (HDACs) (323). The OPLSDA models in this study 
suggest that acetoacetate remains elevated in the second phase (24-96hrs), 
whereas 3-HB decreases to lower levels relative to controls. This could indicate 
increased utilization of acetoacetate by extra-hepatic tissues as an energy substrate 
in preference to 3-HB. Studies of ketone bodies  after severe thermal injury, trauma 
and sepsis have generally shown that, despite evidence of increased peripheral 
lipolysis and b-oxidation of fatty acids, ketone production is not increased which is 
hypothesized to be related to hyperinsulinaemia with increased insulin resistance 
(324). However, many of these studies were performed in the context of starvation 
and patient studies were performed before the introduction of early enteral feeding as 
a burn care standard(325).  
A more recent study measured arterial and portal blood concentrations of ketone 
bodies early after polytrauma and found that at 6hrs post-injury 3-HB was elevated in 
the portal circulation but not systemically suggesting ketogenesis driven by the gut. 
At 24hrs post-injury, however, portal blood levels of 3-HB decreased whilst systemic 
levels increased indicating gut utilization of ketone bodies as an energy source (326). 
 151 
No recent studies have been performed re-evaluating ketone body metabolism or 
kinetics in thermal injury. The ratio of acetoacetate and 3-HB reflect mitochondrial 
redox potential and one study showed that acetoacetate in arterial blood declined 
with time over 3-weeks post-burn and this trend was associated with the 
development of MOF. They also showed a decrease in the Acetoacetate:3-HB ratio 
over time, indicating a progressive decline in mitochondrial redox potential (327).  
Pyruvate and glucose were also highly weighted in the models and show relative 
increases after thermal injury compared to controls. This is consistent with the known 
profound alterations in carbohydrate metabolism after thermal injury that are due to 
the combination of acute inflammation and the imbalance of catabolic stress 
hormones (catecholeamines, cortisol, glucagon) and the anabolic hormone, insulin. 
Hyperglycaemia is well documented after burn injury (328,329) and is due to 
increased peripheral resistance (skeletal muscle) to insulin, increased central insulin 
resistance (liver) and increased glucose production via glycolysis and 
gluconeogenesis (330). This ‘stress diabetes’ is felt to an adaptive response to injury 
and infection to prioritize glucose supply to non-insulin dependent vital organs unable 
to metabolise other substrates in the context of the stress response (331). Although 
the availability of glucose increases post-burn, the increase in glucose oxidation by 
33% (193) is insufficient to keep up with supply (192).  
The data also show increased levels of glycerol, lactate and the amino acids alanine 
and glycine relative to controls. Studies of the upregulated gluconeogenesis after 
burn injury, show that there is increased uptake of 3-carbon precursors pyruvate, 
lactate and amino acids, particular alanine (332). There is also increased availability 
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of these precursors, in addition to glycerol from increased lipolysis of triglycerides in 
adipose tissue (168). The elevations in lactate in the injured patients are common to 
all forms of critical illness and are in the initial phase due to tissue hypoxia during 
resuscitation. There is also a contribution from the highly specialized immune cells 
activated in the burn wound, that demonstrate increased lactate output even in the 
absence of hypoxia (201). This lactate contributes to glucose production as it is 
transported to the liver for gluconeogenesis and this cycle is termed the Cori-cycle 
(324). Another contributor to the elevations in serum lactate, could be the use of 
Ringer’s lactate as intravenous resuscitation fluid, which is used to replace volume 
losses and maintain tissue perfusion during the first few days post-injury. 
In addition to changes in alanine and glycine, decreases were also seen in the 
injured patients relative to control in other amino acids proline, valine and glutamine. 
The metabolic response to thermal injury when compared to non-stressed starvation 
bears similarities but the major difference is that in the former, the switch to lipids as 
the major fuel does not spare protein catabolism. After severe thermal injury, there is 
increased protein synthesis, but there is also increased protein catabolism and this 
outstrips synthesis, resulting in a net decrease in protein balance (333). This protein 
catabolism occurs in skeletal muscle and results in losses of lean body mass (LBM) 
which leads to increased rates of infection, delayed wound healing and delays in 
rehabilitation (330). The goal of this amino acid liberation from muscle, is to provide 
substrates for acute phase protein synthesis, wound healing and gluconeogenesis 
(228). 
 153 
Glutamine is an alpha amino acid that becomes conditionally essential in critical 
illness states. It has been demonstrated to decrease in patients with sepsis, burns 
and trauma. In patients with burn injury, plasma levels decreased by 58% and 
remained significantly low for 3 weeks post-injury (334). Glutamine plays important 
roles in modulation of the immune response (334), provides a primary fuel source for 
enterocytes and is necessary for maintaining mucosal associated lymphoid tissue 
(MALT) and therefore maintenance of gut integrity (335). It also is an important 
precursor to the anti-oxidant glutathione, which is relevant in the context of oxidative 
stress that occurs after injury (336). Stable isotope studies in thermally injured 
patients have shown that muscle intracellular levels of glutamine are low due to 
increased rates of outward transport and consumption (337). Valine is a branched 
chain amino acid that is essential and thus must be provided in the diet. Valine can 
serve as a precursor to the TCA cycle intermediate succinyl CoA and therefore 
decreased levels after burn injury, as with glutamine and proline, may reflect 
increased TCA cycle flux to drive increased ATP production as part of the stress 
response. Valine also has an important role in the renewal of haemopoietic stem 
cells (338). Previous comprehensive studies of amino acid metabolism in thermally 
injured humans and animal models show acute decreases in valine, glycine, proline, 
glutamine and alanine in plasma (339). Proline and glycine are abundant amino acids 
in human collagen which is essential for wound healing, so wound sequestration may 
contribute to decreased circulating levels post-burn. 
The OPLSDA metabolite model that discriminated patient serum samples taken 24-
84hrs post-burn from control samples shows a different pattern to the model from 
earlier samples. There is increased weighting of the amino acids alanine, glycine and 
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glutamine suggesting increasing protein catabolism as the flow phase is entered. 
Citrate is lower relative to controls and this suggests that there is ongoing increased 
TCA cycle flux drive ATP production and therefore its consumption is increased 
(Figure 3.17). 
 
Figure 3-16. Overview of key pathways and metabolites discriminating serum samples taken from 
patients with severe thermal injuries between 24-96hrs post-injury and healthy control samples. Red 
metabolites were elevated relative to controls and blue metabolites were decreased relative to 
controls. 
3.5.2 NMR metabolomics can distinguish between burn injured patients with 
and without inhalation injury 
Inhalation injury has long been known to be a significant determinant of outcome 
following thermal injury and is associated with increased mortality and length of stay 
(340). The clinical data from our study corroborates with previously published data, 









































































<24hrs serum NMR data, OPLSDA could only be used to produce a model to 
discriminate inhalation injury samples from non-inhalation samples through overfitting 
of the model. As was seen with the MOF and sepsis prediction models, the data 
obtained from the samples taken slightly later, between 24 and 84hrs post-burn did 
yield useful discriminatory models for inhalation injury using OPLSDA. Possible 
reasons for the later data yielding better models may be that the metabolic 
disturbances that relate to the effects of inhalation injury may not develop until after 
24hrs post-burn. Alternatively, the systemic metabolic effects specific to inhalation 
injury are masked in the first 24hrs post-injury by the initial systemic inflammatory 
and metabolic alterations secondary to the cutaneous thermal injury. 
 
The top 50 ranked spectral bins in the 24-84hrs serum sample metabolomics model 
only featured 7 metabolites, owing to the predominant representation of glucose 
peaks in the model. Clearly, the additional inflammatory stress generated by the 
inhalation trauma in addition to the cutaneous burn has significant effects on glucose 
homeostasis. Previous studies have shown after adjusting for age and burn size, that 
severity of inhalation injury correlates with circulating plasma levels of cytokines IL-
1RA, IL-6, IL8, G-CSF and MCP-1 (72). Other metabolites that were elevated were 
kynurenine, a tryptophan metabolite with immune and vasoactive effects (see section 
3.5.4), glycerol and allantoin. Elevations in glycerol and decreases in lysine reflect 
increased fat and protein catabolism respectively. The presence of allantoin is an 
interesting finding, as it is a product of purine metabolism and can be generated from 
conversion of uric acid by reactive oxygen species (ROS). Allantoin has been 
described as a marker of oxidative stress in a number of inflammatory diseases 
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including rheumatoid arthritis (RA)  and Behcet’s disease (BD) (341,342). Elevations 
of this metabolite may reflect increased ongoing oxidative stress generated by the 
additional inflammatory hit of the inhalation injury and no specific studies have 
previously measured this metabolite in patients with thermal injury or inhalation 
injury. 
 
3.5.3 NMR metabolomics reveals changes in novel serum metabolites after 
thermal injury 
Two other unusual metabolites were observed to be elevated in the <24hr post-injury 
serum relative to control serum in the multi-variate model. Propylene glycol is an 
organic compound that is used as a food additive and as a common excipient for 
pharmaceuticals, the latter being a probable cause for relative elevations in the 
patient group. It is metabolized to either pyruvate, lactate, acetate or 
propionaldehyde. The organic acid 2-hydroxybutyrate (alpha-hydroxybutyrate, 2-HB) 
is derived from alpha-ketobutyrate produced through catabolism of threonine and 
methionine or as a by-product of the synthesis of glutathione (343).  A recent 
untargeted human metabolomics study demonstrated 2-HB to be an early biomarker 
of insulin resistance and impaired glucose regulation. The mechanisms proposed for 
elevation of 2-HB include hepatic oxidative stress leading to increased demand for 
the anti-oxidant glutathione and elevation of the NADH/NAD+ ratio secondary to 
increased fatty acid oxidation (344). This metabolite has not been investigated in 
thermal injury, but warrants further study given its link to insulin resistance and anti-
oxidant production. Severe thermal injury is documented to result in increased 
oxidative stress and mitochondrial dysfunction in skeletal muscle (345,346).  
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3.5.4 NMR metabolomics can predict poor outcomes from early serum 
samples after thermal injury 
The second aim of this study was to evaluate if early serum metabolomics could be 
used to predict later poor clinical outcomes. The study has shown that 1H-NMR 
metabolomics analysis of serum samples taken within the first 96hrs post-burn can 
predict poor outcomes with high accuracy including: mortality, multiple organ failure 
(MOF) and sepsis. The most discriminatory mortality prediction model was created 
from OPLSDA analysis of the serum samples taken from the first 24hrs and showed 
an AUROC of 0.92. The cross validated model had high specificity (92%) but only 
moderate sensitivity (78%). The most significantly weighted metabolites in the model 
included elevations in non-survivors of: 3-HB, ethanol, glycerol, kynurenine, acetate, 
methyl-malonate and as expected glucose and lactate. The amino acids lysine, 
alanine and glutamine were decreased in non-survivors, again demonstrating the 
relationship of protein catabolism to mortality in thermal injury, consistent with data 
that shows skeletal muscle catabolism correlates directly with poor outcomes (231). 
Kynurenine is a major degradation product of tryptophan, with potentially toxic 
downstream metabolites such as quinolinic acid and 3-hydroxykynurenine which are 
neurotoxic and can induce free radical production. Circulating kynurenine levels have 
not been studied in burns, but one study showed increased urinary excretion of 
kynurenine in burned children (347). Kynurenine has become the subject of studies 
in critically ill, trauma and septic patients after observations that the enzyme 
indoleamine 2,3-dioxygenase (IDO) which catalyzes the breakdown of tryptophan to 
kynurenine has immunoregulatory effects on T-cells (348) and its expression is 
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responsive to cytokines Interferon-g (349) and IL-10 (350). Moreover, IDO mediated 
kynurenine production in vascular endothelium contributes to vascular relaxation 
(351). Studies in humans, have shown that IDO expression is increased in patients 
with septic shock and correlated with hypotension (352). Increased IDO activity was 
associated with dysregulated immune responses and microvascular responsiveness 
in sepsis (353). Studies in trauma patients, suggest that plasma levels of kynurenine 
were increased on the first day post-injury in patients who later developed sepsis and 
increased kynurenine:tryptophan ratios predicted later MOF and death (354). 
Kynurenine has been investigated in the field of wound healing and has been shown 
to decrease scar formation in animal models of hypertrophic scar formation. This is 
postulated to be secondary to upregulated production of matrix metalloproteinases 
(MMP1 and MMP3) and suppression of the expression of type I collagen in dermal 
fibroblasts (355). 
Methylmalonate (MMA) is a vital intermediate in lipid and protein metabolism and is a 
metabolite in the valine degradation pathway in addition to its roles in pyrimidine 
metabolism and propanoate metabolism. There are no previous studies of this 
metabolite in thermal injury but the metabolite accumulates in the condition 
methylmalonic acidaemia, caused by a defect in the enzyme methylmalonyl CoA 
mutase which converts methylmalonyl CoA into succinyl CoA for entry in the TCA 
cycle. This enzyme is vitamin B12-dependent and therefore MMA can accumulate in 
vitamin B12 deficiency. It can also be derived from metabolism of propionate 
produced by enteric bacteria and absorbed into the portal circulation, although 
elevations of MMA through this mechanism have only been described in 
methylmalonic acidaemia (356). Interestingly, MMA accumulation is also associated 
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with impairment of mitochondrial oxidative function, possibly through inhibitory effects 
on enzymes involved in mitochondrial glutamate metabolism (357). This metabolite 
warrant further investigation in thermal injury, given the known gut dysfunction that 
occurs (358) that may lead to changes in gut microflora and increased absorption of 
certain metabolites. 
The finding of relatively increased levels of acetate in the early serum samples from 
non-survivors is another finding of potential interest. The two major sources of 
acetate in humans are endogenous production and from colonic fermentation of 
carbohydrates by enteric bacteria (359). Endogenous acetate is formed from acetyl 
CoA by acetyl CoA synthetase and acetyl CoA hydrolase and the liver is felt to be 
primary site of acetate metabolism (360). Acetate is known to be utilized in peripheral 
tissues (361) and total body oxidation may account for between 2 and 10% of energy 
expenditure (362). It’s role in endogenous metabolism is not fully understood, but 
may serve to aid in the redistribution of oxidisable substrates to the myocardium and 
brain, particularly in situations of caloric deprivation (359).  
Elevated levels acetate may be relevant to changes in metabolism in thermal injury 
for several reasons. Studies in diabetes mellitus have shown elevated plasma 
acetate concentrations, possibly due to increased availability of acetyl CoA from 
increased b-oxidation of fatty acids, with reduced TCA cycle activity (363). More 
recently, a study in rats has shown that increased acetate production by enteric 
bacteria, drives increased glucose stimulated insulin secretion via increased 
parasympathetic activity and may contribute to the development of metabolic 
syndrome and obesity. Within this study, they also showed that gastric provision of 
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acetate led to increases in insulin resistance, with increases in plasma and liver lipid 
and triglyceride content (364). These studies pose the question as to whether 
alterations in the gut function and changes in the gut microbiome after thermal injury 
could lead to increased enteric acetate production and absorption and could 
contribute to insulin resistance and alterations in lipid metabolism. 
In the prediction models of MOF and sepsis, it was found that the changes in the 
metabolite profile of serum samples taken in the second metabolic phase (24-96hrs) 
showed greater discriminatory power than the early first 24hr serum profiles. The 
discriminatory performance of these models showed the MOF model to have an 
AUROC of 0.92 and the sepsis model to have an AUROC of 0.89. These models 
show a globally different pattern of change compared to the mortality prediction 
model. The predominant pattern was for metabolites to be lower in the poor outcome 
groups, including the ketone bodies and amino acids. This could reflect the more 
severe injuries seen in these poor outcome groups resulting in more dramatic fluid 
shifts in or more severe perturbations in metabolism. Glucose and glycerol remained 
higher in the poor outcome groups, reflecting the importance of hyperglycaemia and 
lipid metabolism in relation to later clinical outcomes. 
The sepsis prediction model included some curious findings including decreases in 
ethanol and methanol. The detection of these metabolites from samples taken >24 is 
less likely to be from exogenous sources, i.e. alcohol intoxication on admission to 
hospital. The most likely source of these metabolites is therefore from gut bacterial 
metabolism, although low levels of endogenous production do occur in humans 
(365). Why the serum levels of these would be lower in patients who later go to 
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develop sepsis is not clear and confirmation of this finding would need confirmation 
with targeted assays. Decreases in ketone bodies in the septic group have previously 
been described in severe trauma, burns and sepsis. Animal models suggest this may 
be due to increased peripheral utilization of ketone bodies or greater impairment of 
hepatic ketogenesis (366). 
Carnitine was also lower in the septic group and has been previously shown to be 
low in general for 2 weeks following thermal injury (367). Carnitine is a quaternary 
ammonium compound, which plays an essential role in fatty acid metabolism. It 
facilitates transport of long chain fatty acids across the mitochondrial membrane so 
they can undergo b-oxidation to generate acetyl CoA, a substrate that enter the TCA 
cycle to generate ATP. Circulating levels are also depleted in human sepsis (368) 
and animal studies have shown L-carnitine supplementation can decrease the 
inflammatory response to lipopolysaccharide (LPS), ameliorate lipid metabolism 
abnormalities and improve survival in sepsis models (369). 
 
3.5.5 Comparison with published metabolomics studies of thermal injury  
To date there has been only one other metabolomics based study of human thermal 
injury from a group in China. They used 1H-NMR to study changes in the plasma 
metabolome in 21 patients with very large thermal injuries of >50% TBSA and 
compared the changes to 3 healthy controls (271). The mean burn size in their cohort 
was therefore 77% TBSA, approximately twice that of the cohort in this study. Their 
cohort was also slightly older and had a high proportion of male subjects. They used 
multi-variate analysis to construct a model, they term an ‘Eigen-metabolome’ of 12 
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metabolites that were significantly different between the patients and controls. In 
terms of similarities, their model also interestingly contained 2-HB and a metabolite in 
the valine synthesis/degradation pathway, alpha ketoisovaleric acid (3-methyl 2-
oxobutanoate) which has been to accumulate with mitochondrial dysfunction in liver 
disease (370). Their model also included increased 3-methylhistidine, an amino acid 
formed from degradation of skeletal muscle actin and myosin. This is classically 
studied measured in urine as a marker of skeletal muscle catabolism (371). 
Interestingly, they also detected a range of hormone metabolites including 
aldosterone, deoxycorticosterone and 2-methyoxyestrone highlighting the importance 
of endocrine dysfunction after severe thermal injury. The study does suffer from 
some methodological issues, including utilizing sample creatinine peak to scale the 
metabolite data and the use of citrated blood samples which can mask the detection 
of other metabolites. However, the study does, complement our work in showing that 
metabolomics can be applied to try to understand the complex network of metabolic 
changes after severe thermal injury. 
Metabolomics has been applied to animal models of thermal injury to study changes 
in muscle metabolism and develop metabolite models predict injury severity and 
sepsis. Righi et al used Total through Body correlation Spectroscopy (TOBSY) NMR 
to quantify metabolites in muscle in a mouse hind limb burn model. They showed 
increased levels of lipids, taurine, phosphocreatine and decreased levels of 
glutathione, carnosine, glucose, glutamine, glutamate and alanine in the burned limb 
compared to an unburned limb (269). Izamis et al measured targeted groups of blood 
metabolites in a 20% TBSA rat burn model and developed a neural network model 
that could predict the severity of the burn injury with 88% accuracy. The two 
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metabolites most significantly contributing to the model were very low density 
lipoprotein (VLDL) and acetoacetate which both inversely correlated with severity of 
burn. Liu et al. performed LC-MS metabolomic analysis of plasma samples in a 30% 
TBSA rat burn model and compared profiles of burn injury alone to burn plus caecal 
ligation and puncture (CLP), a recognized animal model of sepsis. They identified 
seven putative biomarkers of sepsis, that were significantly elevated in the burn 
sepsis compared to burn (372). 
3.5.6 Limitations of the study 
There are several limitations of the study, the first being the broad range of burn 
sizes included in the study which ranged from 15-95% TBSA. The potential 
disadvantage of this is that the less severe burns would logically have less severe 
metabolic derangements which could blunt observation of the changes seen in the 
larger injuries. Future studies should perhaps employ a lower burn size cut-off of 20 
or 30% TBSA. The advantage of including a broad range of burn sizes is wider 
applicability of the data. Fully quantitative data on the metabolite concentrations has 
not been presented and calculation of these and application of traditional univariate 
statistics to assess if group trends hold up with give a more thorough assessment of 
the changes and potential biomarkers identified. From a technical point of view, pH 
correction was not applied to the serum samples, so there may be have been some 
pH variation across samples, resulting in varying shifts in metabolite peaks on the 
NMR spectrum for some metabolites. Generally, pH correction is more important for 
urine samples as human serum has a narrower pH range. Potential solutions to this 
would include pH correction with buffering agents, pH checking and inputting into 
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analysis software for automated correction or the addition of a pH reference standard 
such as imidazole to the samples.  
3.5.7 Conclusions 
Changes in the early serum metabolome after severe human thermal injury have 
been delineated using 1H-NMR metabolomics. The approach has allowed an 
assessment of the global changes in the metabolic network, with simultaneous 
identification of metabolites from a range of metabolite classes. Multi-variate analysis 
techniques have allowed the metabolomics data to be interrogated and deconvoluted 
to identify only the most important metabolites contributing to class differences. The 
changes identified in serum in the first 24hrs after thermal injury reflect increased 
energy production, altered glucose homeostasis, lipolysis, ketone production and 
increased TCA cycle activity. Many of this study’s findings agree with previous 
targeted studies of thermal injury metabolism spanning the last 40 years, with a few 
exceptions that warrant further investigation. Metabolomics predicted later poor 
outcomes based on patient’s metabolite profiles and predictive models demonstrated 
excellent discriminatory performance. However, the potential future utility of this 
approach is not to predict binary clinical outcomes which can be done equally well 
with currently available clinical scoring systems. Rather, this approach could be a first 
step on the road towards personalized healthcare, with early stratification of care 
pathways based on early metabolic profiles with the aim of improving outcomes in 
burn care. The study has also identified novel putative outcome biomarkers that 
could be taken forward into targeted metabolomics studies. 
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Future directions of this research include an analysis of urine samples from the same 
cohort of patients to add further weight to findings from serum and identify putative 
urine biomarkers of outcome. This approach could also be used to search for 
putative sepsis biomarkers in human thermal injury, which has not yet been studied. 
The focus of this study has been on the early changes in the metabolome after 
thermal injury and how they may relate to later clinical outcomes of the patients. The 
effects of thermal injury are however prolonged compared to other forms of trauma 
(299), with increases in resting energy expenditure (REE) persisting for up to 1 year 
in patients with >30% TBSA burns (REF). Metabolomics could therefore be applied to 
study the longitudinal changes in metabolism after thermal injury to give a global view 
of how the metabolic network changes across time. This may reveal changes in 
unstudied areas of metabolism which could be targetable with pharmacotherapeutics 



























Chapter 4: Metabolomic study of the 
longitudinal metabolic response to 
severe thermal injury in adults 
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4 Metabolomic study of the longitudinal metabolic 
response to severe thermal injury in adults 
4.1 Introduction 
Severe thermal injury, defined as thermal burns affecting ≥20% of the total body 
surface area (TBSA), results in a profound and prolonged stress response (38). This 
parallels the systemic inflammatory response and is characterized by elevations in 
circulating stress hormones leading to a hyperdynamic circulation, hyperthermia, 
increased resting energy expenditure (REE), derangements in lipid and glucose 
metabolism and skeletal muscle proteolysis leading to dramatic reductions in lean 
body mass (LBM) (333).  This hypermetabolic response (HMR) is a catabolic state 
that is seen other forms of trauma and in sepsis, but is more prolonged after thermal 
injury (299), in which there is evidence of ongoing metabolic derangements up to 3 
years after injury (42). Although the HMR is intended to be an adaptive response to 
trauma, its persistence leads to delayed rehabilitation and is associated with 
increased morbidity and mortality (42). 
Studies over the past three decades have led to an increased understanding of the 
biochemical and metabolic changes that occur after severe thermal injury. These 
have led to the introduction into clinical practice of supportive measures to try to 
reduce the HMR, such as early burn wound excision, improved nutritional support 
with adequate provision of protein, environmental warming and exercise training. 
Research has also led to clinical trials of pharmacotherapies including oxandralone 
and propranolol which have shown safety and efficacy (240,242), but no single drug 
has yet been shown to completely abolish the HMR. Longitudinal analysis of burn 
outcomes suggests modern medicine has currently reached a plateau in terms of 
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improvements in burn survival (284). This highlights the need for new biological 
information and novel therapeutic targets to drive the next step changes in burn care. 
Systems biology approaches such as transcriptomics, genomics and proteomics are 
starting to help us recognize the complexity of the human response to thermal injury 
and identify new avenues of research. Metabolomics is a relatively recently 
developed systems biology technique that harnesses advances in analytical 
platforms such as Nuclear Magnetic Resonance (NMR) Spectroscopy and mass 
spectrometry (MS) coupled to advanced chromatographic separation techniques 
such as Ultra-high performance liquid chromatography (UHPLC). Metabolomics aims 
to quantify all low molecular weight products (<1.5kDa) of metabolism in a biological 
system, the spectrum of which is termed the metabolome (252). These products of 
metabolism, fall downstream of upstream biochemical processes such as gene 
transcription, protein translation, thus metabolomics can most sensitively and 
dynamically define the true functional state, or phenotype of an organism or system. 
It can also identify how the metabolome changes in response to environmental 
influences, diet, drugs or stimuli, for example, thermal injury. 
To date, metabolomics has been applied to the study of burn injury in a limited 
number of studies, mainly in animal models to study metabolic changes in skeletal 
muscle (269,373,374) and to try to differentiate sepsis from burn related inflammation 
(272). The only human metabolomics study of thermal injury, utilized 1H-NMR 
metabolomics to investigate the metabolome in a single early plasma sample taken 
from patients with very large burns (>50% TBSA) (271). These studies have 
demonstrated that metabolomics certainly has potential to yield important new 
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biological information regarding the complex changes in metabolism after severe 
thermal injury. However, the response is dynamic and changes across time, 
therefore a longitudinal approach may yield more useful biological data. Such 
longitudinal metabolomics approaches have recently been applied in study of human 
trauma (375) and animal models of sepsis (376). 
A further exciting avenue of research is being fueled by the increasing recognition of 
the interplay between immune function, inflammation and metabolism. The functional 
coordination of immunity and metabolism is felt to be important in the development of 
immune responses but also in the resolution of inflammation (377). Metabolites 
previously considered as simple waste by-products of metabolism, are now being 
shown to have immunomodulatory functions. Lactate, for example, is a metabolite 
produced by cells under hypoxic conditions (anaerobic glycolysis) or due to high flux 
of glycolysis in proliferating cells. It has been recently shown to modulate pro-
inflammatory migratory and effector functions of T-lymphocytes (378). The 
simultaneous longitudinal study of inflammation, immune cell function and the 
metabolome in patients with severe thermal injury may allow identification of 
metabolites that influence post-burn immune dysfunction. 
Metabolomics therefore has the potential to provide a more global assessment of the 
metabolic changes that form the hypermetabolic response to severe thermal injury. 
This could provide new areas of therapeutic potential, to focus more targeted 
metabolic studies with targeted metabolomics studies and/or conventional 
biochemical techniques. Other potential advantages of the approach would be the 
first step towards developing more sophisticated metabolic monitoring of thermally 
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injured and other critically ill patients, thus allowing more tailored and personalized 
nutritional and metabolic support with the ultimate goal of improving patient 
outcomes. 
 
4.2 Aims & objectives 
3. To identify the longitudinal changes in the serum metabolome after severe 
thermal injury (≥ 15% TBSA) in adults aged 16-64 years applying a discovery-
based metabolomic approach 
4. To relate any metabolic changes to laboratory measures of hypermetabolism 
and inflammation. 
 
4.3 Materials and Methods 
4.3.1 Study group and recruitment 
Samples for this study were obtained from patients recruited to a UK prospective 
multi-centre observational study, the SIFTI study (Scientific Investigation of biological 
pathways Following Thermal Injury, UKCRN ID: 13654). The inclusion criteria for the 
patients enrolled in to this study were: age ³16 years and <65 years, thermal burns 
with injury size ³15% TBSA, arrival to the burn centre and first sample obtained 
within the first 24hrs of injury and a complete set of 9 serum samples up to 6-months 
post-injury as per the study protocol (see section 4.3.4). Exclusion criteria for this 
study were: chemical or deep electrical injury, associated traumatic injuries with an 
injury severity score (ISS) of >25, early decision (first 24hrs) for comfort care only 
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due to severity of injury and the presence of certain co-morbid conditions (congestive 
cardiac failure, malignancy, patients receiving glucocorticoid therapy, multiple limb 
amputations). All patients included in this study were recruited and treated at the 
same regional burns centre at the Queen Elizabeth Hospital Birmingham (QEHB) in 
the UK.  
Patients were recruited within the first 24 hours of sustaining injury either by direct 
informed consent, or, through a legal consultee if required due to the severe nature 
of their injuries or due to unconsciousness so that they were not able to consent 
themselves. This method of recruitment was agreed through an UK NHS research 
ethics committee (NHSREC, reference 12/EM/0432). 
4.3.2 Treatment of patients 
Treatment of all patients included in the study was standardized through the 
application of local treatment guidelines used in the QEHB burns centre. This 
included the use of fluid resuscitation with Ringer’s lactate (Hartmann’s solution) 
according to the Modified Parkland Formula (2-4 ml/kg/% TBSA burn) over the first 
24hrs post-burn. All patients underwent invasive monitoring of central venous 
pressure (CVP) and arterial blood pressure and urine output and resuscitation targets 
were: urine output 0.5-1.0 ml/kg/hr and mean arterial pressure (MAP) of >60 mmHg. 
Patients with oliguria or hypotension despite adequate crystalloid resuscitation were 
given 250-500 ml boluses of 5% human albumin solution (HAS) and ionotropic 
support with noradrenaline. All patients received early enteral nutrition commenced 
within 24hrs of injury via a nasogastric or nasojejunal tube with energy requirements 
calculated using the Toronto Formula (379), with resting energy expenditure (REE) 
calculated using the Harris-Benedict Equation (380).  Nutritional support also 
 172 
included enteral supplementation of glutamine and vitamin C and intravenous 
supplementation of trace elements until wound closure. All patients admitted to the 
intensive care unit (ICU) who were expected to have prolonged ventilator support 
received bowel management via an indwelling bowel management system. All 
patients received gastro-protection with intravenous ranitidine and 
thromboprophylaxis with subcutaneous injections of enoxaparin. Patients requiring 
surgery underwent first burn excision within 72hrs of admission and coverage with 
split-thickness skin autograft. Patients with burns >40% TBSA typically required 
wound coverage with combinations of autograft, cadaveric allograft and skin 
substitutes. 
4.3.3 Clinical data Collection 
Detailed clinical data were collected for all patients in a standardized case-report 
form (CRF) which was later entered onto an electronic database. Data included 
demographics, burn injury data and clinical outcomes including length of ICU stay, 
total length of stay, survival, the occurrence of sepsis (ABA consensus sepsis trigger 
criteria) (309) and the occurrence of multiple organ failure (MOF) according to the 
Denver 2 MOF score (33).  
4.3.4 Sample collection and preparation 
Blood samples were collected between 08:00 and 10:00. A total of 9 samples for 
each patient were collected at the following time-points: Day 1 (D1 - first 24hrs post-
injury), D3-4, D5-9, D19-24, D26-29, Month 2 (D60+/-7 days), Month 3 (D90 +/- 7 
days) and Month 6 (D180 +/-14 days). Patients admitted to the ICU had 6ml blood 
samples collected from the indwelling arterial or central venous catheter using a 
Vacuette® blood collection system into Vacuette® Z-serum clot activator tubes 
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(Greiner Bio-One Ltd, Gloucester, UK). Patients admitted to a burns ward HDU bed 
who did not have an indwelling vascular catheter had blood drawn by peripheral 
phlebotomy using an upper arm tourniquet and using an identical blood collection 
system and tubes as described above. Blood samples were kept upright and allowed 
to form a clot at room temperature for 30mins before processing into serum aliquots. 
To obtain serum, blood tubes were then centrifuged at 3000 rpm for 10 minutes at 
20°C in a swinging bucket rotor centrifuge (Eppendorf Centrifuge, model 5804 R, 
ThermoFisher Scientific). Serum aliquots of 400-600 μl were placed in 1.5 ml plastic 
cryovials and stored upright in a temperature monitored freezer at -80°C. 
4.3.5 Sample preparation for metabolomics analysis 
Serum samples were randomized from their original collection order, were assigned 
a new sample identifier and were batch thawed (3 batches) on ice at 4°C. Serum 
aliquots of 200 l were transferred to sterile Eppendorf tubes and deproteinised by 
addition of 600 l methanol, vortex mixing for 15 seconds and centrifugation for 15 
minutes at 13,865 xg. After centrifugation, 370 l aliquots of the supernatant were 
transferred into two sterile Eppendorf tubes and lyophilized at 45°C for 16 hours 
using a vacuum centrifuge (Heto-Holten VR-Maxi) attached to a refrigerated vapour 
trap (Thermo Scientific Savant RVT 4104, ThermoFisher Scientific, USA). A pooled 
Quality Control (QC) sample was also prepared by combining 50 l aliquots of  all 
biological samples and vortexing for one minute. 200 l aliquots of the pooled QC 
sample were deproteinised and lyophilized using the same protocol as described 
above. The lyophilized samples were stored at 4°C until they were reconstituted in 
HPLC grade water/methanol in a 1:1 ratio, vortex mixed and centrifuged for 15 
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minutes at 15,871g. The resulting supernatants were transferred into analytical vials 
and placed in the UPLC autosampler and stored at 4°C during analysis. 
4.3.6 Ultra-high performance liquid chromatography-mass spectrometry 
(UHPLC-MS) 
The reconstituted serum samples were analysed by UHPLC-MS in 3 analytical 
batches with QC samples being analysed for the first ten injections of each batch and 
then after every 6 individual patient samples. All samples for one subject were 
analysed in the same batch and each subject was randomized across the batches.  
UHPLC-MS measurements were performed using and a Thermo Scientific Ultimate 
3000 coupled to a Q-ExactiveTM Hybrid Quadropole-Orbitrap mass spectrometer 
(ThermoFisher Scientific, MA, USA). A Hypersil Gold C18 column was applied for 
metabolite separation prior to mass spectrometric detection. Samples were analysed 
in positive and negative ion modes separately and data were acquired in the m/z 
range 50-1000Da with a scan rate of 0.4s. The analytical method applied is available 
at (381).The UHPLC column was washed with 100% methanol for 60 minutes 
between analytical batches.  
4.3.7 Pre-processing of data, quality assurance and metabolite identification 
The three-dimensional (3D) raw data (m/z vs. retention time vs. response) was 
deconvoluted using the freely available XCMS software (382). The deconvolution 
process includes peaking picking, integration and alignment, and converts the 3D 
raw data into a two-dimensional (2D) matrix of samples in columns and metabolite 
features in rows and peak responses reported for each metabolite feature detected 
for each sample. A peak response is defined as the sum of intensities over a window 
of specified mass and time ranges. 
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In this study, QC samples were employed as they provide four advantages to 
metabolomic studies: 1) To provide instrument conditioning through initial injection of 
ten QC samples to provide instrument stability for important biological sample 
analysis; 2) To provide signal correction for instrument response drift across each 
batch; 3) To provide a method of quantifying analytical experiment reproducibility and 
4) To permit integration of data across batches as not all samples could be run in a 
single batch (383). Prior to quality assurance (QA) procedures being applied to the 
data, metabolite features were removed that were present in <50% of the QC pooled 
samples. The QA process used in the study was that used for the HUSERMET 
project (384). Quality control-Robust Loess Signal Correction (QC-RLSC) was 
applied within and across the three batches to correct for technical variations in the 
data whilst maintaining biological variation. All features were then removed whose 
response had a relative standard deviation (RSD) >20% across the QC samples after 
QC injections 1 to 8 for each analytical batch were removed. Finally, metabolite 
features with >60% missing values across all the samples were removed from the 
dataset. The data was assessed for technical variation using Principal Component 
Analysis (PCA) using Metaboanalyst v3.0 (385). 
Metabolite features were annotated on the QC filtered dataset using the PUTMEDID-
LCMS workflows operated in the Taverna workbench (384). This putative annotation 
is consistent with the Metabolomics Standards Initiative (MSI) level 2 standard of 
reporting (386). In some cases, metabolite features were annotated with multiple 
metabolites due to having the same molecular formula or similar monoisotopic 
masses and therefore similar retention times and the same accurate m/z.  
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4.3.8 Measurement of serum cytokines 
Serum cytokine measurements were performed as a 9-plex assay, measuring IL-1b, 
IL1-RA, IL-6, IL-8, IL-10, IL-17, TNF-a, MCP-1 and G-CSF (Performed by Dr. Peter 
Hampson). This was done using the Biorad Multiplex immunoassay platform and Bio-
Plex 200® reader (Bio-Rad laboratories, Germany) according to the manufacturer’s 
instructions. To calculate the concentrations of cytokines, standard curves were 
generated by making 4-fold serial dilutions using the standards supplied. Cytokine 
measurements were also conducted on serum processed from 9 healthy volunteers 
to serve as control values. Samples were collected and processed identically to 
those from the patients. 
4.3.9 Measurement of urinary urea nitrogen excretion (UUN) 
24 hour urine collections were conducted by regular emptying of the patient’s urine 
catheter bag into a 5-litre sterile plastic container. Collections were started after 
draining all urine passed overnight from the catheter bag and collecting all urine 
passed between 08:00 hrs and 08:00 hrs the following day. The total volume of urine 
excreted was measured using a measuring a cylinder and a 5ml aliquot sent to the 
routine biochemistry laboratory at QEHB. Urinary urea was reported as mmol of urea 
in 24hrs and this was converted to urinary urea nitrogen (UUN) excretion (g/24hrs) by 
multiplying by 0.028. 
4.3.10 Statistical analysis 
Metabolomics data analysis was performed using Metaboanalyst v3.0 (385,387,388). 
To identify key trends in the longitudinal metabolomics data, univariate methods 
including one-way ANOVA with Tukey’s post-hoc analysis was applied separately to 
the positive and negative ion mode datasets. Pre-processing of data for univariate 
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analysis included no imputation of missing values and normalization by sum (total 
peak area per sample). To select and focus on key metabolite features changing 
over 0-6-months post-injury, false discovery rate (FDR) corrected (Benjamini-
Hochberg) p-values with a cut-off p=<0.05 were used. Multi-variate analysis methods 
were also used which included PCA and Partial Least Squares Discriminant Analysis 
(PLS-DA). For PCA and PLS-DA, pre-processing steps included KNN missing value 
imputation, normalization by sum and generalised-log transformation (g-log). 
Patient demographic, burn injury and outcome data were analysed using univariate 
methods in SPSS v23.0 statistical software (IBM, USA). Datasets were assessed for 
normal distribution using the Shapiro-Wilkes test. Parametric data are displayed as 
means with standard deviation (SD) and groups compared using the Independent 
Samples t-test. Non-parametric data are displayed as medians with interquartile 
range (IQR) and groups were compared using the Mann-Whitney U-test. Categorical 
variables were compared using Fisher’s exact test. Serum cytokine data were 
analysed using GraphPad PRISM v7.0 software (GraphPad Software Inc., USA). 
Data were assessed for normality using the Shapiro-Wilkes test and analysed using 
non-parametric ANOVA with Dunn’s multiple comparison post-hoc test, with each 
data point being compared to control values measured from healthy volunteers. 






4.4.1 Demographics and outcomes of the study group 
A total of 13 adult patients with severe burns >15% TBSA were selected from the 
SIFTI study for inclusion in this longitudinal study of metabolism (Table 4.1). The 
mean age of the study group was 36 (range 17-55) years, male:female ratio was 
1.6:1 and the mean burn size was 42% (range 16-66) TBSA. Flame burn was the 
most common mechanism of injury (84%), with only 1 patient sustaining a scald 
injury and 1 patient sustaining a combined flame/flash injury. The key outcomes for 
the study group are summarized in Table 4.2. 
Admission parameters Values 
n 13 
Age (years) 36.0 (+/- 12.1) 
Male n (%) 8 (62.0) 
BMI (kg/m2) 26.6 (+/-4.6) 
TBSA (%) (IQR) 42.0 (19.5-61.0) 
TBSA-FT (%) (IQR) 16.0 (4.0-54.8) 
Inhalation injury n (%) 5 (38.5) 
ICU Admission n (%) 9 (69.2) 
APACHE II first 24hrs (IQR) 28.0 (9.5-29.0) 
SOFA first 24hrs (IQR) 8.0 (1.0-11.0) 
Denver MOF first 24hrs (IQR) 2.0 (0.0-3.5) 
R-Baux 81.5 (+/- 26.8) 
ABSI (IQR) 7.0 (6.0-11.0) 
BOBI (IQR) 3.0 (1.0-4.5) 
 
Table 4-1. Demographic and injury data for adult severe burns cohort (>=15% TBSA). 
Abbreviations: APACHE (Acute physiology, age and chronic health evaluation score), SOFA 
(Sequential organ failure assessment) score, ABSI (Abbreviated burn severity of illness) score and 





Outcome variable Value 
Mortality n (%) 1 (7.7) 
MOF (Denver > 2) n (%) 5 (38.5) 
Time to organ recovery (days) (IQR) 12.0 (0.0-48.0) 
Sepsis n (%) 9 (69.2) 
ICU LOS (days) (IQR) 13.0 (0.0-54.5) 
Mechanical Ventilation days (IQR) 10.0 (0.0-37.0) 
Hospital LOS (days) (IQR) 54.0 (21.0-116.0) 
Hospital LOS (days/% TBSA)  1.6 (+/- 0.7) 
Table 4-2. Summary of the key clinical outcomes for the adult severe burns 
cohort. (MOF=multiple organ failure, ICU= intensive care unit, LOS=Length of stay, 
IQR=interquartile range). 
 
4.4.2 Overview and quality assurance of data 
The complete metabolomic experiment included 292 serum samples and 54 pooled 
QC samples (after removal of QC injections 1-8 in each analytical batch) analysed by 
UHPLC-MS. The raw data included 9509 metabolite features identified in positive ion 
mode and 8016 metabolite features identified in negative ion-mode (total of 17,525 
metabolite features). QC-RLSC was applied to correct for small levels of technical 
variance and to integrate each analytical batch in to a single dataset for each ion 
mode. After quality assurance (QA) methods had been applied to the data this 
decreased to 4639 metabolite features in positive ion-mode (48.8%) and 3546 
metabolite features (44.2%) in negative ion-mode (total 8185 metabolite features). 
PCA analysis was applied to assess technical variability across the 3 analytical 
batches after QA for the positive ion-mode (Figure 4.1a) and negative ion-mode 
(Figure 4.1b) datasets. The scores plots both show a good spread of the data from 
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across the three batches with no clear clustering of any of the 3 batches, confirming 
no technical problems associated with the biological data. PCA analysis comparing 
individual patient samples and QC pooled samples for both positive and negative ion-
mode showed good tight clustering of the QC samples and a larger spread of the 
patient samples (Figure 4.2a and Figure 4.2b for positive and negative ion modes, 
separately). The data to be applied for the longitudinal study were then separated 
from other data.  
 
 
Figure 4-1 PCA scores plot of LC-MS data from serum samples in all 3 analytical batches. A: 
Positive ion mode data, B: Negative ion mode data. 
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Figure 4-2. PCA scores plot of LC-MS data from individual serum samples and pooled QC 
samples. A: Positive ion mode data, B: Negative mode data.  
 
4.4.3 The longitudinal changes in the serum metabolome following severe 
thermal injury 
4.4.3.1 Overview 
UHPLC-MS data from a total of 117 serum samples from 13 patients were used for 
analysis of the key longitudinal changes in the serum metabolome after severe 
thermal injury. ANOVA analysis showed a total of 459 metabolite features that were 
statistically significantly different (q<0.05 following Benjami-Hochberg method for 
FDR) across the study time course. The metabolite class of each metabolite feature 
annotation was checked using the Human Metabolome Database (HMDB) 
(www.hmdb.ca) and the LIPIDMAPS database (ww.lipidmaps.org). This identified 27 
metabolite features with annotation from distinct metabolite classes which were 
removed from the final dataset, leaving 432 metabolite features from 35 classes 
(Table 4.3). The filtering process applied to the raw data is shown in a flow-diagram 
(Figure 4.3). 
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Further in-depth analysis focused on 348 metabolite features within eight classes in 
which ³10 metabolite features were statistically significant across the time-course. 
These were ranked 1-8 by the number of metabolite features changing within each 
class (Table 4.3). Within these eight classes, changes in lipid metabolism pre-
dominated with five classes represented and a total of 295 metabolite features being 
lipids (85%). The lipid classes were sub-classified according to the LIPIDMAPS lipid 
classification system to make trend analysis interpretation simpler. The longitudinal 
changes seen within each class are presented below, with representative trends 
plotted for individual metabolite features. Only metabolite features with annotations to 




Figure 4-3. Flowchart of process of selection of metabolite features for further detailed analysis 
from the young severe burn LCMS data. (LC-MS = Liquid chromatography mass spectrometry, 














































Table 4-3. Summary of all metabolite classes changing significantly in serum over 6 months post 








7 Phenylalanine,& Tyrosine&and&Tryptophan&metabolism 16
8 Aromatic&metabolites 11
9 Other&mixed&classes 9

























35 Vitamin& B&metabolism 1
TOTAL 432
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4.4.3.2 Lipid Metabolism 
Lipids make up a large proportion overall (300/432, 70%) of all the annotated 
metabolite features that are changing significantly over the first 6-months post 
thermal injury. The classes with the highest frequencies were the fatty acyls (FA) 
(n=92) and the glycerophospholipids (GP) (n=80). The frequencies observed in the 
data for all the lipid sub-classes are summarized in Table 4.4. The classes of lipids 
showing the greatest number of concentration changes were further subdivided per 
the LIPIDMAPS lipid classification system.  
 
Table 4-4. Frequency table of lipid metabolite features significantly changing in serum across the 6 
month time course after severe thermal injury.  
 
4.4.3.3 Fatty acyl metabolism 
A total of 93 fatty acyl (FA) metabolite features statistically significantly changed 
across the time-course in the study group (Table 4.5). Within sub-classes of FAs, the 
highest frequencies of significantly changing metabolites were seen in the Fatty acids 
and conjugates sub-class (n= 56) and Eicosanoids class (n=10).  
No. Lipid class No,of,metabolites,FDR,p=<0.05
1 Fatty%acyls%(FA) 93
2 Glycerophospholipids (GP) 80
3 Sterol lipids%(ST) 73
4 Glycerolipids (GL) 30
5 Sphingoplipids (SP) 19




Table 4-5. Frequency table of fatty acyl metabolite features within each sub-class, significantly 
changing across the 6-month time course after burn injury.  
 
Within the fatty acids and conjugates sub-class of fatty acyls, the commonest trend 
observed was a steep decline from admission normalized peak intensities to levels 
on D3-4 and then further decline until a nadir at 3 weeks post-injury. This was 
followed by a gradual increase up to M6 at which levels were close to admission 
levels. Examples of this trend are seen in all the sub-classes of fatty acids observed 
(unsaturated fatty acids, dicarboxylic acids and branched chain fatty acids) and are 
shown in Figure 4.4 (a-d). The next most common trend observed was an initial 
decline of normalized peak intensities after admission, with a nadir at D10 post-injury 
and then a rise with a late peak 4-8 weeks post-injury and then decline again below 
admission levels. Examples are shown in box and whisker plots in Figure 4.5 (a-c).  
No. Fatty(acyl sub.class No(of(metabolites(FDR(p=<0.05
1 Fatty%acids%and%conjugates 56
2 Eicosanoids 10









Figure 4-4 Box and whisker plots showing common longitudinal patterns of change in peak intensity 
seen in fatty acid metabolite features after severe burn injury. A: M3706 (methyl-hexacosadienoic acid 
or heptacosadienoic acid) (Branched chain FA) (p=0.0063), B:  M1629, octadecatrienoic acid 
(Unsaturated FA) p=0.0017, C: M3386, Hexacosanedioic acid (Dicarboxylic acid) (p=0.0005) and D: 
Summary of trend. 
 
 
Figure 4-5. Box and whisker plots showing common longitudinal trend for fatty acid metabolite 
features after severe burn injury. A: M4837, tetratriacontatetraenoic acid (unsaturated FA) (p=0.0150) 


























































































Another trend seen in all sub-classes of FAs was a decline from admission levels 
with a plateau at low levels compared to admission and no return to peak intensity 
levels seen during the first 24hrs after burn injury. Examples are shown in box and 
whisker plots in Figure 4.6. 
 
Figure 4-6. Box and whisker plots showing common longitudinal trends for fatty acid metabolite 
features after severe burn injury. A: M2029, Octadecenetrienoic acid (straight chain FA) (p=<0.0001), 
B: M2582, Hydroxy-tridecenoic acid and/or oxo-tridecanoic acid (Hydroxy-FA) (p=<0.0001) and C: 
Summary of trend. 
 
 
4.4.3.4 Eicosanoids and Docosanoids 
The eicosanoids are typically pro-inflammatory mediators primarily synthesised from 
arachidonic acid and in contrast the docosanoids which are derived from the fatty 
acids eicosapentaenoic acid (EPA) (C20:5) and docosahexaenoic acid (DHA) 
(C22:6) (389). Although classified in the LIPIDMAPS classification system in a 
separate sub-class of fatty acyls, the docosanoids are considered together in this 










































and are biologically related in function. The docosanoids include the resolvins, 
protectins and maresins. 
The leukotriene metabolite features showed a general trend towards increasing from 
the day of admission and either peaking at D5-9 or D12-15 before either continuing 
to decline or rising again between M2 and M6 (Figure 4.7). The three prostaglandin 
metabolite features showed 2 distinct patterns: 1) Increased from admission to peak 
at D12-15 before decline; or 2) Decreased from admission followed by fluctuating 
levels but generally increasing back up towards admission levels (Figure 4.8). The 
hydroxy/hydroperoxyeicosatrienoic acids and epoxyeicosatrienoic acids similarly 
showed elevated levels during the acute phase, remaining so for 2-4 weeks post-
injury before declining (Figure 4.9). Two docosanoids changed significantly and each 
were annotated with multiple isomers including neuroprotection-D1, resolvins (D5, D6 
and D7) and other DHA-related metabolites so may represent the same metabolite 
(Figure 4.9c). 
 
Table 4-6. Frequency table of metabolite features significantly changing in adult serum after severe 
burn injury in the Eicosanoid and docosanoid classes of lipids, summarized according to frequencies 
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Figure 4-7. Box and whisker plots showing longitudinal trends in significantly changing leukotriene 
metabolite features in serum after severe burn injury. A: M5086, Leukotriene D5 (p=0.0167), B: 4604, 
N-Acetyl-leukotriene E4 (p=0.0002) C: 3457, 10,11-dihydro-20-trihydroxy-leukotriene B4 (p=0.0140). 
 
 
Figure 4-8. Box and whisker plots showing longitudinal trends in significantly changing Prostaglandin 
metabolite features in serum after severe burn injury. A: M4281, annotated isomers: Prostaglandin 
PGE2 1-glyceryl ester; 1(3)-glyceryl-PGD2;1(3)-glyceryl-PGE2;1(3)-glyceryl-PGH2; 2-glyceryl-PGD2; 
2-glyceryl-PGE2; 2-glyceryl-PGH2; PGD2-1-glyceryl ester; (P=0.0212).B: M2369, annotated isomers: 
11-deoxy-PGF1a;11-deoxy-PGF1b;HpEDE; PGE1 alcohol; PGF2alpha alcohol. C: M2502, annotated 

















































Figure 4-9. Box and whisker plots showing longitudinal change in metabolite features in:  
A: Hydroxy/hydroperoxyeicosatrienoic acids: (M1968), annotated isomers: 12S-hydroxy-
5Z,8E,10E-heptadecatrienoic acid; methyl 10,11-epoxy-3,7,11-trimethyltrideca-2,6-dienoate) 
(p=0.0073).B: Epoxyeicosatrienoic acids: (M2930), annotated isomers: 5-Hydroxyeicosatetraenoic 
acid (5-HETE), 8-HETE; 9-HETE, 10-HETE; 11-HETE; 12-HETE; 13-HETE; 15-HETE; 16-HETE; 17-
HETE; 18-HETE; 19-HETE; 20-HETE; 8,9-Epoxyeicosatrienoic acid; 11,12-Epoxyeicosatrienoic acid; 
14,15-Epoxy-5,8,11-eicosatrienoic acid; 18-Hydroxyarachidonic acid; 5,6-Epoxy-8,11,14-
eicosatrienoic acid (p=<0.0001). C: Docosanoids: (M4124), annotated isomers: 15-trans-





A total of 88 glycerophospholipid (GP) metabolite features changed significantly in adult serum after 
severe burn injury in the final dataset, however after removal of metabolite features that had multiple 
annotations within different GP classes this left 41 metabolite feature for trend analysis (Table 4.7). 
The highest frequency sub-classes were the glycerophosphoinositols (Phosphatidylinositols, PI) and 

























Table 4-7: Frequency table of metabolite features significantly changing in adult serum after severe 
burn injury in the glycerophospholipid (GP) class of lipids, summarized according to frequencies in 
each sub-class. Metabolite features with more multiple annotations in different classes of GPs have 
been removed from this analysis. 
 
Multiple individual trends were observed within each sub-class of GPs. Four trends were observed 
across most sub-groups: 1) The most common trend was a decline from initial values down to a nadir 
most commonly at 5-9 days post-injury, followed by an elevation in levels to a peak most commonly at 
M2 before a slight decline again (Figure 4.10); 2) The next most common trend was an initial rise in 
metabolite peak intensity to a peak at D5-9 before a plateau at M2 (Figure 4.11); 3) The next most 
common trend, was a dramatic fall from admission peak intensities over the first 3-9 days with a nadir 
at two-weeks, with levels rising again from M2 to reach admission day levels by M6 (Figure 4.12); 4) 
An unusual trend observed was an initial very low peak intensity maintained for the first 3-4 weeks 
post-injury and then a rise thereafter during the recovery phase with a peak at M6 or decline again 
from M2. (Figure 4.13). 
No. Glycerophospholipid (GP) sub4class No6of6metabolites6FDR6p=<0.05
1 Glycerophosphoinositols (PI) 11
2 Glycerophosphocholines (PC) 9
3 Glycerophosphoglycerols (PGP) 6
4 Glycerophosphoserines (PS) 6
5 Glycerophosphates (PA) 5
6 Lysoglycerophospholipid (LysoP) 3




Figure 4-10. Box and whisker plots showing common longitudinal trend (1) seen within the 
glycerophospholipid metabolite features changing significantly in serum after severe burn injury in 
adults. A: M7672, Phosphatidylserine (PS) (39:1) (p=0.0033) B: M7956, Phosphatidylcholine (PC) 
(44:9) (p=0.0440) and C: Summary of trend.  
 
 
Figure 4-11. Box and whisker plots showing common longitudinal trend (2) seen within the 
glycerophospholipid metabolite features changing significantly in serum after severe burn injury in 
adults. A: M7910, annotated isomers: Phosphatidylinositol (PI) (43:6); PI (41:3); PI (39:0) (p=0.0012) 



















































































Figure 4-12. Box and whisker plots showing common longitudinal trend (3) seen within the 
glycerophospholipid metabolite features changing significantly in serum after severe burn injury in 
adults. A: M6589, PG (28:0) (p=<0.0001), B: M6703, annotated isomers PA (37:5); PA(O-16:0/15:0); 
PA(O-18:0/13:0)  (p=<0.0001) and C: Summary of trend. 
 
 
Figure 4-13. Box and whisker plots showing common longitudinal trend (4) seen within the 
glycerophospholipid metabolite features changing significantly in serum after severe burn injury in 























































































A total of 31 glycerolipid metabolite features changed significantly across the 6-
month study time course post burn injury. The sub-group with the highest frequency 
of statistically significant metabolite feature changes were the diradylglycerols and all 
23 were further sub-classified as diacylglycerols (DG) which are glycerides consisting 
of two fatty acid chains covalently bonded to a glycerol molecule through ester 
linkages. Table 4.8 shows the frequency of significantly changing glycerolipid 
metabolite features. 
 
Table 4-8. Frequency table of glycerolipid metabolite features significantly changing 
longitudinally over 6-months post burn injury. 
 
Within the four triadylglycerols, all were triacylglycerols (TG) and three of the four 
showed a decrease from initial levels after injury with a nadir at either D5-9 or D12-15 
(Figure 4.14). The other (TG 59:0) increased over the 5-9 days post-injury before 
falling again to a nadir at 3 weeks and then continuing to rise again to M6. Within the 
DG sub-class, the predominant trend (91% of metabolite features) was a dramatic 
reduction from levels within the first 24hrs of injury to the second time-point, D3-4 
(Figure 4.15). The peak intensities continued to decrease with a varying nadir within 
the first month, but most commonly at D19-24 post-injury. The levels then increased 






again during the recovery phase to reach levels comparable to those observed on 




Figure 4-14: Box and whisker plots for triacylglycerol (TG) metabolite features changing significantly 
in serum after severe burn injury, three differing trends are observed. A: M6236, Triacylglycerol (33:0) 
(p=<0.0001) B: M7239, Triacylglycerol (50:8) <0.0001 C: M5635, Triacylglycerol (30:0) (p=0.0047) D: 






















































Figure 4-15. Box and whisker plots for diacylglyceride (DG) metabolite features changing 
significantly in serum after severe burn injury in adults. A: M5131, Diacylglycerol (33:4) 
(p=<0.0001); B: M5482, Diacylglycerol (32:3) (p=<0.0001) and C: Summary of main trend 
seen in the DG sub-class. 
 
4.4.3.7 Sphingolipids 
A total of 20 sphingolipid metabolite features changed significantly in serum over the 
6-months post burn injury, one metabolite feature was removed from trend analysis 
due to annotation with multiple sub-classes. The highest frequency of significant 
metabolite features were in the phosphosphingolipid sub-class. There was a 
predominating trend pattern seen in 18/19 (95%) of the metabolite features that was 
previously demonstrated in the fatty acid and glycerophospholipid classes of lipids. 
This was an initial decline from admission levels towards a main nadir at D12-15 
followed by a rise again with a late peak at M2 or M3 and a plateau or slight decline 
in levels at M6 (Figure 4.16). Some metabolite features displayed a small early peak 










































D12-15 (Figure 4.16a). The general pattern was displayed by metabolite features in 
all the sub-classes of sphingolipid.  
 
Table 4-9. Frequency table of sphingolipid metabolite features significantly changing in adult serum 
after severe burn injury, summarized according to frequencies in each sub-class. 
 
Figure 4-16. Box and whisker plots showing common longitudinal trend seen within the sphingolipid 
metabolite features changing significantly in serum after severe burn injury in adults.  
A: M5076, Cer(d14:1/18:1); Cer(d14:2/18:0); Cer(d18:2/14:0) (Ceramide) (p=0.0005), B: M7303, 






















































4.4.3.8 Sterol metabolism 
A total of 68 sterol lipids changed significantly across the time-course of the study 
and the highest frequency seen was within the secosteroid group, which are all 
associated with vitamin D metabolism (n = 28) (Table 4.10). The next largest group 
was the steroid conjugates (n = 21) which were a mix of bile acid metabolites (n = 10) 
and steroid hormone metabolites (n = 10) and sterol metabolites (n = 1). 
 
Table 4-10. Summary table of frequencies of sterol sub-class metabolite features changing 
significantly across study time-course after severe thermal injury. 
 
4.4.3.9 Vitamin D metabolism 
A total of 29 vitamin D metabolite features changed significantly in adult serum after 
severe burn injury (Table 4.12). Most of these were in the secosteroids sub-class of 
sterol lipids (28/29, 97%) with one being a steroid conjugate. Two main trends were 
observed:  
1) An increase from day of admission peak intensities with a peak most commonly on 
D12-15, followed by a decline. Most metabolite features showing this general trend 
No. Sterol)lipid) sub0class No)of)metabolites)FDR)p=<0.05





5 Bile alcohol 1
Total 68
 200 
declined back to admission levels by M2, but a few features plateaued at a slightly 
higher level than admission from D19-24 onwards (Figure 4.17).  
2) The next most common trend seen was a decline from admission levels with a 
nadir on D19-24, followed by a rise back up again to within the range of admission 
levels by M6 (Figure 4.18).  
One metabolite feature (M3837) showed an unusual trend and was annotated as 
1,25-dihydroxyvitamin D3, the active form of vitamin D in addition to other annotations 
including 1alpha,25-Dihydroxy-previtamin D3 (Figure 4.19). This metabolite feature 
showed a decline from admission levels until D12-15 where it plateaued at low peak 
intensities for the remainder of the study (Figure 4.19). 
 
Figure 4-17. Box and whisker plots showing most common serum longitudinal trend (1) in the Vitamin 
D metabolite features after severe burn injury.  
A: M4208, Annotated isomers: 1µ,23,25,26-tetrahydroxycholecalciferol; 6,19-epidioxy-1µ,24-
dihydroxy-6,19-dihydrocholecalciferol; 6,19-epidioxy-1alpha,25-dihydroxy-6,19-dihydrocholecalciferol; 
1µ,26-Tetrahydroxyvitamin D3;3µ,7µ,12alpha-trihydroxy-5µ-cholesten-26-oic acid; 3µ,7µ,12µ-
Trihydroxy-5beta-cholesten-26-oic acid, (p=<0.0001). 
B: M5418, 26,27-diethyl-1alpha,25-dihydroxy-20,21-methano-23-oxacholecalciferol, (p=0.0006). 













































Figure 4-18. Box and whisker plots showing most common serum longitudinal trend (2) in the Vitamin 
D metabolite features after severe burn injury. A: M4285, Vitamin D3 butyrate (p=0.0002).  B: M4018, 
10-ethoxy-10,19-dihydrocholecalciferol (p=0.0005). C: Summary of trend. 
 
Figure 4-19. A: Box and whisker plot showing serum longitudinal trend for metabolite feature M3837 
which was annotated with multiple isomers including the active form of Vitamin D (1,25-
Dihydroxyvitamin D3). Other annotated isomers: 1alpha,25-Dihydroxy-previtamin D3, 18,25-




epicholecalciferol; 1beta,25-dihydroxy-3-epicholecalciferol; 1beta,25-dihydroxycholecalciferol; 22,25-
dihydroxycholecalciferol; 23,25-dihydroxycholecalciferol; 24,25-dihydroxycholecalciferol; 25,26-
dihydroxycholecalciferol; 6,19-epidioxy-6,19-dihydrocholecalciferol (p=0.0090).   














































































4.4.3.10 Steroid conjugates 
A total of 21 steroid conjugates changed significantly in serum over 6-months post-
thermal injury. These could be biologically grouped into conjugates related to bile 
acid metabolism (n= 10), conjugates related to steroid hormone metabolism (n = 10) 
and those related to sterol metabolism (n = 1). The trends for all bile acid metabolite 
(Section 4.4.2.6) features will be presented together in one section and steroid 
hormone metabolite features will be discussed in another separate section (Section 
4.4.2.7). 
4.4.3.11 Bile acid metabolism 
A total of 16 bile acid metabolite features changed significantly in serum post-burn 
and more than half of these were sub-classified as steroid conjugates with the 
remainder being bile acids and derivatives (Table 4.11). Among the steroid 
conjugates, there was an equal mix of taurine conjugates, glycine conjugates, 
glucuronides and sulfates.  
 
Table 4-11. Frequency table of metabolite features significantly changing in adult serum after severe 
burn injury in the Bile acid classes of lipids, summarized according to frequencies in each sub-class. 
 
The predominant pattern of change across the steroid conjugates was an increase 
from admission levels to reach a peak most commonly at D12-15, followed by a 
No. Bile acid sub.class No/of/metabolites/FDR/p=<0.05
1 Steroid conjugates 10
2 Bile acids1and1derivatives 6
Total 16
 203 
gradual decline towards admission levels. Some metabolite features in this sub-class 
displayed an earlier peak at D5-9 and some a later peak at D19-24. Within this 
group, a mixture of primary and secondary bile acids were observed. The primary 
bile acids, for example, glycocholic acid (M3866, p=<0.0001), generally showed a 
trend of elevation from admission levels with a peak at D12-15 (Figure 4.20a). 
Secondary bile acid conjugates, for example, Sulfoglycolithocholate (M5245, 
p=<0.0001), showed an earlier elevation either on D1 or D3-4 before decline to 
admission levels (Figure 4.20b). Another secondary bile acid metabolite feature, 
annotated as Lithocholyltaurine and Taurolithocholic acid (M4780, p=0.0169), 
showed low peak intensities for the first 10 days, then began to rise to a peak at D19-
24 before returning to admission levels by M2 (Figure 4.20c). 
 
Figure 4-20. Box and whisker plots showing longitudinal trends in metabolite features from the Steroid 
conjugates sub-class of bile acids significantly changing in serum after severe burn injury. A: M3866, 
Glycocholic acid (primary bile acid) (p=<0.0001), B: M5245, Sulfoglycolithocholate (secondary bile 
acid) (p=<0.0001), C: M4780, Annotated isomers: Lithocholyltaurine; Taurolithocholic acid (secondary 




























For the bile acids and derivatives sub-class, the predominant pattern of change seen 
was a decline from admission levels to a nadir at D19-24, followed by a rise again 
during the recovery phase back up towards admission levels. Within the bile acids 
and derivatives sub-class, the pattern was generally different. Except for one 
metabolite feature, these showed decline from admission levels with a nadir at D19-
24 and then increased again to approximately reach admission levels by M6 (Figure 
4.21). 
 
Figure 4-21: Box and whisker plots showing longitudinal trends in metabolite features from the bile 
acids and derivatives group of lipids significantly changing in serum after severe burn injury.  
A: M3508, Annotated isomers: 5a-Cholestane-3a,7a,12a,25-tetrol; 5b-Cholestane-3a,7a,12a,23-
Tetrol; 5b-Cholestane-3a,7a,12a,25-tetrol; 5beta-cholestane-3alpha, 7alpha,12alpha, 26-tetrol; 
Cholestane-3,7,12,25-tetrol. (p=0.0005). 
B: M3519, Annotated isomers: 7-Deoxy-5b-cyprinol;"5a-Cholestane-3a,7a,12a,25-tetrol; 5b-
Cholestane-3a,7a,12a,23-Tetrol; 5b-Cholestane-3a,7a,12a,25-tetrol; 5beta-cholestane-
3alpha,7alpha,12alpha,26-tetrol; Cholestane-3,7,12,25-tetrol. (p=0.0006). 














































4.4.3.12 Steroid hormone metabolism 
A total of 12 metabolite features in the steroid metabolism class changed statistically 
significantly in serum after severe burn injury (Table 4.12).  
 
 Table 4-12. Frequency table of steroid metabolite features significantly changing in adult 
serum after severe burn injury, summarized according to frequencies in each sub-class. 
 
Within the steroid hormone metabolite group, most were steroid conjugates, mostly 
conjugated to glucuronic acid (defined as glucuronides). Glucuronidation occurs 
mainly in the liver and is the process of covalent bonding of glucuronic acid to 
metabolites, making them more water soluble for excretion via urine or faeces. This 
is used in the excretion of bile acids, drugs, steroid hormones, fatty acid derivatives 
and retinoids as examples. The predominant pattern in the steroid glucuronides was 
an initial decline from admission levels with a nadir at D12-15 and then a rise again 
to admission levels with a plateau at months 2-6 during the recovery phase (Figure 
4.22). The sulfate conjugated steroids did not show any consistent pattern and the 













Figure 4-22.. Box and whisker plots showing serum longitudinal trends in metabolite features in the 
steroid hormone glucuronide conjugates after severe burn injury. A: M3895, Annotated isomers: 
Dihydrotestosterone glucuronide; Androsterone glucuronide (p=<0.0001). B: M3853, Annotated 
isomers: Dehydroepiandrosterone 3-glucuronide; Dehydroisoandrosterone 3-glucuronide; 
Testosterone glucuronide (p=0.0014). C: Summary of common trend in steroid hormone conjugates 
(glucuronides). 
 
Figure 4-23. Box and whisker plots showing serum longitudinal trends in steroid metabolite features 
after severe burn injury. A: M2977, 4-Hydroxyestrone sulfate (p=0.0011). B: M3216, Annotated 






























































Within the steroid conjugates, there were six metabolites of sex steroids which all 
demonstrated the pattern shown in Fig 4.22. An early metabolite of early steroid 
hormone precursor pregnenolone was observed: pregnenolone sulfate (M3032) 
which demonstrated a dramatic fall in peak intensities from admission levels, with 
nadir D5-9 before a slow rise in levels towards M6 (Figure 4.24a). This may reflect 
reductions in steroid precursor pools due to increased production of stress hormones 
early after injury. Another metabolite feature observed, 11- Hydroxyprogesterone-11-
glucuronide, is a metabolite of 11-hydroxyprogesterone, a precursor in the pathway 
of conversion from progesterone to the mineralocorticoids corticosterone and 
aldosterone (Figure 4.24b). Interestingly this showed a very similar profile to an 
aldosterone metabolite, Tetrahydroaldosterone-3-glucuronide (M5010) indicating 
significant alterations in mineralocorticoid metabolism. This was a rise from 
admission levels, with a peak at weeks 3-4 and then decline again (Figure 4.24c). 
 
Figure 4-24. Box and whisker plots showing serum longitudinal trends in steroid hormone metabolite 
features after severe burn injury. A: M3032, Pregnenolone-sulfate (metabolite of steroid hormone 
precursor pregnenolone). (p=<0.0001) B: M5010, Tetrahydroaldosterone-3-glucuronide and C: 




























4.4.3.13 Peptide metabolism 
A total of 26 metabolite features changed significantly in serum after severe burn 
injury were annotated as peptides and the majority (25/26, 96%) were dipeptides. 
The most common general trend (18/26, 69%) seen in the serum dipeptide 
metabolite features was an increase from peak intensities on the day of admission 
during the acute phase, followed by a decline during the recovery phase. The kinetics 
were variable across the dipeptides but the most common peak was seen at D19-24 
with a decline thereafter (Figure 4.25). Four metabolites showed a slight variation, 
rising from admission, peaking at the same D19-24, with decline but remaining 
elevated at M6 compared to admission levels (Figure 4.26) 
 
Figure 4-25. Box and whisker plots showing the most common serum longitudinal trend in peptide 
metabolite features after severe burn injury. A: M999, annotated with isomers: isoleucyl-proline and 
leucyl-proline (p=<0.0001) B: M2623, Arginyl-proline (p=0.0022) and C: Summary of trend.  
 
The remainder of the peptides displayed a reduction from admission levels which 
continued to decline to plateau at low peak intensities relative to admission (Figure 












































immunomodulatory and endocrine activities. This peptide showed a decline with 
nadir at 2 weeks, followed by a rise again during the recovery phase but not reaching 
admission levels by M6 (Figure 4.27b). 
 
Figure 4-26. Box and whisker plots showing a variant of the common trend seen in the serum peptide 
metabolite features after severe burn injury. A: M2852, Phenylalanylphenylalanine (p=0.0340). B: 
M2461, Tyrosyl-Valine (p=<0.0001) and C: Summary of trend.  
 
Figure 4-27. Box and whisker plots showing a peptide metabolite features changing significantly in 
serum post- severe burn injury that show a less common trend of reduction from initial higher peak 































































4.4.3.14 Phenylalanine, tyrosine and tryptophan metabolism 
A total of 15 metabolite features related to the metabolism of the aromatic amino 
acids Phenylalanine, tyrosine and tryptophan changed significantly in serum after 
severe thermal injury (Table 4.13). Grouping the metabolite features by the main 
amino acid metabolic pathways they are involved in, those involved in tryptophan 
metabolism were most commonly seen (9/15, 60%). 
 
Table 4-13. Frequency table of the aromatic amino acid metabolite features significantly changing in 
adult serum after severe burn injury, summarized by the frequencies in each sub-class. 
 
 Amongst the tryptophan metabolite features, three main trends were observed: 1) 
Elevation from admission peak intensities, followed by a decline after a variable peak 
of between 2-3 weeks post-injury as demonstrated by serotonin (M1949, p=0.0009) 
(Figure 4.28a), 2) Dramatic elevation from admission levels to D3-4 and then gradual 
decline to plateau during the recovery phase from M2 onwards as shown by 
tryptophanol (M1085, p=<0.0001) (Figure 4.28b) and 3) Minor decline from 
admission levels to nadir on D5-9, followed by elevation in peak intensities until the 
end of the time-course, as shown by tryptophan (M761, p=0.0003) (Figure 4.28c). 
Trends (1) and (2) were also observed in the tyrosine metabolite features. 
Interestingly four of the metabolite features are not endogenously produced 




2 Tyrosine metabolism 5
3 Phenylalanine,2tyrosine and2tryptophan2metabolism 1
Total 15
 211 
metabolites in human and are most likely bacterial metabolites including indole, 
indoxyl, 3-dehydroquinate and 3-maleylpyruvic acid. Indole and indoxyl, tryptophan 
metabolites, were elevated early after injury with an early peak the first few weeks 
before decline. 3-dehydroquinate displayed a much later rise with elevation between 
two and 4 weeks post injury and 3-maleylpyruvic acid showed an even later rise from 
4 weeks with a peak at M3 before declining to M6. Another metabolite feature of 
interest in this group was epinephrine glucuronide, a conjugate of the 
sympathetomimetic neurotransmitter epinephrine, which was elevated at the 
admission time point and then declined over the first 4 weeks to plateau at low peak 
intensities thereafter.  
 
Figure 4-28. Box and whisker plots showing longitudinal trends for tryptophan metabolite features 
changing significantly in serum post- severe burn injury A: M1949, serotonin (p=0.0009). B: M1085, 































4.4.3.15 Aromatic metabolites 
This group of 11 aromatic metabolites, are chemically heterogenous and the most 
common three trends observed are the same as in the aromatic amino acid 
metabolite features (Section 4.4.2.9). Several metabolite features may be 
metabolites produced by enteric bacteria including 2-benzylsuccinate, 
phenylethylamine, hydrophenyllactic acid and 3-(3-Hydroxyphenyl)-3-
hydroxypropanoic acid (3-HPPA). 
 
4.4.3.16 Carnitine and Acyl carnitines 
Carnitine and acyl carnitines are essential for fatty acid metabolism (b-oxidation), 
which is the oxidation of long-chain fatty acids in the mitochondrial matrix to yield 
energy in the form of ATP. Fatty acids are activated by conversion to their acyl 
Coenzyme A (CoA) thioesters, however long chain fatty acyl CoAs cannot cross the 
inner mitochondrial membrane without conjugation to the highly polar carnitine 
molecule to form acyl carnitines. Significant changes were seen in serum carnitine 





Figure 4-29. Box and whisker plots showing longitudinal trends for carnitine and acyl carnitine 
metabolite features changing significantly in serum post- severe burn injury A: M375, carnitine 
(p=0.0122) B: M4864, 3-Hydroxyhexadecadienoylcarnitine (p=<0.0001) C: M3072, 
Dodecenoylcarnitine (p=0.0020).  
 
4.4.3.17 Heme metabolism 
Six metabolite features related to heme metabolism changed significantly in serum 
post thermal injury. Bilirubin and urobilinogens showed a similar pattern with decline 
from admission levels and then remaining at a constant low level relative to 
admission (Figure 4.30a). Urobilin was also detected, which showed a rise from 
admission with a peak on D5-9 before declining again (Figure 4.30b). A bacterial 
Heme metabolite, Heme O, was also detected which showed rose from admission 





























Figure 4-30. Box and whisker plots showing longitudinal trends for heme metabolite features changing 
significantly in serum post- severe burn injury A: M5250, bilirubin (p=0.0264) B: M5353, Urobilin 
(p=<0.0001) and C: M7455, Heme O (p=<0.0001).  
 
4.4.4 The cytokine response to thermal injury and its relationship to changes 
in the metabolome 
The pro-inflammatory cytokine IL-6 showed significant elevations compared to 
control values from healthy volunteers for one month post-injury (Figure 4.31a). The 
other classical pro-inflammatory cytokine TNF-a did not show significant increases 
compared to control across the whole time-course. The chemokine IL-8 showed 
significant increases from D3-4 until 1 month post-injury (Figure 4.31b), whilst the 
chemokine MCP-1 showed significant elevations on D1-2 and D3-4 (Figure 4.32a) 
only before levels declined. G-CSF demonstrated a similar pattern to MCP-1, and 
was significantly increased also until D3-4 before declining (Figure 4.32b). The anti-
inflammatory cytokines, IL-10 and IL1-RA showed a significant early peak on D1-2 
and then levels reduced (Figure 4.33). The cytokines IL-17 and IL-1b did not show 
any significant differences in patient serum concentrations across the time course 





























Figure 4-31. Box and whisker plots showing longitudinal changes in serum pro-inflammatory cytokines 




Figure 4-32. Box and whisker plots showing longitudinal changes in serum cytokines compared to 


















































































































































Figure 4-33. Box and whisker plots showing longitudinal changes in serum anti-inflammatory 
cytokines compared to control values. *p=<0.05.  A: Cytokine IL-1RA and B: Cytokine IL-10 
 
To further investigate the relationship between these changes in serum cytokines 
after severe thermal injury, a Spearman correlation analysis was performed between 
IL-6, IL-8, IL-10 and IL-RA and each of the metabolite features that changed most 
significantly in each metabolite class. The most significant correlations for each 
cytokine are presented in tables 4.14 – 4.17. IL-6 serum concentrations correlated 
negatively with metabolite features in 11 classes including: glycerophospholipids, 
sphingolipids, fatty acids, glycerolipids, peptides and bile acids. A weak positive 
correlation was seen with a leukotriene (N-acetyl-leukotriene E4) (r=0.2134, 
p=0.0233) and a lysoglycerophospholipid (LysoPC[22:6]) metabolite feature (r= 
0.2540, p=0.0169). IL-8 demonstrated a greater number significantly correlated 
metabolite features, but showed a similar pattern to IL-6 with again a moderately 
strong negative correlation with a glycerophosphocholine metabolite feature (PC[O-










































































Table 4-14. Summary of the significant correlations between FDR significant metabolites from ANOVA 
analysis (highest ranked in class) and IL-6 cytokine measurements in serum post-burn across the 6-
month time course. FDR = false discovery rate, r=Spearman’s rank correlation coefficient.  
No. Metabolite+class Metabolite+features FDR+P4value r
95%+confidence+
interval P4value
1 Glycerophosphocholines PC(O216:0/0:0)8PC(O28:0/O28:0) 1.26E207 20.6774 20.7685@to@20.5593 <0.0001
2 Glycerophoshoserines PS[42:0]PS[41:1] 0.0013101 20.5648 20.6872@to@20.4112 <0.0001
3 Sphingolipids SM(d18:1/22:1)8SM(d18:2/22:0) 3.85E206 20.4791 20.6133@to@20.318 <0.0001
4 Glycerophosphates PA[37:5]PA(O216:0/15:0)8PA(O218:0/13:0) 8.67E207 20.4451 20.6212@to@20.2262 0.0001
5 Glycerophoshoglycerols PG[28:0] 6.38E209 20.4224 20.6285@to@20.1609 0.0018
6 Dicarboxylic@acids@(Fatty@acids) Tetracosanedioic@acid 5.71E205 20.4143 20.5602@to@20.2434 <0.0001
7 Diglycerides DG[35:6]8DG[33:3]8DG[31:0] 8.88E208 20.3981 20.5468@to@20.2251 <0.0001
8 Peptides Aspartyl2Phenylalanine 2.96E208 20.3783 20.5302@to@20.2028 <0.0001
9 Triglycerides TG[33:0] 3.53E209 20.2898 20.4548@to@20.1056 0.0018








8.78E205 20.2614 20.4301@to@20.07505 0.0052
12 Leukotrienes N2Acetyl2leukotriene@E4 0.00015544 0.2134 0.0243@to@0.3877 0.0233
13 Lysoglycerophospholipids LysoPC[22:6] 0.00063463 0.254 0.04082@to@0.4451 0.0169
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Table 4-15. Summary of the significant correlations between FDR significant metabolites from ANOVA 
analysis (highest ranked in class) and IL-8 cytokine measurements in serum post-burn across the 6-
month time course. FDR = false discovery rate, r=Spearman’s rank correlation coefficient. 
 
The anti-inflammatory cytokines IL-10 and IL-1RA demonstrated generally weaker 
correlations to the metabolite features tested. IL-10 showed only six significant 
correlations with the metabolite features, with negative correlations with 
glycerophospholipids, sphingolipids, diglycerides, unsaturated fatty acids.  A positive 
correlation was observed with carnitine (r=0.2039, p=0.0303). IL-1RA demonstrated 
a greater number of significant correlations (n=12) with the metabolite features. 
Negative correlations were again seen with glycerophospholipids. Weak positive 
correlations were observed with the steroid, 4-hydroxyestrone sulfate (r=0.3397, 
No Metabolite*class Metabolite*feature FDR*P4value r
95%*confidence*
interval P4value
1 Glycerophosphocholines PC(O216:0/0:0)8PC(O28:0/O28:0) 1.26E207 20.6914 20.7791@to@20.5772 <0.0001
2 Glycerophoshoserines PS[42:0]PS[41:1] 0.0013101 20.5571 20.6812@to@20.4018 <0.0001
3 Diglycerides DG[35:6]8DG[33:3]8DG[31:0] 8.88E208 20.4603 20.5981@to@20.2962 <0.0001
4 Sphingolipids SM(d18:1/22:1)8SM(d18:2/22:0) 3.85E206 20.4541 20.5929@to@20.2889 <0.0001
5 Dicarboxylic@acid@(fatty@acids) Tetracosanedioic acid 5.71E205 20.4312 20.5742@to@20.2626 <0.0001
6 Lysoglycerophospholipids LysoPC[22:6] 0.00063463 0.4199 0.2248@to@0.5826 <0.0001
7 Leukotrienes N2Acetyl2leukotriene@E4 0.00015544 0.3413 0.1618@to@0.499 0.0002





1.30E206 20.3394 20.5768@to@20.04913 0.0196
10 Glycerophosphates PA[37:5]PA(O216:0/15:0)8PA(O218:0/13:0) 8.67E207 20.3329 20.5331@to@20.09739 0.0052
11 Triglycerides TG[33:0] 3.53E209 20.3325 20.4915@to@20.152 0.0003
12 Unsaturated@fatty@acids heneicosadienoic@acid 4.78E207 20.3281 20.4878@to@20.1472 0.0004








8.78E205 20.3086 20.471@to@20.1259 0.0009
15 Steroid@hormone@metabolites 242methylene2cholesterol@sulfate 1.23E209 0.2087 0.0002762@to@0.3997 0.0435
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p=0.0022) in addition to fatty acids, peptides, lysoglycerophospholipids and 
aromatics. 
 
Table 4-16. Summary of the significant correlations between FDR significant metabolites from ANOVA 
analysis (highest ranked in class) and IL-10 cytokine measurements in serum post-burn across the 6-
month time course. FDR = false discovery rate, r=Spearman’s rank correlation coefficient. 
 
 
Table 4-17. Summary of the significant correlations between FDR significant metabolites from ANOVA 
analysis (highest ranked in class) and IL-1RA cytokine measurements in serum post-burn across the 
6-month time course. FDR = false discovery rate, r=Spearman’s rank correlation coefficient. 
No. Metabolite+class Metabolite+feature FDR+P4value r 95%+confidence+interval P4value
1 Glycerophosphocholines PC(O216:0/0:0)8PC(O28:0/O28:0) 1.26E207 20.4131 20.5593BtoB20.2421 <0.0001
2 Glycerophoshoserines PS[42:0]PS[41:1] 0.0013101 20.3092 20.4796BtoB20.1163 0.0016
3 Sphingolipids SM(d18:1/22:1)8SM(d18:2/22:0) 3.85E206 20.2597 20.4286BtoB20.07331 0.0055
4 Diglycerides DG[35:6]8DG[33:3]8DG[31:0] 8.88E208 20.2352 20.4071BtoB20.04725 0.0122
5 UnsaturatedBfattyBacids heneicosadienoicBacid 4.78E207 20.2323 20.4045BtoB20.04423 0.0133
6 AcylBcarnitines Carnitine 0.012249 0.2039 0.01443BtoB0.3793 0.0303
No. Metabolite+class Metabolite+feature FDR+p4value r 95%+confidence+interval P4value
1 Glycerophosphocholines PC(O216:0/0:0)8PC(O28:0/O28:0) 1.26E207 20.3771 20.5292AtoA20.2014 <0.0001
2 Steroids 42HydroxyestroneAsulfate 0.0011315 0.3397 0.1217AtoA0.5265 0.0022
3 Glycerophoshoserines PS[42:0]PS[41:1] 0.0013101 20.3298 20.497AtoA20.1389 0.0007
4 Glycerophosphoethanolamines PE[37:7] 2.10E205 20.2989 20.5028AtoA20.06355 0.0113
5 FattyAacids OctadecenetriynoicAacid 8.35E208 0.2754 0.09006AtoA0.4423 0.0032
6 Peptides Neuromedin2N 2.54E206 0.2602 0.05922AtoA0.4409 0.0097
7 Peptides Aspartyl2Phenylalanine 2.96E208 20.2371 20.4087AtoA20.04926 0.0115
8 Lysoglycerophospholipids LysoPC[22:6] 0.00063463 0.2369 0.02257AtoA0.4303 0.0263
9 Sphingolipids SM(d18:1/22:1)8SM(d18:2/22:0) 3.85E206 20.2303 20.4028AtoA20.04212 0.0141
10 Diglycerides DG[35:6]8DG[33:3]8DG[31:0] 8.88E208 20.2217 20.3951AtoA20.03307 0.0183
11 Aromatics 22Phenylglycine 1.44E206 0.1941 20.001268AtoA0.3752 0.0451
12 BranchedAchainAfattyAacids Corchorifatty acidA 8trimethyl2tetradecatetraenoic acid 0.0019748 0.1934 0.001696AtoA0.3714 0.042
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4.4.5 Urinary urea nitrogen excretion (UUN) and its relationship to changes in 
the post-burn metabolome 
Urinary urea nitrogen (UUN) excretion data was collected for all patients up to 3-
months post-injury as thereafter, it became increasingly impractical due patients 
either being discharged home or having no urinary catheter. The UUN data showed a 
rise from admission levels to a peak at D5-9 and declining thereafter but remaining 
elevated above admission levels at D12-15 (Figure 4.34). 
 
Figure 4-34. Box and whisker plots (median and IQR) showing the longitudinal trend in urinary urea 
nitrogen excretion (UUN) over 3-months after severe thermal injury. 
 
The same methods were then used to correlate the UUN data with the most 
significantly changing metabolite features in each class from the ANOVA analysis. 
This showed, as with the cytokine analysis, that the strongest correlations were 
negatively with the glycerophosphocholine, (PC[O-16:0/0:0]; PC[O-8:0/O-8:0]) (r=-
0.445, p=<0.0001). Positive correlations were observed with the steroid hormone, 
































Table 4-18. Summary of the significant correlations between FDR significant metabolites from ANOVA 
analysis (highest ranked in class) and urinary urea nitrogen (UUN) measurements in serum post-burn 




In this study, untargeted LC-MS metabolomics has been used to explore the global 
patterns of change in metabolism that occur longitudinally after severe thermal injury. 
There were significant changes in the serum metabolome across 35 distinct 
metabolite classes and several common trend patterns that were repeated across 
classes. The main findings are a profound early catabolic response phase lasting but 
declining over the first 3 weeks, before a metabolic shift occurs most likely 
representing a metabolic recovery phase. There were also profound shifts in the lipid 
metabolome, with 70% of significant changes seen in lipid classes. In addition, this 
untargeted approach has revealed changes in previously unstudied areas of 
metabolism in thermal injury which warrant further examination through targeted 
hypothesis testing studies. Analysis of the metabolomic data in relation to targeted 
No Metabolite*class Metabolite*feature FDR*P3value r 95%*confidence*interval P3value
1 Glycerophosphocholines PC(O216:0/0:0)8PC(O28:0/O28:0) 1.26E207 20.4445 20.5999AtoA20.2569 <0.0001
2 Glycerophosphates PA[37:5]PA(O216:0/15:0)8PA(O218:0/13:0) 8.67E207 20.3343 20.5684AtoA20.05014 0.0189
3 Diglycerides DG[35:6]8DG[33:3]8DG[31:0] 8.88E208 20.3201 20.4982AtoA20.1161 0.002
4 Glycerophoshoserines PS[42:0]PS[41:1] 0.0013101 20.265 20.4644AtoA20.03994 0.0183
5 SteroidAhormoneAmetabolites
242methylene2cholesterolA
sulfate 1.23E209 0.2474 0.01142AtoA0.4572 0.0349
6 Lysoglycerophospholipids LysoPC[22:6] 0.00063463 0.2424 0.007857AtoA0.4517 0.0374
7 DicarboxylicAacidA(fattyAacids) Tetracosanedioic acid 5.71E205 20.2412 20.431AtoA20.03092 0.0213
8 Sphingolipids SM(d18:1/22:1)8SM(d18:2/22:0) 3.85E206 20.2261 20.4179AtoA20.01498 0.0311
9 Leukotrienes N2Acetyl2leukotrieneAE4 0.00015544 0.2228 0.01151AtoA0.4151 0.0338
10 Triglycerides TG[33:0] 3.53E209 20.2105 20.4043AtoA0.001439 0.0452
 222 
cytokine data revealed significant correlations between pro and anti-inflammatory 
mediators and changes in the metabolome. 
4.5.1 Early post-injury catabolic phase with increased energy production 
Univariate analysis revealed significant changes in large numbers of lipid 
metabolites, which predominated overall in the serum metabolome shifts after 
thermal injury. The most common trend pattern seen in the fatty acids (FAs) and 
triacylglycerides (TGs) was a decline from admission levels, before then increasing 
again after a nadir at 3-weeks post-injury. In the absence of normal control data or 
internal standards in our study, we cannot clearly define whether there was a decline 
in levels from a starting point in the normal concentration range vs. a decline from 
elevated levels. However, much of the evidence in the literature points to an early 
elevation in FAs and TGs after thermal injury. 
Early studies of lipid metabolism after thermal injury showed early increases in 
circulating levels of free FAs (FFAs) and TGs, and this has since been shown to be 
due to increased lipolysis in adipose tissues (163,219,367). This is  mostly in 
response to elevations in catecholeamines and glucagon (stress response) in the 
face of reduced peripherial insulin sensitivity which is seen in non-burn trauma (163). 
Another source of FFAs is the hydrolysis of TGs contained within chylomicrons and 
very low density lipoproteins (VLDL) when delivering their lipids to target cells (390). 
It is clear that thermally injured patients have increased rates of beta oxidation, the 
metabolism of FAs in mitochondria to generate ATP (168,169) and this is required to 
meet the vast demands for wound healing and thermoregulation. Interestingly, 
thermally injured patients are only able to utilize 30% of available FFAs for energy 
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generation, a large proportion undergo ‘futile’ cycling between hydrolysis of TGs and 
esterification back to TGs in the liver (194). 
There are some conflicting studies in the literature suggesting that FFAs actually 
decrease after thermal injury (391,392) and others showing a variable response 
between patients (219). A number of reasons have been postulated for the conflicting 
data, including variations in resuscitation leading to differences in perfusion of 
adipose tissue and also the amount of adipose tissue present on admission and after 
excision of burn tissue (154). A recent targeted lipidomics study of 46 adults with 
burns >20%, studied the longitudinal change in 14 classes of fatty acids from the 
time of injury to 28 days. Their data shows initial elevated levels of both saturated 
and unsaturated FFAs on the day of injury before declining over the first month. They 
also highlighted that persistently elevated saturated FAs were associated with poor 
clinical outcomes and a suppressed pro-inflammatory profile and elevated levels of 
monounsaturated FAs (MUFA) correlate with mortality (393). If we infer from this 
study that our data shows initial elevations in FAs and TGs and then decline, this 
may be due to increased utilization and gradual reductions in peripheral lipolysis as 
the stress response dissipates. The later elevation after 3 weeks is unexplained and 
has not been described previously in the literature. This could be due to ongoing 
peripheral lipolysis and FA-TG substrate cycling with reduced rates of utilization 
through b-oxidation in the liver and in skeletal muscle due to loss of lean body mass 
(LBM). Another contributing factor is the hypoalbuminaemia associated with severe 
thermal injury which may impact FFA levels (367). Since FAs released from 
adipocytes are transported bound to albumin, low serum albumin during the acute 
phase may contribute to declining serum FFAs. Then as albumin levels increase in 
 224 
the recovery phase, this may allow increased release of FAs and TG from adipocytes 
contributing to rising levels. Since we have shown multiple longitudinal trajectories 
within the FA and glycerolipid classes, changes in lipid metabolism are clearly 
complex and suggest varying functions and degree of utilization at different stages 
after injury. 
A related observation that corroborates with increased lipolysis and increased b-
oxidation of FAs, is that significant changes were seen in carnitine and four acyl 
carnitines. Carnitine decreased from admission levels before a second peak and fall 
at 3 weeks (Figure 4.29a). Previous studies have shown acutely decreased levels of 
carnitine for up to 2 weeks in plasma following burn injury. This may be due to urinary 
and wound losses and increased uptake and utilization by the liver and skeletal 
muscle (367). The second decline observed in carnitine between 3-weeks and two-
months post-injury is more difficult to explain, but may be due to increased utilization 
again during rehabilitation as the patients start to mobilise. Late infections and sepsis 
may also contribute as carnitine levels are known to be depleted in sepsis (368). 
Significant changes in peptide metabolism were observed, with large numbers of 
dipeptides increasing from admission to a peak at 3-weeks post-burn before 
declining. This most likely represents the increased skeletal muscle protein 
catabolism that is well described following thermal injury. Studies have shown that 
although there is concurrent increase in protein synthesis and degradation in skeletal 
muscle, the balance leans towards catabolism, resulting in net protein loss and 
wasting of skeletal muscle and therefore LBM (333). Radio-isotope studies have 
shown increased uptake of amino-acids in the burn wound paralleling the increased 
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efflux from skeletal muscle, leading to the conclusion that this response is to support 
wound healing (236). The protein catabolism is also felt to provide substrates for 
gluconeogenesis and to support the liver in the production of acute phase proteins 
(228). Urinary urea nitrogen (UUN) excretion is one crude measure of protein 
catabolism and in this cohort of patients the peak UUN occurred at D5-9, whilst the 
peptide peak occurred later at 3-weeks post-injury. It is accepted in the literature that 
whilst UUN is a significant predictor of protein balance, although it lacks the 
quantitative accuracy of isotope based methods in studying protein kinetics (394). 
4.5.2 Endocrine changes in the metabolome 
Severe thermal injury results in a profound stress response with activation of the 
sympathetic nervous system, with increases in the circulating catecholamines, 
noradrenaline and adrenaline (163). This together with activation of the hypothalamo-
pituitary adrenal (HPA) axis and increased secretion of cortisol from the adrenal 
cortex, drives the catabolic response, increased resting energy expenditure (REE) 
and changes in glucose metabolism. There are significant changes in 12 steroid 
hormone metabolites, eight of which were metabolites involved in sex hormone 
pathways, typically terminal metabolites of testosterone, estrone and estriol. These 
generally showed a trend to decline from admission before increasing during the 
recovery phase. Dehydroepiandrosterone 3-glucuronide, a conjugate of 
Dehydroepiandrosterone (DHEA) decreased from admission with a nadir at 2-weeks 
before gradually increasing again. DHEA is an adrenally synthesised C19 steroid and 
an intermediate in the testosterone and oestrogen synthesis pathway. This and its 
active sulfated form (DHEAS) have been previously shown to be low for 4 weeks 
after burn injury (395). DHEAS is also an immune enhancer able to stimulate 
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neutrophil function (396). The reduction in DHEA and DHEAS may thus contribute to 
immuneparesis and catabolism seen in burn injury. Furthermore, in murine models of 
thermal injury, DHEA supplementation has demonstrated beneficial effects including 
normalizing hepatic cellular metabolism, minimizing immunosuppression, improving 
resistance to infection and preventing burn wound progression (397-400). To date 
there are no clinical trials of DHEA supplementation in burn injury patients, though 
our data suggest this may be well worthwhile pursuing. 
As expected corticosteroid and mineralocorticoid pathway metabolites also changed 
significantly and interestingly pregnenolone, a very early steroid hormone precursor, 
decreased dramatically from admission levels and remained at that constant lower 
level for the remainder of the study. This may due to increased utilization in the 
synthesis of corticosteroids as part of the stress response, but has not previously 
been studied in thermal injury. The steroid hormone findings need to be interpreted 
with a hint of caution given that eight patients (62%) received anabolic steroid 
treatment from day 4-5 of admission in the form of oral Oxandrolone. It would be 
interesting with a larger cohort to examine the differences in steroid hormone 
metabolites between those treated with and without anabolic steroids, however burn 
size may confound this. 
4.5.3 Inflammation and immunomodulatory metabolites 
Significant changes were observed in Eicosanoid metabolite features, with 
leukotrienes and prostaglandins increasing acutely over the first 2-weeks post-injury. 
Eicosanoids are biologically active lipid mediators derived from arachidonic acid and 
related C20 polyunsaturated fatty acids (PUFA) and include the prostaglandins (PG), 
leukotrienes (LT), thomboxanes (TX), lipoxins (LX) and other derivatives. They are 
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known to regulate inflammatory processes, have diverse homeostatic roles and are 
implicated in many diseases. Eicosanoids are synthesized through oxidation of 
arachidonic acid or its related PUFAs by the enzymes cyclooxygenase (COX), 
lipoxygenase (LOX) and cytochrome P450 and via free radical mechanisms (401). 
Metabolites of LTD5 and of LTA4, LTE4 and LTB4 changed significantly. The latter is 
known to effect neutrophil recruitment and chemotaxis, vascular permeability and 
enhanced epithelial barrier function. There are limited studies of leukotrienes in 
thermal injury, however human neutrophils produce less LTB4 post-burn and an 
increase in biologically less active, omega oxidized metabolites. This correlated with 
increased bacterial growth in the burn wound (402) and a shift to higher proportions 
of circulating immature neutrophils (403). Later studies showed an association 
between decreased neutrophil adhesion to vascular endothelium and attenuated 
LTB4 production (404). Interestingly other studies on the SIFTI cohort have identified 
increased levels of immature granulocytes (IGs) and found that a combination of IG 
frequency, cell free DNA and rBaux score were powerful prognostic indicators for 
development of sepsis (405). Whether the metabolites identified here might also be 
of prognostic utility is worth investigating. 
Prostaglandin metabolite features changing significantly after thermal injury, included 
annotations of metabolites of PGD2, PGF1, PGE1, PGH2 and multiple PGE-2 
metabolites. PGE2 is felt to play a pivotal role in post-burn inflammation and is 
significantly elevated in plasma of thermally injured patients with monocytes 
(406,407); higher levels of PGE2 also correlated with poor outcomes (408). 
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The docosanoids are biologically related to eicosanoids and are synthesized from 
omega-3 fatty acids such as docosahexanoic acid (DHA). They include the resolvins, 
protectins and maresins and their roles as specialised pro-resolving mediators 
(SPMs) in inflammation are just being understood (409). Several docosanoid 
metabolite features, included annotations with neuroprotectins and resolvins were 
identified and showed a gradual rise from admission, peaking at 3 weeks before 
declining. These SPMs may have an important role in the resolution of inflammation 
after severe thermal injury. Furthermore, Resolvins have therapeutic potential as they 
have been shown in animal burn models to restore neutrophil migration defects in 
vivo (101), prevent dermal necrosis and neutrophil mediated damage to the burn 
wound (410) and ameliorate burn induced renal and hepatic tissue injury (411). 
Multiplex analysis of the serum cytokines in this study, showed evidence of an 
ongoing inflammatory response for 4-weeks post-injury, as evidenced by significant 
elevations, relative to controls, in IL-6 and IL-8 for this duration. These profiles were 
consistent trends with previously published data (57,60,82) and the duration of 
inflammation comparable to a recent lipidomics study with similar injury severity 
(393). The cytokines MCP-1 and G-CSF were only significantly elevated for a shorter 
period, until D3-4 and the anti-inflammatory cytokines, IL-10 and IL1-RA were only 
significantly elevated during the first 24-48 hrs post injury. This very early anti-
inflammatory signaling response is consistent with previous studies (412) and with 
the currently held theory, supported by genomic data, of early simultaneous anti-
inflammatory processes driving immunosuppression early after injury (51).  
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The interplay between metabolism and inflammation is increasingly being studied 
and correlation analysis of cytokine data with the most significantly changing 
metabolites in serum after severe thermal injury reveals moderately significant 
correlations in longitudinal trends. The inflammatory cytokines correlate negatively 
with lipid class metabolite features including, phospholipids, sphinoglipids, fatty acids, 
triglycerides and diglycerides. Positive correlations were seen with a leukotriene and 
lysoglycerophospholipid. The anti-inflammatory cytokine trends correlated negatively 
with a range of lipid classes and positively with an estrogen metabolite, fatty acids, 
aromatics, lysoglycerophospholipids and carnitine. There was correlation between 
Neuromedin-N, a hexapeptide related to neurotensin and IL1-RA. Neuromedin-N has 
been shown in mice to have immunomodulatory properties, including stimulation of 
macrophage phagocytic function (413) and adherence and chemotaxis of 
lymphocytes (414). It has also been demonstrated to modulate the function of the 
hypothalamo-pituitary axis (HPA) (415). Whether the associations we have seen play 
a causal role in influencing the SIRS/CARS response or immuneparesis now needs 
further investigation. 
4.5.4 Oxidative stress and mitochondrial dysfunction 
Major thermal injury is known to be associated with oxidative stress, which is defined 
as a disruption of the balance between the production of reactive oxygen species 
(ROS or oxygen free radicals) and the anti-oxidant mechanisms designed to prevent 
them from damaging cells (416). The sources of ROS, such as superoxide anion (02-
•), hydrogen peroxide (H202) and hydroxyl radical (•OH)× are multi-factorial in burn 
injury. Thermal energy from the initial insult causes homolytic bond fission to 
generate ROS (417) and subsequent activation of inflammatory pathways activate 
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and stimulate neutrophils to produce ROS via their NADPH oxidase (superoxide 
burst) (418). Complement mediated increases in histamine activity, combined with 
toxic metabolites from ischaemia reperfusion injury lead to increased xanthine 
oxidase activity produces ROS (419). One of a cells most significant source of ROS 
is the mitochondrial electron transport chain (ETC) due to single electron reduction of 
O2 generating the 02-• radical which is converted to H202 (420). The other contributing 
sources are peroxisomal beta oxidation of fatty acids, which generates H202 as 
byproduct and lipid peroxidation, which is the oxidative degradation of cell membrane 
lipids, especially PUFAs which results in the production of lipid radicals, reactive 
aldehydes (e.g. malondialdehyde) and other ROS (421). Smoke inhalation injury 
which often coexists in patients with major flame burns also results in the increases 
in tissue lipid peroxidation (422). 
Significant changes in certain classes within the metabolome, including heme 
metabolism, oxidized fatty acids (OFA) and lysoglycerophospholipids are compatible 
with increased oxidative stress post-burn. Intravascular haemolysis after thermal 
injury is well documented (423,424)  and one of the main mechanisms is felt to be 
erythrocyte damage from ROS produced by complement mediated activation of 
neutrophils (425). This erythrocyte destruction leads to the presence of free 
haemoglobin and heme in plasma (426), which is then able to cause oxidative 
damage in the vasculature and exposed tissues (427). In humans, the main heme 
degradation pathway is conversion to biliverdin by the enzyme heme-oxygenase-1 
(HO-1) and subsequently to bilirubin by biliverdin reductase. HO-1 is a rate-limiting 
enzyme in the catabolism of heme and is inducible by many factors including 
oxidative stress, cytokines, hypoxia, nitric oxide and oxidized lipids (428). The 
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metabolomics data shows early elevations in bilirubin and downstream degradation 
products urobilinogen over the first 24hrs post-injury followed by decline. This is 
consistent with early increases in free heme from haemolysis and is consistent with 
animal and human published data (423-425).  
Interestingly, significant changes were seen in Vitamin E metabolites, with early 
decline from admission levels with nadir at 3-4 weeks before a rise again during the 
recovery period. Vitamin E is an important anti-oxidant and has been shown to be 
decreased, along with other anti-oxidants, due to increased consumption in the face 
of increased ROS activity post-burn (429). Since the Vitamin-E metabolites continued 
to decline over the first 3 weeks despite supplementation, this would suggest that its 
initial utilization is very high or that there is ongoing utilization due to prolonged 
oxidative stress. Indeed, adipose tissue stores of Vitamin E have been shown to 
remain low for 3-weeks post-injury in severely burned children (430). 
4.5.5 Changes in bile acids reflect intrahepatic cholestasis 
Primary bile acids are synthesized and conjugated with glycine or taurine in the liver 
and represent the major excretory pathway for cholesterol in humans. The major bile 
acids that are synthesized in the liver are cholic acid and chenodeoxycholic acid 
which are conjugated with taurine or glycine before secretion into bile. Since bile 
acids are amphipathic they readily form micelles and are highly effective detergents, 
which enables them to facilitate digestion and absorption of dietary lipids. Most bile 
acids (95%) that are secreted in bile are reabsorbed in the terminal ileum of the small 
intestine and return to the liver via the enterohepatic circulation (hepatic portal vein). 
Small amounts of bile acids undergo faecal excretion (5%) and a very small amount 
reach the systemic circulation and are absorbed by the kidneys (431,432). The 200-
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800mg of bile acids that escape reabsorption undergo metabolism by anaerobic 
bacteria in the colon, resulting in over 20 different secondary bile acids in adult 
faeces. The types of chemical conversions include deconjugation, oxidation, 
epimerization of hydroxyl groups, esterification, desulfation and 7-dehydroxylation 
(433). 
Significant changes were seen in 16 bile acid metabolites, with primary bile acids 
such as glycocolic acid and glycochenodeoxycholic acid increasing from admission 
and peaking at 2-weeks post injury before declining. Bile acid derivatives showed a 
similar pattern to the fatty acids and glycerolipids with a decline from admission 
before increasing again after 3 weeks. These changes are consistent with alterations 
in bile acid synthesis and or secretion. Severe thermal injury is associated with liver 
dysfunction, with deranged liver function tests (LFTs), fatty infiltration of the liver with 
hepatomegaly and increases hepatic apoptosis (434). Autopsy studies have 
demonstrated the presence of intrahepatic cholestasis in 26% of cases of severe 
thermal injury and in all cases the patients had developed sepsis (435). No detailed 
studies have been undertaken in burn to identify the underlying mechanisms for 
cholestasis, but in studies of sepsis, intrahepatic cholestasis is associated with 
impaired transport of bile acids in hepatocytes (436). More recent studies are starting 
to unpick the mechanisms of cholestasis in critically ill patients, with evidence of 
down regulation of the apical bile salt export pump (BSEP) and upregulation of 
expression of the basolateral multidrug resistance associated protein (MRP) 3, 
leading to reversal of bile acid transport and reflux of bile acids back into the 
circulation (437). The changes in the bile acid metabolites may also be compounded 
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by increased cholesterol import and conversion to bile acids, demonstrated by 
expression profiling in animal burn models (438).  
4.5.6 Changes in the post-burn metabolome suggest gut dysfunction and 
bacterial translocation 
The human intestinal lumen contains vast concentrations of bacteria in addition to 
bacterial endotoxins, which are prevented in normal health from crossing the 
intestinal mucosa through several complex defense mechanisms. Animal studies of 
gut dysfunction after burns and major trauma suggested bacterial translocation 
across the gut barrier was a cause of systemic inflammation and multiple organ 
dysfunction syndrome (MODS) after injury (439-441). This translocation was 
theorized to occur due to the combination of physical disruption of the barrier, 
overgrowth of normal gut flora and impaired immunity. There are a number of 
contributing factors to this altered gut barrier function including, hypoperfusion during 
burn shock and with the use of vasoactive drugs, intestinal oedema due to systemic 
capillary leak and impaired peristalsis leading to bacterial overgrowth (358). The gut 
origin hypothesis of post-injury MOF, has evolved through more recent studies to the 
gut-lymph hypothesis, which proposes that gut derived inflammatory mediators in 
response to barrier dysfunction and gut ischaemia travel in mesenteric lymph to drive 
systemic inflammation and distant organ dysfunction (442). This transbiosis 
represents a possible novel target in burns patients as it may well contribute to the 
SIRS response and this is an active area of research. 
Within the final dataset of metabolite features that changed significantly over 6 
months post-burn, there are multiple annotations that are bacterially derived 
metabolites, which could be absorbed from enteric bacteria due to barrier 
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dysfunction. There were moderate numbers of significantly changing tryptophan 
metabolites which are not produced via human pathways, including: indole, indoxyl, 
3-methylindole, indolelactic acid. Enteric and other bacteria metabolise tryptophan to 
form indole, pyruvate and ammonia using the enzyme tryptophanase and can act as 
an intercellular signal between bacteria and controls diverse aspects of bacterial 
physiology (443). These metabolites demonstrated early elevations in a similar 
pattern to the pro-inflammatory cytokines IL-6 and IL-8. The tyrosine precursor, 3-
dehydroquinate, increased between weeks 2 and 4 post-injury. It is an intermediate 
in the Shikimate pathway in bacteria and plants, used in the synthesis of aromatic 
amino acids (444). Secondary bile acids, which are produced from bacterial 
degradation of primary bile acids, were also elevated early after thermal injury, with 
peaks either on admission or D3-4 before decline. Heme O, is an interesting 
metabolite, that also decreases from elevated levels on D3-4. It is a bacterially 
derived heme that is essential for aerobic respiration is closely related to human 
heme A (445). The pattern of early elevations of bacterial metabolites in serum also 
parallels the early increases in pro-inflammatory cytokines IL-6, IL-8, G-CSF and 
MCP-1. 
4.5.7 Vitamin-D metabolism 
There are two major forms of Vitamin D, Vitamin D3 (cholecalciferol) and Vitamin D2 
(Ergocalciferol) and both are fat-soluble secosteroid vitamins. Both may be obtained 
from the diet but Vitamin D3 is synthesised in the skin from 7-dehydrocholesterol in 
response to ultraviolet light (UVB). It is transported to the liver by vitamin-D binding 
protein (DBP) where it is converted to an inactive form through hydroxylation to 25-
hydroxyvitamin D3 (25-D3), the major circulating form of Vitamin D. Subsequently, it is 
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further hydroxylated to its active form, 1,25-dihydroxyvitamin D3 (1,25-D3) in the 
kidneys. Vitamin D plays important roles in bone metabolism and calcium and 
phosphate homeostasis in addition to anti-inflammatory and immune-regulatory 
properties. Vitamin D deficiency in the general population is associated with 
infectious diseases, muscle weakness and increased risk of mortality (446). 
 A total of 29 Vitamin D metabolites changed significantly over 6-months post-burn 
and the predominant pattern was gradual increases in the levels of these metabolite 
features to a peak at 2 weeks before declining again. A smaller group of the 
metabolite features declined from admission and remained low for one month before 
increasing again. It was difficult to stratify groups of metabolite features and many 
had multiple annotations which makes trend interpretations difficult. One metabolite 
feature that was annotated with 25-D3 and the active form, 1,25-D3, showed a decline 
from admission levels over the first 2 weeks and remained almost undetectable for 
the rest of the study.  
Previous studies in severely burned children and adults show that there is a high 
prevalence of Vitamin D deficiency during their admission. In children with burns of 
>25% TBSA, 62.3% of patients were Vitamin D deficient during admission (447). A 
recent large study in burned adults showed that Vitamin D levels on admission were 
deficient in 14.5% of patients, insufficient in 65%, and normal in 20.4%. Low levels of 
Vitamin D were associated with prolonged ICU and hospital LOS and increased 
incidence of infectious complications, sepsis and graft loss (448). No longitudinal 
profiling studies of Vitamin D have yet been conducted in thermally injured patients. 
Since severe thermal injury is associated with immunoparesis, muscle catabolism 
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and defects in bone metabolism and that low vitamin D levels are associated with 
poor outcomes, further detailed exploration of the change in vitamin D metabolites is 
warranted. 
4.5.8 Limitations of the study 
The main limitations of this study are the relatively small sample size of 13 patients. 
A larger sample size would increase the generalizability of the data and allow 
meaningful subgroup analyses such as comparison of the metabolome response to 
thermal injury stratified by age, burn size and outcomes such as mortality, sepsis and 
MOF/MODS. It would also reduce the inevitable biasing of the metabolome signals 
from the more severely injured patients; it is assumed that these patients show more 
significant changes. The dataset did include a broad range of age groups and burn 
sizes but the less severely injured patients were treated on the burns ward, whilst the 
patients with larger burns required ICU level care. There would therefore be 
treatment differences between these groups over time, including duration of 
nutritional support, use and duration of anti-catabolic drugs, use of vasopressor 
drugs, mechanical ventilation and renal support. The ideal cohort to study would be a 
larger sample size of patients with larger burns (e.g. >30%) that were all treated in 
the ICU, giving a more homogenous study group.  
Controls were not used in this discovery phase study, with the reason that acquiring 
representative control metabolomics data would require a large control sample size 
with implications on the cost of the study. The lack of control data meant some of the 
interpretation of trends was more challenging but was aided by reference to 
previously published data. Finally, the UHPLC columns used in this study could have 
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caused potential bias towards resolution of lipids, contributing to the high proportion 
of lipid species that changed significantly across the time-course. 
4.5.9 Future research and implication of the study 
This study was a longitudinal discovery phase untargeted study in a small cohort of 
severely burn injured adults from a single bio-fluid. This has identified at least 10 
target groups of metabolites to focus on and has formed some testable hypotheses. 
The next steps would be to scale up the study to look at a larger cohort and start to 
relate the important changes in the metabolome to differences in injury 
characteristics, age, treatment and outcomes. This larger follow-up study could be a 
more targeted study, allowing the use of LC-MS platforms developed for the 
acquisition of more quantitative data, possibly with the use of internal standards, 
where available. The study has shown huge changes in lipid metabolism after severe 
thermal injury, so lipidomics based strategies may allow more detailed investigation 
of these. The parent study, the UK SIFTI study has now completed its recruitment of 
150 severely thermally injured patients, and therefore has generated a bio-repository 
of serum, plasma and urine samples that could form the basis of future metabolomics 
studies.  
In terms of longer term utility of the metabolomics approach to the study of human 
thermal injury, apart from identifying new potential avenues of research, it paves the 
way for the development of personalized healthcare approaches in burn care. A 
baseline metabolic map of the expected changes after thermal injury could allow 
early identification of metabolic poor responders (‘outliers’) and stratification of care 
pathways for these patients in terms of resuscitation, organ support and nutritional 
support. At present, much of burn care is protocolled and nutritional support, 
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although adjusted according to protein and nitrogen balance, is not really tailored to 
an individual based on their own specific metabolic response. Another avenue for 
metabolomics based research is in biomarker identification for diagnostics, for 
example in the early recognition of sepsis, a significant challenge in the thermally 
injured patient. An increased number of studies are exploiting this approach in 
critically ill and trauma patients (280,281,372,449-452) but it has not yet been applied 
to human thermal injury. 
4.5.10 Conclusions 
Untargeted LC-MS metabolomics has been applied to serum taken from a cohort of 
patients with severe thermal injury and longitudinal analysis of changes in the 
metabolome has demonstrated a massive shift in the lipid metabolome from the time 
of injury, a ‘lipid storm’. This is characterized by changes large numbers of fatty 
acids, reflecting increases in lipid catabolism and beta-oxidation. Other lipid classes 
with large numbers of metabolites that shift dramatically, include the 
glycerophosholipids and sphingolipids. There appears to be a biphasic shift in the 
metabolome from a catabolic state (acute phase) towards an anabolic state (recovery 
phase) from 3-weeks post injury onwards. In some cases, a triphasic signal is seen 
and this may represent late responses occurring due to later episodes of sepsis. 
Significant changes were seen in previously unexplored areas of the metabolome 
and warrant further investigation through larger targeted studies. This would facilitate 
a better understanding of the complex metabolic derangements that occur in patients 

















Chapter 5: Metabolomics analysis of the 
response to thermal injury in the elderly 
 240 
5 Metabolomic analysis of the response to thermal injury 
in the elderly 
5.1 Introduction 
Thermal injury in the elderly is associated with poorer outcomes for a given burn size 
and improvements seen in burn care have benefited this patient group the least, with 
the least improvement in survival in this group compared to younger adults and 
children (14). A retrospective study looking at 228 elderly burn patients admissions 
between 2004 and 2012 at the Birmingham Burns centre in the UK shows improved 
survival overall compared to a previous cohort (see chapter 2) (453). Age is a 
significant risk factor for poor outcomes after thermal injury and probit analysis shows 
that in the 65-74 years age group, the LA50 is approximately 40% TBSA, compared 
to the over 85 years age a 10% TBSA burn carries a 50% mortality (453).  
The reasons postulated for poorer outcomes with advancing age include increased 
prevalence of comorbid disease (454), reduced physiological reserve to cope with 
the stress response, relatively deeper injuries to skin thinning and inability to escape 
the burning source (141), frailty (140,294) and delays in wound healing(455). Normal 
physiological ageing is also associated with alterations in immune function affecting 
both the innate and adaptive arms of the immune system, termed 
immunesenesence. This term also encompasses the increased chronic low-grade 
systemic inflammation with alteration of the balance of circulating cytokines (143). 
This is termed inflammaging and is characterized by increased pro-inflammatory 
cytokines IL-6 and TNF-a, whilst IL-10 levels are reduced (456). Studies in animal 
models of thermal injury also demonstrated increasing mortality with ageing 
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concomitant with increased immune suppression.  Aged mice display reduced 
delayed type hypersensitivity (DTH) responses, decreased immune cell proliferation 
and a greater TH1 to TH2 shift in the cytokine profile relative to younger mice (457). 
Age related defects in innate immunity have been studied in hip fracture patients, 
demonstrating that neutrophil reactive oxygen species (ROS) production is reduced 
on admission and the defect persists for 5-weeks post-injury. The reduction was 
more significantly reduced in hip fracture patients who developed infectious 
complications (190,458).  Recent genomic data from the Host Response to Injury 
(Glue grant) study in the US, is adding weight to the hypothesis that ageing related 
immunesenescence and injury related immune dysfunction become additive in the 
severely injured elderly patient(459). Vanzant et al. studied gene expression in 
circulating neutrophils in shocked trauma patients with prolonged ICU admission and 
compared expression profiles between groups aged <55yrs and those aged >65yrs. 
Interestingly, they found age-related differences in the genomic response, with 
elderly patients exhibiting an initial decreased perturbation of gene expression 
compared to the younger patients. At 4 days post injury, as genomic changes were 
recovering in younger patients, the elderly patients neutrophils exhibited ongoing 
alteration in genes related to decreased chemotaxis, increased inflammation and 
decreased adaptive and innate immune function (460). 
Severe thermal injury is associated with a profound and prolonged inflammatory and 
hypermetabolic response characterized by increased resting energy expenditure 
(REE), hyperthermia, a hyperdynamic circulation and a multitude of metabolic 
defects in carbohydrate, fat and protein metabolism (333). Activation of the 
sympathetic nervous system and hypothalamo-pituitary adrenal (HPA) axis as well as 
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systemic elevations in circulating pro-inflammatory cytokines provide a milieu that 
promotes hyperglycaemia, central and peripheral insulin resistance, increased 
peripheral lipolysis and profound catabolism of skeletal muscle (300). The vast 
majority of thermal injury metabolism research has been focused on children and 
younger adults with thermal injuries >20-30% TBSA, very little is known regarding the 
metabolic changes in the thermally injured older patient. Physiological ageing is 
associated with increases in insulin resistance, changes in body composition with 
increased central adiposity, sarcopenia and progressive loss in mitochondrial 
function (461). The aim of this study was therefore to utilize metabolomics to study 
global patterns of change in the metabolism in thermally injured elderly patients early 
after injury and progressively over time during their recovery. 
 
5.2 Aims & objectives 
5. To identify the key changes in the serum metabolome in the acute phase after 
thermal injury in the elderly (age ³65 years). 
6. To identify the longitudinal changes in the serum metabolome after thermal 










5.3.1 Study group 
This study included a cohort of elderly patients aged ≥65 years with ≥1% TBSA full-
thickness burns (but <15% total TBSA) that were recruited into a UK multi-centric 
observational study called the SIFTI study (Scientific Investigation of biological 
pathways Following Thermal Injury) (UKCRN ID: 13654) and were admitted to the 
adult Burns Centre at Queen Elizabeth Hospital Birmingham (QEHB), UK (2012-
2014). Any patients that were initially unable to consent to the study due to lack of 
capacity (injury severity, unconsciousness, confusion) were recruited through a legal 
consultee advice process until they regained capacity to consent themselves. As a 
comparison group, 5 healthy elderly volunteers (>65 years), matched to the study 
group by age, sex and body mass index (BMI), underwent blood sampling. Samples 
were taken in the morning between the hours of 8-10am. For each volunteer, age 
(years), sex, height (m), weight (kg) and body mass index (BMI) (kg/m2) was 
recorded.  
5.3.2 Treatment of subjects 
All patients received treatment according to standardized local burn care guidelines 
which includes admission to high dependency unit (HDU) level rooms warmed to 
thermal neutrality. All patients received thromboprophylaxis unless contraindicated 
and analgesia according to standard protocols. Some patients in this group received 
supplemental nasogastric feeding if required following nutritional assessment by a 
specialist burns dietician. In patients sustaining deep burns excisional surgery was 
performed if appropriate in this group after medical optimization and anaesthetic 
assessment. Patients with deep burns that were initially deemed unsuitable for 
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excisional surgery and skin grafting were treated with daily topical application of 
Flammacerium® cream. These patients underwent eschar excision and skin grafting 
as necessary when their medical condition had been optimised. 
5.3.3 Data Collection 
Patient demographics, burn injury details and clinical outcomes were recorded 
prospectively using case-report forms (CRF). Key outcomes included: 
• In-hospital mortality 
• Pneumonia (CDC criteria, www.cdc.gov) 
• Sepsis - American Burn Association (ABA) 2007 consensus trigger criteria 
(309) 
• Multiple organ failure (MOF) - Denver 2 MOF score (33) 
• Hospital length of stay (LOS) 
• Intensive care LOS (ICU-LOS) 
• Mechanical ventilation days 
5.3.4 Sampling 
During the study, study day 1 (D1) was defined as the calendar day of injury and day 
2 (D2) the second calendar day and so forth. All patients underwent an initial blood 
sampling within 24hrs of their injury. A second blood sample was taken in the 
morning (8-10am) between 48 and 96hrs post-burn, either on D3 or D4. These two 
samples were utilised for the NMR metabolomics study. For the LCMS longitudinal 
metabolomics study, further samples were taken at the following timepoints: D5-9, 
D19-24, D26-29, Month 2 (D60+/-7 days), Month 3 (D90 +/- 7 days) and Month 6 
(D180 +/-14 days). 6mL blood samples were collected either via peripheral 
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venepuncture using an arm tourniquet or via a central venous catheter (CVC) or 
arterial line if present. Blood was collected using a Vacuette® blood collection system 
into Vacuette® Z-serum clot activator tubes (Greiner Bio-One Ltd, Gloucester, UK). 
The same blood tubes were used throughout the study. The same peripheral 
phlebotomy technique and equipments was used for the healthy volunteers. Blood 
samples were kept upright and allowed to form clot at room temperature for 30mins 
before processing into serum.  
5.3.5 Processing of serum 
Blood samples were clotted for 30 minutes at room temperature with the tubes 
placed upright and were then centrifuged at 3000 rpm for 10 minutes at 20°C in a 
swinging bucket rotor centrifuge (Eppendorf Centrifuge, model 5804 R, 
ThermoFisher Scientific). Aliquots of 400-600 μL were placed in 1.5 mL plastic 
cryovials and stored upright in a freezer at -80°C. 
5.3.6 Serum sample preparation  
Serum samples were prepared for NMR analysis identically to that described in 
Chapter 3, see section 3.3.4. Serum samples for LCMS analysis were thawed, 
prepared and deproteinised using the same techniques described in Chapter 4, see 
section 4.3.4. 
 
5.3.7 NMR Spectroscopy 
Prepared serum samples were analysed on a Bruker AVANCE II 600 MHz NMR 
spectrometer (Bruker Corp., USA) equipped with a 1.7 mm cryoprobe using the 
methods described previously in Chapter 3, see section 3.3.6. The 1D-NMR spectral 
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data was imported into MATLAB V2013a (MathWorks, Natick, USA) and were pre-
processed using NMRLab (V3.5) (310) Metabolab (V3.5) (311). Pre-processing was 
performed as described previously in Chapter 3, see section 3.3.7. 
5.3.8 Ultra-high performance liquid chromatography-mass spectrometry 
(UHPLC-MS) 
Reconstituted serum samples were analysed together with QC samples for quality 
assurance using a Thermo Scientific Ultimate 3000 coupled to a Q-ExactiveTM Hybrid 
Quadropole-Orbitrap mass spectrometer (ThermoFisher Scientific, MA, USA) as 
described previously in Chapter 4, see section 4.3.6. 
 
5.3.9 Statistical analysis of NMR metabolomics data 
Data analysis was performed using PLS Toolbox software Version 7.5.2 (Eigenvector 
Research, INc. Manson, USA) running in MATLAB (Release 2013a, Mathworks, 
Natick, USA). Data analysis approaches were as described in Chapter 3, section 
3.38 and included principle components analysis (PCA) and orthogonal partial least 
squares discriminant analysis (OPLSDA). The metabolite peaks highly weighted in 
the multi-variate models according to VIP scores were identified from the 1D NMR 
spectra using Human Metabolome Database version 3.6 (www.hmdb.ca) and 
Chenomx NMR suite (Chenomx, professional version 4.0, Chenomx Inc, Canada).  
5.3.10 Data pre-processing, quality assurance metabolite identification for 
LCMS study 
The pre-processing, quality assurance (QA) and metabolite identification methods 
were identical to those previously described in Chapter 4, section 4.3.7. 
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5.3.11 Statistical analysis of LCMS data 
Metabolomics data analysis was performed using Metaboanalyst v3.0 (385,387,388). 
Univariate analysis was applied to the dataset using one-way ANOVA with Tukey’s 
post-hoc analysis this was applied separately to the positive and negative ion mode 
datasets. Pre-processing of data for univariate analysis included missing value 
imputation and data was normalized by sum (total peak area per sample). 
Statistically significant metabolites were selected using p-value <0.05. 
5.3.12 Statistical analysis of demographic data 
Demographic and injury data were compared using SPSS v23.0 statistical software 
(IBM, USA). Datasets were assessed for normal distribution using the Shapiro-Wilkes 
test. Parametric data are displayed as means with standard deviation and groups 
compared using the Independent Samples T-Test. Non-parametric data are 
displayed as medians with interquartile range (IQR) and groups compared using 
Mann-Whitney U-test. Categorical variables were compared using Fisher’s exact test. 










5.4.1 1H-NMR Metabolomics analysis of the early metabolic response to 
thermal injury in the elderly 
 
5.4.1.1 Demographics and outcomes  
A total of 15 patients were included in the NMR study with a mean age of 78.2 (+/-
10.7) years, a male-to-female ratio of 1:3 and median burn size 6 % TBSA (IQR:3-
13). The demographics of the cohort are highlighted in table 5.1. The commonest 
injury mechanisms were flame (40%) and contact (40%) burn and scald (20%) 
(Figure 5.1). No patients sustained an inhalation injury but two patients required 
admission to the ICU during their hospital stay for treatment of sepsis.  
Admission data Cohort B 
n 15 
Age (years) 78.2 (+/-10.7) 
Male n (%) 5 (33) 
BMI (kg/m2) 25.1 (+/-4.8) 
TBSA (%) (IQR) 6 (3-13) 
TBSA-FT (%) (IQR) 3 (2-6) 
Inhalation injury n (%) 0.0 (0) 
Co-morbid disease 14 (93) 
ICU Admission n (%) 2 (13) 
APACHE II first 24hrs (IQR) 13 (10-18) 
SOFA first 24hrs (IQR) 1.0 (0-4) 
Denver MOF first 24hrs (IQR) 0 (0-2) 
R-Baux 85.1 (+/-11.2) 
ABSI (IQR) 7 (7-8) 
BOBI (IQR) 2 (2-3) 
Table 5-1. Demographic and injury data for elderly patients in NMR study. Abbreviations: TBSA 
(Total body surface area), BSA-FT (full thickness) APACHE (Acute physiology, age and chronic health 
evaluation score), SOFA (Sequential organ failure assessment) score, ABSI (Abbreviated burn 
severity of illness) score and BOBI (Belgian outcomes in burn injury) score. 
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Figure 5-1. Mechanism of injury for elderly patients in NMR study. 
 
Within the study cohort 3 patients did not survive giving an observed in-hospital 
mortality rate of 20%. Two patients developed at least one episode of MOF (13%) 
and 5 patients developed pneumonia (33%) and 5 patients developed at least one 
episode of sepsis (33%). The outcomes for the cohort are summarized in table 5.2. 
Outcome variable Value 
In-hospital mortality n (%) 3 (20) 
MOF (Denver 2) n (%) 2 (13) 
Sepsis n (%) 5 (33) 
Number of septic episodes/patient (n) 1 (+/-1) 
Pneumonia 5 (33) 
ICU LOS (days) 0.3 (+/- 0.8) 
Mechanical Ventilation days 0.1 (+/- 0.4) 
Hospital LOS (days) 24.0 (+/- 22.8) 
LOS (days/% TBSA) 6.5 (+/-11.3) 
Table 5-2. Clinical outcomes for elderly patients in NMR study. Abbreviations: MOF (multiple organ 








To assess the change in the metabolome early after burn injury in the elderly patient 
group, six control subjects underwent blood sampling. The demographics of the 
control group were not statistically different to the patient group (Table 5.3).  
Parameter Healthy Elderly controls Patients (Cohort B) p-value$ 
n 5 15  
Age (years) 71 (70-77) 77 (67-89) 0.735 
Male n (%) 3 (60) 5 (33) 0.347 
BMI (kg/m2) 25.3 (21.5-29.0) 25.5 (20.3-29.1) 1.000 
Table 5-3. Comparison of demographics between burn injured patients and healthy elderly 
controls. Abbreviations: BMI (Body mass index). $ = Fisher’s Exact test for comparison of 
proportions, Mann-whitney U-test for comparison of medians between groups. 
 
5.4.1.2 Changes in the metabolome after burn injury in the elderly patient 
A total of 35 blood samples were collected, 30 from 15 elderly burn injured patients 
and 1 from each of 5 healthy elderly controls. NMR spectral data was obtained from 
26 patient serum samples and 5 healthy control samples, as 4 samples (11%) had 
protein contamination interfering with spectral quality. The NMR data from the first 
24hrs post-injury samples and control samples was first subjected to unsupervised 
PCA to look for any general trends or unexpected clustering. A 3-principle 
component (PC) model could explain the following percentages of variation: PC1 
(31.12%), PC2: (19.39%), PC3 (12.55%) after removal of 1 outlier sample that fell 
outside the Hotelling’s T2 confidence ellipse. The PCA scores plot showed some 
clustering of the control and patient samples, particularly in the first two PCs.The 
dataset (with 2 PCA outliers removed) was then subjected to OPLS-DA analysis. A 
model with 3 LVs could discriminate between the elderly burn patient samples and 
elderly control samples with 100% Sensitivity and 89% specificity after 5-fold cross-
 251 
validation. The scores plots show good separation of the two classes (Figure 5.2) 
(R2: 0.9, Q2 0.7) and the AUROC for this model was 0.98 after cross-validation, 
confirming the model discriminated first 24hr post-injury patient samples from control 
samples based on NMR spectral profiles. The VIP loadings plot (Figure 5.3) shows 
the key metabolite peaks contributing to the model. 
 
Figure 5-2. OPLS-DA Scores plot of serum samples taken in the first 24hrs post-burn vs. 
matched healthy controls. Burn injured elderly patients (red) separate away from healthy controls 
(green).  
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Figure 5-3. VIP loadings plot from OPLSDA discriminating elderly patient samples taken in first 
24hrs post-burn and elderly healthy controls. NMR spectral peaks contributing to the model are 
labelled. The height of the peaks corresponds to VIP score and therefore greatest contribution to the 
variance between the first 24hrs samples from elderly burn patients and healthy elderly controls. 
 
NMR spectral peak assignment was performed for the top 50 peak bins weighted in 
the OPLSDA model according to the VIP score. A total of 21 metabolites were 
identified through spectral fitting of the 1D NMR peaks and these are listed in table 
5.4. 2 metabolite peaks were not identifiable using the Chenomyx spectral library and 
require further investigation to assign metabolites. The PPM values for these peak 
bins were 7.1595 and 7.3585 and were ranked 43rd and 49th according to VIP scores. 
A total of 14 metabolites were decreased in patients relative to controls and 7 
metabolites were increased in patients relative to controls. Decreases were seen in 
the patients relative to controls of ethanol, dimethyl sulfone, creatinine, creatine, 7 
amino acids, betaine and methanol. Increases were seen in acetaminophen 
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(paracetamol), glucose, ketone bodies (3-hydroxbutyrate, acetoacetate and acetone), 
myo-inositol and pyruvate. 
Rank Metabolite Change$ VIP* Chemical shift of peaks (ppm) 
1 Ethanol ¯ 55.95 1.18, 1.19, 1.20, 3.66. 3.67 
2 Dimethyl sulfone ¯ 50.91 3.16 
3 Acetaminophen ­ 31.74 2.17 
4 3-Hydroxybutyrate ­ 22.92 1.21 
5 Alanine ¯ 21.62 1.48, 1.49 
6 Valine ¯ 19.66 0.99, 1.00, 1.01, 1.04, 1.05 
7 Leucine ¯ 15.34 0.94, 0.96, 0.97,  
8 Glutamine ¯ 14.82 2.14, 2.45 
9 Creatinine ¯ 14.78 3.03, 3.04 
10 Glucose ­ 11.99 3.50, 3.86, 3.87, 3.89  
11 Acetoacetate ­ 10.73 2.28 
12 Creatine ¯ 10.23 3.04, 3.05 
13 Isoleucine ¯ 9.34 1.02 
14 Carnitine ¯ 8.28 3.23 
15 Acetone ­ 7.96 2.24 
16 Lysine ¯ 7.03 1.73 
17 Phenylalanine ¯ 6.21 3.11 
18 Myo-inositol ­ 6.05 3.63 
19 Betaine ¯ 5.51 3.30 
20 Pyruvate ­ 5.47 2.38 
21 Methanol ¯ 5.15 3.35 
Table 5-4. Metabolites identified within the top 50 ranked peaks in OPLS-DA model 
discriminating early first 24hrs serum samples from Elderly patients and elderly control 
subjects.  Metabolites are ranked according to peaks with the highest VIP score. Arrows indicate the 
direction of change in patient samples compared to controls. (VIP – Variable Importance of Projection, 
PPM – parts per million). 
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The same workflow was utilised to study the changes in the serum metabolome in 
elderly patients after the first 24hrs post burn-injury but within the first 3-days post-
burn (up to 96hrs). NMR spectral data obtained from serum samples taken >24-96 
hrs post-burn from 14 patients and 5 elderly control subjects was subjected to PCA. 
This identified two outliers (1 control, 1 patient) which were removed, resulting in a 
PCA that explained the following percentage of variation in the model: PC1 = 
39.87%, PC2 = 16.96% and PC3 = 14.68%. Some clustering and separation of 
control and patient samples was seen on the 3D scores plot of all 3 components. The 
filtered dataset was then subjected to OPLSDA. A 2-LV model (Figure 5.4) 
discriminated between elderly control serum samples and patient samples taken 24-
74 hrs post-burn with 100% accuracy, sensitivity and specificity. The metrics form the 
confusion matrix showed better overall performance of this model than the model 
employing earlier samples, however the Q2 metric was lower (Table 5.5).  
Parameter First 24hrs 24-74 hrs 
Latent variables (n) 3 2 
Samples  14 (9 Patient, 5 control) 16 (12 Patient, 4 control) 
Accuracy % (95% CI) 93 (61-93) 100 (83-100) 
Sensitivity % (95% CI) 89 (64-89) 100 (83-100) 
Specificity % (95% CI) 100 (56-100) 100 (49-100) 
PPV % (95% CI) 100 (72-100) 100 (83-100) 
NPV % (95% CI) 83 (46-83) 100 (49-100) 
AUROC 0.98 1.00 
R2 0.93 0.76 
Q2 0.72 0.56 
Table 5-5. Summary of statistical measures of performance of cross-validated OPLSDA model 
to discriminate between Elderly patient samples taken 24-74 hrs post-burn and healthy elderly 
control samples. PPV = Positive predictive value, NPV = negative predictive value, AUROC = Area 
under the receiver operating characteristic curve. 
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Figure 5-4. OPLS-DA Scores plot of serum samples taken 24-96hrs post-burn vs. matched 
healthy controls. Burn injured elderly patients (red) separate away from healthy controls (green). 
 
The peak bins within the model were arranged by VIP score and the top 50 peaks 
identified and annotated with metabolites from a representative patient sample NMR 
spectrum using spectral peak fitting as before. The metabolites identified are shown 
in table 4.16. A total of 19 distinct metabolites were identified by spectral fitting from 
the top 50 ranked peak bins in the OPLSDA model discriminating between 24-74 
post-burn elderly patient samples and elderly control samples. Two metabolite peaks 
were not identifiable using the spectral library and require further investigation to 
assign metabolites. The PPM values for these peak bins were 1.1537 and 3.6766 
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and were ranked 33rd and 48th according to VIP scores. Within the 17 identified 
metabolites, 10 were increased and 7 decreased in patient samples relative to 
control samples. As with the earlier serum samples, there were decreases in 
dimethyl sulfone, ethanol and 5 amino acids. Relative increases were seen in 
glycerol, ketone bodies, glucose, 3-methyl-2-oxovalerate, myo-inositol and succinate. 
 
Figure 5-5: VIP loadings plot from OPLSDA discriminating elderly patient samples taken 24-
96hrs post-burn and elderly healthy controls. NMR spectral peaks contributing to the model are 
labelled. The height of the peaks corresponds to VIP score and therefore greatest contribution to the 






Rank Metabolite Change$ VIP* Chemical shift of peaks (ppm) 
1 Dimethyl sulfone ¯ 91.69 3.16 
2 Ethanol ¯ 64.68 1.18, 1.19, 1.20 
3 Glycerol ­ 27.72 3.58, 3.65 
4 Alanine ¯ 25.33 1.48, 1.49 
5 3-Hydroxybutyrate ­ 20.60 1.21 
6 Acetaminophen ­ 17.27 2.17 
7 Valine ¯ 13.70 0.99, 1.00, 1.01, 1.05 
8 Acetoacetate ­ 12.40 2.28 
9 Glucose ­ 11.27 
3.40, 3.45, 3.48, 3.50, 3.51, 
3.55, 3.56, 3.57, 3.75, 3.81, 
3.84, 3.90 
10 Glutamine ¯ 9.63 2.14, 2.46 
11 3-Methyl-2-oxovalerate ­ 8.76 1.14, 1.15 
12 Myo-inositol ­ 8.38 3.63 
13 Acetone ­ 7.42 2.24 
14 2-Hydroxybutyrate ­ 6.79 0.90 
15 Isoleucine ¯ 6.52 1.02 
16 Leucine ¯ 6.38 0.95. 0.96, 0.97 
17 Succinate ­ 4.49 2.39 
 
Table 5-6: Metabolites identified within the top 50 ranked peaks in OPLS-DA model 
discriminating serum samples taken 24-96hrs post-burn from Elderly patients and elderly 
control subjects.   Metabolites are ranked according to peaks with the highest VIP score. Arrows 
indicate the direction of change in patient samples compared to controls. (VIP – Variable 






5.4.2 Longitudinal LCMS metabolomics analysis of the elderly response to 
thermal injury 
 
5.4.2.1 Demographics of the study group 
A total of 6 patients were included in the longitudinal metabolomics analysis. The 
mean age for the cohort was 74.6 (+/-11.1) years and the median burn size was 4.5 
(3.0-13.1) %TBSA (Table 5.7). This was comparable with data from the retrospective 
analysis performed of 2004-2012 elderly burn admission (Chapter 2), suggesting that 
they were a representative sample to study. In terms of outcomes no patients died 
during their hospital stay but 1 developed MOF (17%) and 2 developed infectious 
complications and were diagnosed with sepsis (33%). 
Admission parameters Values 
n 6 
Age (years) 74.6 (+/-11.1) 
Male n (%) 2 (33) 
BMI (kg/m2) 23.3 (+/-6.0) 
Co-morbidities 5 (83) 
TBSA (%) (IQR) 4.5 (3.0-13.1) 
TBSA-FT (%) (IQR) 2.7 (2-5.6) 
Inhalation injury n (%) 0 (0) 
ICU Admission n (%) 1 (17) 
APACHE II first 24hrs (IQR) 14.5 (4.5-18.0) 
SOFA first 24hrs (IQR) 1 (0-5) 
Denver MOF first 24hrs (IQR) 1 (0-2) 
R-Baux 81.4 (+/-9.1) 
ABSI (IQR) 7 (7-8) 
BOBI (IQR) 2 (2-2) 
Table 5-7. Demographics and injury data for the elderly patients included in the longitudinal 
LCMS study. Abbreviations: APACHE (Acute physiology, age and chronic health evaluation score), 
SOFA (Sequential organ failure assessment) score, ABSI (Abbreviated burn severity of illness) score 
and BOBI (Belgian outcomes in burn injury) score, R-Baux (Revised Baux Score). 
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Outcome variable Value 
In hospital mortality n (%) 0 (0) 
Mortality at 1 year 1 (17) 
MOF (Denver > 2) n (%) 1 (17) 
Sepsis n (%) 2 (33) 
Pneumonia 2 (33) 
Wound infection 1 (17) 
ICU LOS (days) (IQR) 0.0 (0.0-0.8) 
Mechanical Ventilation days (IQR) 0.0 (0.0-0.3) 
Hospital LOS (days) (IQR) 24.5 (16.5-45.8) 
Hospital LOS (days/% TBSA)  5.8 (+/-4.9) 
Table 5-8. Summary of outcomes data for the elderly patients included in the LCMS 
longitudinal study. (MOF=multiple organ failure, ICU= intensive care unit, LOS=Length of stay, 
IQR=interquartile range). 
 
5.4.2.2 Overview of metabolomics data 
A total of 42 serum samples were analysed from the 6 thermally injured elderly 
patients in the study. The samples were run within the same batches as the young 
adult severe burn cohort presented in Chapter 4 with the use of pooled QC samples. 
The quality assurance of the overall dataset was checked with PCA and is presented 
in Chapter 4, section 4.4.1.1. After removal of metabolite features with >60% missing 
values, those with <50% of the features present in the QC samples and those with 
>20% relative standard deviation (RSD) across batches, 8185 metabolite features 
remained for the ANOVA analysis. ANOVA applied to the positive and negative ion 
mode datasets separately identified 379 metabolite features changing significantly 
(p=<0.05) from the time of injury to 6-months follow-up. No metabolite features were 
identified with an FDR corrected p-value<0.05 and therefore the uncorrected p-
values were utilised for feature selection. From this dataset, 312 metabolite features 
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were filtered according to the criteria used in the young adult burn study, leaving a 
total of 67 metabolite features for final analysis. Trend analysis then focused on a 
final 50 metabolite features in 13 classes after removal of mixed class annotations 
(Figure 5.6).  
 
Figure 5-6. Flowchart of process of selection of metabolite features for further detailed 
analysis from elderly burn LCMS serum data. (LC-MS = Liquid chromatography mass 
spectrometry, RSD = Relative standard deviation). 
 
Serum LC-MS Raw data 
17,525 Metabolite features 
(Postive and negative ion-
modes) 
ANOVA  
Tukey’s Post-hoc analysis 
(n = 8,185) 
Metabolite features for final 
analysis  
(n=67) 
Metabolite features removed 
• Duplicates (n=11) 
• Significant but no change 
between time-points on 
post-hoc analysis (n=49) 




(n = 118) 
Metabolite features removed: 
 >60% missing values 
Present in <50% of QC samples 
>20% RSD across batches 
Metabolite features for final 
detailed analysis  
(n=50) 
13 classes 
Metabolite features removed: 




(n = 194) 
Metabolite features changing 
significantly (p = <0.05) 
 Day 1 - 6m post-burn 
(n = 379) 
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Within the final 67 metabolite features dataset the class with the highest frequency of 
significantly changing metabolite features was the glycerolipids (acyl glycerides), 
followed by mixed classes and then polyketides, fatty acyls and steroid hormone 
metabolites (Table 5.9). 
 
Table 5-9. Summary of all metabolite classes changing significantly in serum over 6 months 
post thermal injury in thermally injured elderly patients and number of significantly changing 
metabolites in each class (p=<0.05). 
 
5.4.2.3 Lipid metabolism 
In the overall dataset 36 metabolite features (54%) were lipids showing significant 



















thermal injuries. Among the lipid classes, 9 glycerolipids and 6 fatty acyls changed 
significantly. All of the glycerolipids were annotated as diacylglycerides (DG). All of 
these DGs displayed a pattern of decline from admission levels to a nadir at M2, 
followed by elevation from M2 to M6. Representative metabolite features are shown 
in Figure 5.7. 
 
Figure 5-7. Box and whisker plots showing common longitudinal trend for diacylglycerols after 
thermal injury in the elderly. A: M5764, DG(34:3) (p=<0.001) B: M4964, DG(28:1) (p=0.016) and C: 
Summary of trend. 
 
Within the 6 fatty acyl metabolites identified, there was a mixture of unsaturated fatty 
acids, fatty esters, fatty amides and octadecanoids. The predominant trend was very 
similar to that seen in the DGs with a decline from admission to a nadir at M2 before 
increasing again to M6 (Figure 5.8a and b). One metabolite feature, annotated as N-
ethyl arachidonoyl amine and N,N-dimethyl arachidonoyl amine, a fatty amide, 
showed a different pattern with a rise from admission to a peak at 2 weeks before 

































































Figure 5-8. Box and whisker plots showing common longitudinal trend for fatty acyls after 
thermal injury in the elderly.  
A: M960, annotations: :5,8-Tetradecadienoic acid; 6,9-tetradecadienoic acid; Alepric acid; Allyl 
undecylenate; alpha-Terpineol butanoate; Bornyl butyrate; Ethyl -dodecadienoate; Geranyl 2-
methylpropanoate;Goshuyic acid;Isobornyl isobutyrate; Linalyl butyrate; Linalyl isobutyrate;Neryl 
butyrate; R-cucujolide III;S-cucujolide III. (p=<0.009)  
B: M4802, annotations: Mayolene-16; hentriacontane-14,16-dione; Pentadecyl palmitoleate; (p=0.022) 
C: M3135, N-ethyl arachidonoyl amine and N,N-dimethyl arachidonoyl amine (p=0.017) 
 
5.4.2.4 Steroid hormone metabolism 
Within the group of 8 sterol lipids changing significantly, 4 metabolite features were 
related to steroid hormone metabolism. Ptilosteroid A is a a saturated derivative of 
the C21 steroid, pregnane. Tetrahydroaldosterone-glucoronide and cortolone-
glucoronides are mineralocorticoid and glucocorticoid steroid conjugates allowing 
excretion of these in bile. Ptilosteroid A (p=0.001) showed a trend of decline from 
admission to nadir at M2 and levels increased at M6 (Figure 5.9a). The other steroids 
showed a common pattern of decline from admission levels to a plateau between D5-















































Figure 5-9. Box and whisker plots showing common longitudinal trend for steroid hormone 
metabolites after thermal injury in the elderly. A: M3639, Ptilosteroid A (p=0.001) B: M5488, 
tetrahydroaldosterone-glucuronide (p=0.007) and C: M4798, cortolone-glucuronide (p=0.024). 
 
5.4.2.5 Bile acid and heme metabolism 
Within the dataset, 4 bile acid metabolites changed significantly over the course of 
the study and showed a trend of elevation from the time of injury to a peak at either 
D5-8 or D12-15 (Figure 5.10b and c). Two of the bile acids metabolites also showed 
a late peak at M3, but the interquartile range is very large for that timepoint. One 
metabolite feature was annotated with urobilin and urobilinogen, heme degradation 
pathway metabolites and they showed a trend of early elevation after injury for at 
least 4 days. Levels were then low or undetectable from D5-8 until M3 before 















































Figure 5-10. Box and whisker plots showing common longitudinal trend for Heme and bile acid 
metabolites after thermal injury in the elderly.  
A: M5543, d-urobilinogen, urobilin (p=0.003)  
B: M5407, 3a,12b-Dihydroxy-5b-cholanoic acid; 3a,7a-Dihydroxycholanoic acid; 3alpha,15alpha-
dihydroxy-5beta-cholan-24-oic acid; 3b,12a-Dihydroxy-5a-cholanoic acid; 3b,12a-Dihydroxy-5b-
cholanoic acid; 3b,12b-Dihydroxy-5b-cholanoic acid; 3b,7a-Dihydroxy-5b-cholanoic acid; 7a,12b-
dihydroxy-5b-Cholan-24-oic acid; 7b,12a-Dihydroxycholanoic acid; Allochenodeoxycholic acid; 
Allodeoxycholic acid; Avideoxycholic acid;Chenodeoxycholic acid; Deoxycholic acid; Hyodeoxycholic 
acid; Isodeoxycholic acid; Isohyodeoxycholic acid; Isoursodeoxycholic acid; Murocholic acid; 
Ursodeoxycholic acid; 3beta-(3-methyl-butanoyloxy)-villanovane-13alpha,17-diol (p=0.007) 
C: M5470, Taurochenodeoxycholate-3-sulfate;Taurochenodeoxycholate-7-sulfate; AFN911; 10-
Deoxymethymycin (p=0.010). 
 
5.4.2.6 Carbohydrates and TCA cycle metabolism 
Two carbohydrate metabolites were identified as changing significantly and both had 
multiple annotations. They showed almost opposite trends across time with M1255 
declining from admission with a nadir at 3 weeks before increasing again and 
peaking at M3. M1787 declined slightly from admission before peaking 3 weeks and 
declining again to M2 before increasing again (Figure 5.11 a and b). One TCA cycle 














































the study and this was also identified in the young adult severe burns analysis. 
Interestingly it showed the same trend pattern as the carbohydrate M1255 (Figure 
5.11c). 
 
Figure 5-11. Box and whisker plots showing common longitudinal trend for carbohydrates and 
TCA cycle intermediates after thermal injury in the elderly.  
A: M1787, 1-Deoxy-D-xylulose 5-phosphate; Deoxyribose 1-phosphate; Deoxyribose 5-phosphate; 2-
Keto-3-deoxy-D-gluconic acid; 3-Keto-b-D-galactose;D-Arabino-hexos-2-ulose; Galactonolactone; 
Gluconolactone;L-Gulonolactone; Methylthiomethyl 2-methylbutanethiolate; Melizame; 2-Acetyl-3-
methylpyrazine; N-Methylnicotinamide; A (p=0.02)  
B: M1255, 3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid; Allopurinol riboside; 
Arabinosylhypoxanthine; Inosine; Ethyl glucuronide; (p=0.002)  
C: M1502, oxoglutaric acid (p=0.003). 
 
5.4.2.7 Peptides 
Two peptide metabolite features changed significantly across the course of the study 
including Neuromedin N(1-4) (p=<0.001) and Melanostatin (p=0.041). Neuromedin 
N(1-4) is a hexapeptide with known immunomodulatory and endocrine properties and 
showed the same trend pattern as seen in the young adult severe burn group. 














































inhibits the release of melanocyte-stimulating hormone. It was undetectable until M3 
where it showed a slight rise and then decline again. 
 
Figure 5-12. Box and whisker plots showing common longitudinal trend for steroid hormone 




In this study 1H-NMR metabolomics has been used to explore the early changes in 
serum after thermal injury in a cohort of 15 thermally injured elderly patients. 
Secondly, a preliminary study of the longitudinal changes in the metabolome after 
thermal injury in elderly patients has been conducted using a discovery phase LC-MS 
metabolomics approach.  
5.5.1 NMR metabolomics analysis of the early response to thermal injury 
In the first study, we have shown that serum metabolomics profiles could be utilised 































thermally injured elderly subjects and samples from healthy elderly control subjects. 
Multi-variate models showed high discriminatory performance as assessed by 
accuracy, sensitivity and specificity and ROC analysis. The predominant pattern of 
change in the first 24hrs post-injury samples was of relative decreases in metabolites 
compared to controls with 14/21 (67%) of the top 50 weighted metabolites in the 
model. The pattern changed in the second samples taken between 24 and 96 hrs 
post-injury with a predominant pattern of increases in metabolites relative to control 
subjects with 10/17 (59%) of metabolites being increased. Interestingly, this was the 
opposite pattern to that seen in the study of younger adults with more severe injuries. 
The other interesting finding when comparing the results of the two different cohorts 
is that in the elderly cohort there were greater variation in the number of different 
metabolites featuring within the top 50 weighted ones in the OPLSDA models. In the 
younger adult models, several metabolites dominated with multiple peaks featuring in 
the highest weightings, including glucose, 3-hydroxybutyrate and lactate. This may 
represent more significant peturbations in these metabolites relative to the control 
subjects.  
As was seen in the 1H-NMR study of larger burns in younger adults, many amino 
acids, both essential and non-essential were shown to decrease after thermal injury, 
suggesting this is not an age specific response. These changes are consistent with 
previous findings in the burn literature (462,463). It was an unexpected finding that 
there would be so many changes in amino acids in the elderly group relative to 
controls, since the average burn size for the group was only 6% TBSA versus 38% 
TBSA in the young adult group. These decreases seemed to persist in the second 
sample with ongoing relatively lower levels of even essential amino acids valine, 
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isoleucine and leucine. The underlying cause of these reductions is unclear as 
circulating levels only tell half the story without knowing the whole-body kinetics and 
flux of these amino acids. This may represent acute increases in utilisation by the 
burn wound and liver for acute phase protein synthesis(228). If these findings do 
however represent acute skeletal muscle catabolism as has been shown in children 
and adults with much larger injuries, then this could have an impact on the delayed 
recover of elderly patients with thermal injury. This could be especially problematic 
since with increasing age it is known there is increasing loss of skeletal muscle, 
known as sarcopenia, due to altered muscle metabolism, contributing to increased 
frailty (464). Longer-term quantitative data on blood changes and whole-body kinetics 
of amino acids, combined with ultrasound measurement of muscle thickness and 
functional measurement of muscle function are a priority in the elderly burn patient. 
As was seen in the younger adult cohort, the elderly patients also exhibited increases 
in ketones, glucose and pyruvate relative to controls. In the second sample, 
increases were seen in succinate, the TCA cycle intermediate. These data suggest 
that despite smaller injuries, there may also be a significant enough stress response 
in the elderly after thermal injury to increase energy demands and altered glucose 
homeostasis. Ageing is associated with increases in insulin resistance (IR), which 
may be potentially worsened by the metabolic changes in thermal injury. A recent 
study looking at a cohort of elderly patients with moderate sized burns (median 
TBSA, 15%) compared inflammatory and metabolic indices with an injury severity 
matched group of younger patients with burn injury. They found the elderly patients 
had average higher daily glucose levels and a greater insulin requirement which 
persisted for the whole study period of 1 month post-injury. The study also performed 
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oral glucose tolerance testing (OGTT) and found no differences in insulin resistance 
between the age groups but did find that the elderly had impaired insulin production 
by the pancreas (465). The consequences of more persistent hyperglycaemia are 
increased risk of infections, decreased wound healing and increased mortality (466). 
Other observations of interest that were not seen in the younger adult cohort, include 
elevations in myo-inositol, a cyclic polyalcohol and source of important second 
messengers in cells. Studies in rat burn models have shown that D-myo-inositol-
1,2,6-triphosphate (IP3), a metabolite of myo-inositol, decreased burn oedema and 
inflammation and inhibition of dermal ischaemia after burn (467). Elevations in this 
metabolite may therefore be protective in response to deeper thermal injury, 
preventing inflammation mediated burn wound progression. Decreases in ethanol in 
the patient group relative to controls could either be due to alcohol consumption by 
the healthy volunteers or alterations in gut metabolism. Dimethyl sulfone (DMSO2) is 
normally found in human plasma and CSF and can be derived from food sources and 
endogenous conversion of methanethiol which is derived from gut bacterial 
metabolism (468). This decrease in DMSO2 in the patients seen at both time points is 
curious and could be related to acute alterations in gut perfusion or gut microbial 
metabolism. 
Decreased alterations in dimethyl sulfone and ethanol in the patients relative to 
controls are a curious finding and could be a spurious result owing to volunteers 
drinking alcohol prior to sampling. The DMSO2 levels could be related to altered gut 
bacterial metabolism in the patients relative to controls. Alternatively, it could be due 
to alterations in methanthiol metabolism in blood 
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5.5.2 LCMS metabolomics study of the longitudinal response to thermal 
injury in the elderly. 
In the second study, we have performed a preliminary untargeted longitudinal 
metabolomics analysis of a small cohort of elderly patients with thermal injury. The 
same analytical methods and approach were used as for the longitudinal study 
conducted on a cohort of younger adults with severe burns >15% TBSA (Chapter 4). 
The first finding that relative to the younger cohort, there were much fewer metabolite 
features that changed significantly across the 6-months of the study (67 vs. 432). and 
none that were significant according to FDR correction. There are several possible 
explanations for this finding. Certainly, the much smaller cohort of patients with far 
fewer serum samples included in the analysis will have impacted the number of 
metabolite features demonstrated as significant. Secondly, the severity of injury was 
much lower in the elderly cohort and since hypermetabolism correlates directly with 
burn size (71), it seems logical that there would be overall less changes in the 
metabolic network with a smaller injury burden. As part of the filtering process, any 
metabolite features that only changed significantly between two time-points were 
filtered out. Re-examining the raw data, there were another 28 metabolites that 
changed significantly between the either of the initial two samples and the other time-
points in the first two weeks. Briefly looking at the annotations for these, they include 
heme metabolites (bilirubin, biliverdin), bile acids, steroid hormone, eicosanoids and 
docosanoids. These metabolites are associated with oxidative stress, stress 
response and inflammation and since they are only significantly changing at early 
time-points, this may represent a short stress response in this cohort. In order to test 
this hypothesis, it would useful to conduct a much larger study, with a range of burn 
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injury sizes included for burn size group comparisons and correlations against injury 
severity. 
Comparison of the elderly burn LC-MS data with the younger adult burn dataset, 
shows that there were, despite the differences in injury size, similar classes of 
metabolite features that changed significantly across the time course. There were 
again large numbers of lipid metabolite features that changed significantly including 
multiple glycerolipids and fatty acids. The glycerolipid class was entirely made up of 
DGs which could be related to increased triglyceride breakdown in adipose tissue. 
This is a potentially interesting finding since increased intracellular levels of DGs, 
together with fatty acyl CoAs, have been linked with muscle insulin resistance 
through protein kinase C activation triggering signalling cascades modulating the 
insulin receptor substrate-1 (IRS-1) activity (469). Another similarity between the 
datasets is the most common trend pattern seen across classes was very similar, 
with a reduction from admission levels to a nadir, albeit later in the case of the elderly 
patients, being at 2-months post-injury. This raises the possibility of a delayed 
recovery in metabolic responses. There was again evidence of oxidative stress with 
early increases in circulating heme metabolites and evidence of biliary dysfunction 
with several bile acids peaking within the first 2 weeks post-injury. Neuromedin-N 
was found to be most highly significantly changing metabolite and displayed a similar 
pattern as seen in the younger adult cohort, suggesting a common response 
irrespective of age. It is related to the neurotensin family of neuropeptides innate and 
adaptive immunomodulatory properties and can modulate the HPA axis. This 
metabolite should be investigated further to investigate potential roles in post-injury 
immunosuppression and endocrine dysfunction. 
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5.5.3 Limitations of the study 
The main limitations of this work as that given the sample size, it is essentially 
preliminary in nature and larger analysis of the remainder of the SIFTI cohort of 
patients could be analysed as a next step to confirm or refute the findings above. It 
would be worthwhile including larger burns in the elderly group, accepting the 
difficulties in following up these patients who are often repatriated to intermediate 
care or other hospitals once they are out of their acute phase. 
5.5.4 Conclusions 
In this study, we have utilised complementary analytical platforms to apply 
metabolomics to the study of thermal injury in an understudied subgroup of burn 
patients who suffer poorer outcomes relative to their injury burden. The 
metabolomics data has highlighted similarities and differences between metabolic 
changes early and across the recovery phase between older and younger thermally 























Chapter 6: General discussion 
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6 General discussion 
6.1 Overview 
The focus of this thesis has been on applying metabolomics, a systems biology 
approach, to the study of metabolic changes after severe thermal injury. The 
hypermetabolic response that ensues after severe cutaneous burns is profound, 
prolonged and associated with poor clinical outcomes (333). Much of the knowledge 
so far acquired regarding post-injury metabolic disturbances has been gleaned from 
targeted studies of classes of metabolites. Although these studies have led to 
advances in burn and trauma care, clinical outcomes are plateauing. 
 The Scientific Investigation of biological pathways Following Thermal Injury (SIFTI) 
study was an ambitious project set up at the Birmingham Scar Free Foundation 
Burns Research Centre in the UK with the aim of studying in parallel the immune, 
inflammatory, endocrine and metabolic responses to severe thermal injury. The 
research presented in this thesis focused on a sub-cohort of these severely injured 
patients, applying both 1H-NMR and LC-MS metabolomics, to study global changes 
in metabolic networks after thermal injury. The study has shown that there are early 
global metabolic profiles that distinguish patients who go to develop poor outcomes 
from those who have an uncomplicated recovery. Applying metabolomics analysis 
longitudinally after thermal injury, has identified major shifts in lipid metabolism, a 
‘lipid storm’ paralleling changes in metabolites reflective of increased energy 




6.2 Metabolomics as an approach to study the acute response to severe 
thermal injury 
The application of 1H-NMR metabolomics of serum samples taken within the first 
96hrs of thermal injury highlighted significant changes in the metabolome during the 
first 24hrs after injury that were different to those seen 24-96hrs post injury. This may 
represent transitioning from the ‘ebb’ into ‘flow’ or ‘plateau’ phases first described by 
Cuthbertson in 1942 (146). During the first 24hrs, key changes in the metabolome 
reflected anaerobic metabolism (­lactate), increased glucose availability and 
increased energy production through glycolysis (­pyruvate) and increased 
mobilization of fat stores (­glycerol), most likely to provide fatty acids for b-oxidation. 
This findings do perhaps validate the metabolomics data, since they agree with 
published studies demonstrating post-burn hyperglycaemia (173) and increased 
lipolysis (367). The acute relative decreases in the non-essential amino acids (NAA) 
alanine, glycine, proline and glutamine and the branched chain amino acid, valine are 
also consistent with previous studies (462,463). The explanation for these changes is 
net protein catabolism, despite increases in protein synthesis to skeletal muscle with 
increased flux towards the burn wound and liver, providing substrates for wound 
healing and gluconeogenesis and acute phase protein synthesis respectively (228). 
One finding that disagrees with some studies of the metabolic response to injury is 
the relative increases in ketone bodies seen in the early samples taken in the first 
24hrs post injury. Although ketogenesis is a normal response to starvation with aim 
of sparing muscle protein catabolism, many studies have found that the stress 
response to injury and infection does not induce a ketogenic response and skeletal 
muscle amino acids are mobilized. Many of these studies were performed in the 
1970’s and early 1980’s prior to the introduction of early enteral feeding. Moreover, 
 277 
more recent studies in traumatic injury have shown a gut-liver interaction, with initial 
ketogenesis in the gut, followed by gut ketolysis and liver ketogenesis at 24hrs post 
injury (326).  Perhaps it is time for a further reappraisal of ketogenesis following 
thermal injury as it may contribute a useful source of energy early of injury in some 
tissues. 
6.3 Metabolomics to predict later clinical outcomes 
 
The metabolite profile during the first 24hrs after thermal injury was predictive of later 
mortality, demonstrating the relationship of the early metabolic response to later 
complications. Elevations were seen in previously studied metabolites such as 
glycerol, glucose, ketone bodies and lactate probably reflective of increased 
metabolic dysfunction in related to increased severity of injury in the non-survivor 
group (mean TBSA: 50%, non-survivors vs. 27.5%, survivors). Several potential 
interesting metabolites were weighted highly in this model that could warrant further 
investigation in targeted studies.  
Kynurenine is a product of the tryptophan degradation pathway and has been 
recently investigated in non-burn trauma. These studies showed early elevations 
predicted later sepsis, whilst increased kynurenine:tryptophan ratios predicted later 
MOF and non-survival (354). In addition, elevations in critical ill patients of the toxic 
metabolite of kynurenine, quinolinic acid, was able to predict later development of 
sepsis with good discriminatory power (470). The biology behind these associations 
is unclear, but kynerenine and the enzyme that produces it from tryptophan, 
indoleamine 2,3-dioxygenase (IDO), has links to vascular endothelial dysfunction 
(352) and immunoregulatory  functions (348). There are no studies examining 
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kynurenine metabolism in relation outcomes in thermally injured patients, but a study 
in children with large burns demonstrated increased tryptophan metabolism 
associated with an increase in urinary excretion of kynurenic acid and kynurenine 
(471). A number of recent metabolomics studies have also highlighted kynurenine as 
an important biomarker that is associated with sepsis related mortality in a non-
human primate model (278) and in humans (282,308). 
Two other metabolite of interest in the mortality prediction model are methylmalonate 
(MMA) and acetate which could potentially be metabolite signals of early gut 
dysfunction during the resuscitation phase. MMA is an endogenous metabolite in the 
valine degradation pathway but is also produced by enteric bacteria through 
metabolism of propionate and can be absorbed in the portal circulation (356). Acetate 
could be related to endogenous acetyl CoA metabolism in the liver due to acetyl CoA 
excess from fatty acid oxidation and can be oxidized by the peripheral tissues, 
particularly in the heart and brain. Alternatively, it could also be derived from enteric 
bacterial metabolism and studies an animal model of obesity and metabolic 
syndrome has found links between gut bacterial derived acetate and abnormalities in 
insulin secretion and sensitivity (364). 
Metabolite profiles from serum samples taken 24-96hrs post-injury were able to 
predict the later development of sepsis and MOF in this cohort of thermally injured 
patients. It is not clear why the first 24hr serum samples were more predictive of 
mortality but the later samples during the flow phase were more predictive of these 
other outcomes. Interestingly the pattern of change in these two models 
demonstrated a higher proportion of metabolites that were relatively decreased in the 
poor outcome groups. Many of these relatively decreased metabolites were amino 
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acids, reflecting early skeletal muscle protein catabolism in the flow phase. This is 
not a surprising finding given that the sepsis and MOF groups of patients had 
significantly larger burns than their counterparts and burn size is a predictor of the 
extent of protein catabolism post-burn (234). Burn size (TBSA) is also an 
independent predictor of the degree of hypermetabolism as measured by resting 
energy expenditure (REE) (71). 
Currently no other studies have attempted to use early metabolomic profiles to 
predict later clinical outcomes in human thermal injury. The approach has been used 
in predict survival following severe trauma (472) and critically ill patients on 
admission to the ICU (308). Cohen et al. studied 32 severely injured patients and 
performed whole blood extraction 1H-NMR metabolomics from samples taken on 
admission and identified 7 metabolites that discriminated later survivors from non-
survivors. These metabolites included glucose, lactate, glycerol, b-hydroxybutryrate 
as in this study, plus glutamate and triacylglycerides and monounsaturated fatty 
acids (472). Rogers et al. studied ICU admission plasma samples from 90 critically ill 
patients and 149 adults with pneumonia presented to the emergency department. 
Using GCMS and LCMS and Bayesian Network analysis they identified 31 plasma 
metabolites that were predictive of 28-day mortality in both cohorts of patients, which 
included amino acid metabolites, acyl carnitines, glycerophospholipids and bile acids 
(308). They highlight that one third of 187 metabolites differed between the outcome 
groups and thus metabolomics has the advantage of being able to simulataneously 
quantify metabolites across a range of classes to uncover novel biological 
information. Only one study has utilized metabolomics as an approach to try to 
predict later sepsis in trauma patients. In this small study, Blaise et al. used 1H-NMR 
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to measure metabolite profiles in plasma samples taken from 22 severely injured 
patients on admission to ICU. Their multi-variate model included b-hydroxybutryrate, 
citrate, aspartate and allantoin and predicted later sepsis in this cohort with an AUC 
of 0.778 (275). The model statistics suggest significant overfitting, highlighting the 
important of cross-validation in metabolomics. 
 
6.4 Metabolomic analysis of longitudinal changes in metabolism after thermal 
injury 
 
Untargeted LC-MS metabolomics was applied to study global changes in metabolism 
after severe thermal injury in young adults. This novel approach revealed widespread 
changes in 35 classes of metabolites across the metabolome and profound 
alterations in circulating lipids and lipid metabolism, possibly reflecting a ‘lipid storm’ 
after severe thermal injury. There also appeared to be several common patterns 
across different classes of metabolites. Many, including fatty acids (FAs), 
glycerolipids, glycerophospholipids and sphingolipids demonstrated a reduction from 
injury levels down to a nadir at 3 weeks, before levels elevated again towards 
admission levels during the recovery phase. The majority of peptides showed an 
inverse pattern to this, peaking at 3-weeks post-injury. These temporal changes may 
represent the catabolic phase after major thermal injury which appeared to outlast 
the changes in nitrogen excretion observed which peaked at 10-days post-injury.  
The significant shifts in lipid metabolites after severe thermal injury is an interesting 
finding and changes in FAs and glycerolipids are compatible with the known stress 
hormone mediated increases in peripheral adipose lipolysis to generate substrates 
for energy production via mitochondrial b-oxidation (169). The widespread changes 
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in FAs corroborates the recently published targeted metabolomics study by Jeschke 
et al. in which they demonstrate acute increases in all major classes of FAs, followed 
by decline. Importantly, they also highlight a metabolite signal of poor outcomes, with 
non-survivors demonstrating persistently elevated plasma FAs, particularly saturated 
FAs (SFA), monounsaturated FAs (MUFA) and w-6 polyunsaturated FAs (wPUFA) 
(393). Fatty acid metabolism is intrinsically linked with inflammation and depending 
upon the sub-type, some have beneficial roles in resolving inflammation and some 
are pro-inflammatory. SFA have been shown to induce inflammatory gene 
expression via toll-like receptor 4 (TLR4) signaling in vitro and PUFA have been 
demonstrated to be able block inflammatory responses induced by LPS (473). The w-
6 PUFAs such as arachidonic acid are also precursors for the pro-inflammatory 
eicosanoids and w-3 PUFAs such as docosahexeanoic acid (DHA) and 
eicosapentaenoic acid (EPA) are precursors for the synthesis of docosanoids or 
specialized pro-resolving mediators (SPMs) such as the resolvins, protectins and 
maresins (409). These have not yet been extensively studied in thermal injury but 
several of these SPMs were identified in the LCMS analysis as increasing from 
admission and peaking at around 3-weeks post-injury. A recent genomic study in 
polytrauma patients demonstrated that patients with uncomplicated recoveries had 
higher expression of resolving genes and lower expression of leukotriene genes 
across the 28-days post-injury (474). Fatty acid and docosanoid metabolism in 
thermal injury certainly required further detailed investigation to examine the links 
between lipid profiles and clinical outcomes. 
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Another interesting observation from the LCMS data was the detection of probable 
bacterially derived metabolites that changed significantly, with early elevations that 
showed the same pattern observed with the pro-inflammatory cytokine levels in the 
cohort. The appearance of these metabolites in the blood of severly injured patients, 
such as the tryptophan metabolites, indole, indoxyl and 3-dehydroquinate and Heme 
O could represent potential early biomarkers of gut ischaemia and inflammation. 
Further study of these in a targeted study with indirect measures of gut perfusion and 
monitoring of poor gut dysfunction related outcomes such as enteral feeding 
intolerance is warranted. 
A final group of metabolites of interest in the study were the sex steroid hormone 
metabolites.  Most of these demonstrated a trend of decline from admission levels to 
a nadir at 2-3 weeks before increasing again, including a degradation metabolite of 
the androgen precursor dehydroepiandrosterone (DHEA). The sulfated form of 
DHEA, DHEAS has already been demonstrated to decrease for up to 4 weeks post 
burn injury (395). Recent studies from our own institution in a large cohort of severely 
injured military patients have shown serum DHEA and DHEAS levels were low after 
injury with the latter remaining low for 6- months post-injury (MA Foster, unpublished 
data). DHEAS has also been shown to be low in other systemic inflammatory disease 
states such as sepsis. Targeting DHEA/DHEAS pathway represents a potentially 
beneficial strategy in severe thermal injury since DHEAS has anabolic and immune 
enhancing properties. This includes the stimulates of neutrophil superoxide burst 
generation (396). In the SIFTI cohort, including some of the patients in this study, our 
group has shown neutrophil superoxide burst activity and phagocytic function is 
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reduced after thermal injury for 28 days and decreases were greater in patients who 
developed sepsis (405).   
 
6.5 Thermal injury in the elderly and changes in metabolism 
 
The elderly are an understudied group in the context of thermal injury. Many studies 
have highlighted that they experience poorer outcomes for a given burn size, but few 
studies have attempted to understand the pathophysiological mechanisms underlying 
this. A retrospective study at our centre highlights some improvements in outcomes 
in elderly burn injured patients over the last decade (453). We hypothesize this to be 
due general improvement in burn care, local infrastructure, use of burn care 
guidelines locally and increasing involvement of geriatric physicians. The study also 
highlights that burn mortality in this group remains high and one of the leading 
causes of death are infection related complications. We sought to use metabolomics 
as an approach to study metabolic changes in thermally injured elderly patients to 
see if new pathophysiological information could be acquired to generate new 
hypotheses. 1-H NMR metabolomics analysis revealed similar increases in glucose, 
ketones and similar decreases in amino acids in serum samples taken during the first 
96hrs post-injury. Relative decreases in multiple essential and non-essential amino 
acids suggests increased utilization as energy substrates and for wound related 
protein synthesis. Further studies are required if these metabolic signals reflect 
increased skeletal muscle catabolism which could impact recovery from even small 
burn injuries in aged individual who may already have age related sarcopenia. 
Altered glucose metabolism was also observed, consistent with findings in recent 
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studies that elderly patients have higher average daily glucose levels and higher 
insulin requirements than injured size matched younger counterparts (465). 
A preliminary LC-MS metabolomics study of the longitudinal response to thermal 
injury in a relatively small cohort of elderly patients revealed less overall significant 
changes compared to the younger cohort. This was probably related to the relatively 
small sample size but reduced metabolic response to different injury severity may 
have been contributory. There were however many similar areas of metabolism 
changing after relatively small injuries in the elderly group including changes in 
glycerolipids, fatty acids, steroid hormones, bile acids and heme metabolites.  
 
6.6 Strengths and limitations 
 
The main strengths of this research are firstly the overarching SIFTI study. The study 
is unique in its combination of prospective detailed collection of clinical and outcomes 
data whilst collecting multiple biofluids for parallel analysis of immune, inflammatory, 
metabolic and endocrine indices. This type of research study has not been 
conducted in the UK or Europe before and is a large collaborative of many research 
groups. The study has utilized two different analytical techniques used in 
metabolomics which have allowed complementary coverage of the post thermal 
injury metabolome. Discovery based approaches have been used rather than 
targeted metabolomics allowing us to both confirm the findings of previous studies 
and find new avenues of research and testable hypotheses.  
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In the NMR study, the main limitations are that the metabolite concentrations were 
not calculated due to problems with batch process analysis using the Chenomx 
software. This may be related to subtle differences in sample pH, which was not 
problematic for the multi-variate analysis of spectral peaks since an alignment 
algorithm was used. Future studies should include pH standardization or the use of a 
pH ‘indicator’ metabolite such as imidazole. The next step for completion of this work, 
would the calculation of metabolite concentrations and univariate statistical analysis 
to assess if inter-group differences observed in multi-variate analysis still hold true. 
The number of controls used could be increased diversity among that group and 
ensure a representative healthy metabolome for comparison. Other limitations of the 
study include the relatively small sample sizes in the elderly study, accepting the 
difficulties in recruiting and following up this patient group. With completion of the 
SIFTI study recruitment, a larger cohort of elderly patients have been recruited, 
provided samples for future work. 
 
6.7 Future studies  
 
Further studies planned include further correlation of the data with markers 
inflammation and immune dysfunction collected in the SIFTI study, including 
neutrophil phagocytic and superoxide activity, mitochondrial DNA and sex hormone 
analysis including DHEA/DHEAS and cortisol. 1H-NMR and LC-MS data has also 
been acquired from urine samples collected from the same cohort of patients, 
allowing cross-biofluid comparisons of the data. An attractive prospect is the 
identification of a novel sepsis biomarker or biomarker panel to try to diagnosis 
sepsis earlier and with greater accuracy. This has been a particular area of focus of 
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metabolomics studes in critical care and trauma and several studies have identified 
promising candidate biomarkers (277,279,281,282,308). The main challenge with 
sepsis biomarker studies has been obtaining a clear clinical definition of sepsis as a 
‘gold standard’, hence many studies have focused on more severe groups such as 
those with septic shock. The clinical definition of sepsis has recently been redefined 
(475) so applying this in future studies may increase the chances of feeding the 
biomarker needle in the metabolome. A number of potential novel biomarkers have 
been identified in this study that warrant further targeted investigation including: 1) 
kynurenine metabolites and Neuromedin-N as potential immunomodulatory agents 
contributing to post-burn immune dysunction, 2) bacterial metabolites (Heme O, 
acetate, methylmalonate, indole metabolites, secondary bile acids) as markers of gut 
dysfunction and bacterial translocation. 
In addition to biomarker discovery and generation of new biological information for 
hypothesis testing, metabolomics analysis has other potential used in the field of 
burn care research. The 1H-NMR study of early serum samples demonstrates that 
there is any early systemic metabolic signal which related to later clinical outcomes. 
Early metabolic profiles could be used to potentially stratify patients into those highly 
likely to develop complicated outcomes and those not, so that those patients who 
need more aggressive or intensive treatment can be prioritized. This approach could 
open the door to personalized healthcare approaches with tailored rescuscitation, 
drug therapy and nutritional support personalized to ongoing monitoring of the 
metabolic response. Another exciting area is pharmacometabolomics, which is the 
use of biofluid metabolic profiles to predict beneficial and negative effects of drugs 
(476). One of the major difficulties in setting up clinical trials, particularly in the field of 
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critical care, is identification of target groups of patients that drugs will benefit. It has 
been advocated in the field of sepsis, that biomarker driven studies should be used to 
identify at risk individuals who are most likely to benefit from a new treatment 
(477,478). A follow-up study to SIFTI (SIFTI-2) has recently opened at the 
Birmingham Scar Free Foundation Burns Research Centre, specifically geared 
towards identification of early biomarkers of sepsis and any biomarkers identified 
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